var title_f38_63_39920="Steviocalcitriol: Drug information";
var content_f38_63_39920=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Steviocalcitriol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16058784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Preflin&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16058786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Dietary Supplement",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16058788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Medicinal food for the nutritional requirements of patients with prediabetes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88616 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39920=[""].join("\n");
var outline_f38_63_39920=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16058784\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16058786\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16058788\">",
"      Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88616\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88616|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_63_39921="CBD and PD pressures manometry";
var content_f38_63_39921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Comparison of pressures in the pancreatic and common duct segments of the sphincter of Oddi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sphincter of Oddi manometry. Comparison of the sphincter of Oddi (SO) pressures obtained from both the pancreatic segment (PD) and common duct (CBD) segment of the SO during catheter pull-through of the sphincter in the same patient. The pressures are equivalent. (BM refers to \"black marks\" noted on the catheter.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Walter J Hogan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39921=[""].join("\n");
var outline_f38_63_39921=null;
var title_f38_63_39922="Intermediate case 10 answer";
var content_f38_63_39922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Multifocal atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 99px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCABjAggDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD12y0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Gixu7ZLG4Bt3zuvjldJn/wCe7Y5xwR6/wdDzRrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gn7vKfXJ1vbLWXxPo+78i3faPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6U3y2MoOtbeXwvo+3oSW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCrdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ0PluUnW97WWy6Pv6FpNH0zdL/xLNP/ANYn/MMJ/wCWzD8PTHcfL1FVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGraXtrul/0eT/WJ/zB5z/y2YenHHGO4+XqKqWN3bJY3ANu+d18crpM/wDz3bHOOCPX+DoeaPduCdaz1luuj7PyDW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+Hoat32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0oXLcE63KtZby6Py8iO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CajvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpUlte2plswbeQ5jjznR52z8knUY+b6jrwf4TQuXUmTrci1l8PZ935FS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW00fTN0v8AxLNP/wBYn/MMJ/5bMPw9Mdx8vUVVtru2+3yOYHwbWyH/ACCZyc+ZJnPHfPXo/QdDVpL213S/6PJ/rE/5g85/5bMPTjjjHcfL1FC5SqrrXdnLp0fZeRUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4RwaNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehosbu2SxuAbd87r45XSZ/+e7Y5xwR6/wAHQ80a3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehpe7ylp1vbLWXxPo+78i3faPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6U3y2MoOtbeXwvo+3oSW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCrdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ0PluUnW97WWy6Pv6FpNH0zdL/AMSzT/8AWJ/zDCf+WzD8PTHcfL1FVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGraXtrul/0eT/AFif8wec/wDLZh6cccY7j5eoqpY3dsljcA2753Xxyukz/wDPdsc44I9f4Oh5o924J1rPWW66Ps/INb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehq3faPpgW4xpmnjEjdNMKY/c579Oecdj83Sqmt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat317ahbjFvIMSN00edMfuc9149cdj83ShctwTrcq1lvLo/LyI7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8ACajvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpUlte2plswbeQ5jjznR52z8knUY+b6jrwf4TQuXUmTrci1l8PZ935FS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW00fTN0v/ABLNP/1if8wwn/lsw/D0x3Hy9RVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1aS9td0v8Ao8n+sT/mDzn/AJbMPTjjjHcfL1FC5SqrrXdnLp0fZeRUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4RwaNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehosbu2SxuAbd87r45XSZ/+e7Y5xwR6/wdDzRrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gl7vKWnW9stZfE+j7vyLd9o+mBbjGmaeMSN00wpj9znv055x2PzdKjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpTfLYyg61t5fC+j7ehJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wAJqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCrdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ0PluUnW97WWy6Pv6FpNH0zdL/wASzT/9Yn/MMJ/5bMPw9Mdx8vUVUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4Rwatpe2u6X/AEeT/WJ/zB5z/wAtmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/wA92xzjgj1/g6Hmj3bgnWs9Zbro+z8g1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKqa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKFy3BOtyrWW8uj8vIjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmo7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0Ll1Jk63ItZfD2fd+RUttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVtNH0zdL/xLNP8A9Yn/ADDCf+WzD8PTHcfL1FVba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDVpL213S/6PJ/rE/wCYPOf+WzD0444x3Hy9RQuUqq613Zy6dH2XkVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGjW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+HoaLG7tksbgG3fO6+OV0mf8A57tjnHBHr/B0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4XoaXu8padb2y1l8T6Pu/It32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUl9e2oW4xbyDEjdNHnTH7nPdePXHY/N0qO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulN8tjKDrW3l8L6Pt6Elto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/ABYwKt217amWzBt5DmOPOdHnbPySdRj5vqOvB/hNVba7tvt8jmB8G1sh/wAgmcnPmSZzx3z16P0HQ0PluUnW97WWy6Pv6FpNH0zdL/xLNP8A9Yn/ADDCf+WzD8PTHcfL1FVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGraXtrul/0eT/WJ/wAwec/8tmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/z3bHOOCPX+DoeaPduCdaz1luuj7PyDW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+Hoat32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0oXLcE63KtZby6Py8iO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CajvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpUlte2plswbeQ5jjznR52z8knUY+b6jrwf4TQuXUmTrci1l8PZ935FS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW00fTN0v/Es0/8A1if8wwn/AJbMPw9Mdx8vUVVtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0NWkvbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUULlKqutd2cunR9l5FSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Gixu7ZLG4Bt3zuvjldJn/wCe7Y5xwR6/wdDzRrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gl7vKWnW9stZfE+j7vyLd9o+mBbjGmaeMSN00wpj9znv055x2PzdKjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpTfLYyg61t5fC+j7ehJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmqltpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/xYwKt217amWzBt5DmOPOdHnbPySdRj5vqOvB/hNVba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDQ+W5Sdb3tZbLo+/oWk0fTN0v/Es0/8A1if8wwn/AJbMPw9Mdx8vUVUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4Rwatpe2u6X/R5P9Yn/MHnP/LZh6cccY7j5eoqpY3dsljcA2753Xxyukz/APPdsc44I9f4Oh5o924J1rPWW66Ps/INb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehoo1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DRWNa19D6Th/n9nPnvv1+Zb09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNGvM39han+6m/49LzrLN6/7vbvng/xYNVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upra/unzapP2ydvtPqu78zx2+8QaybS4b+0tTB/4Wa1huN5OcW23Hkc8bMcbT27Yrt/hlqV9f6hr5vpb67MHjTUIIvNubhjHGtuwWNeCQFHTvjsBmu2vri8K3GItPOZGxjVpXz+5x3j59M9z8vSo7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmh7HHRwso6+Uuq7epoWzN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTinas39pS/upj/AKJY/wDLWb/nrL/s9+2OB/Dk0W1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jVS2nuhfyfu7Df9lsgQdVkAGJJP8AY69cj+HqM5pt6nSqT97Touq7+prox3S/upv9Yn/LWb/ns3+z+HPOeR82RVPT2b7Bcfuph89//wAtZv8Anu3qvbvng/xYNCXF5ul/daf/AKxP+YtKP+WzH/nnzxznsPm6mqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxRfUSpOz06rquz8zwm98b+JIvFerJeapfjR21/UdG8p5EaLYVPlxBNolBDEZcnH3cgc5+jL5iVuP3UwzI3WWY4/c+6/jzzjj7vNcjqfh/SoI9V1OLQPDkOoywXjyXkV0fPZiT827ygWYgnGT8+ck10V9cXhW4xFp5zI2MatK+f3OO8fPpnufl6UJ6kUqE4wSeur6ry8ye+dv7V079xP8A8f54864z/wAesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44Jxn3lxc/wBqWBZNPH+nErjWJSD/AKM45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jQnuOVJ8i0+z3Xd+YWrN/aUv7qY/wCiWP8Ay1m/56y/7Pftjgfw5NXEY7pf3U3+sT/lrN/z2b/Z/DnnPI+bIrItp7oX8n7uw3/ZbIEHVZABiST/AGOvXI/h6jOatpcXm6X91p/+sT/mLSj/AJbMf+efPHOew+bqaEyqtJ3enbquy8w09m+wXH7qYfPf/wDLWb/nu3qvbvng/wAWDRrzN/YWp/upv+PS86yzev8Au9u+eD/Fg1StrueLTbp2GnCNTfszPq0gA/fMT/BjHXH94cnFUY/EMPiHwhc6jpU2nXFhPZ3hWRNUl3cnpsaMHd/stjd3xSuuUtQ/fpf3n9pd35nT3zErcfuphmRussxx+591/HnnHH3eaivnb+1dO/cT/wDH+ePOuM/8esnH3c575644xjmoL64vCtxiLTzmRsY1aV8/ucd4+fTPc/L0qO8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9OabehlTpO232X1Xb1NC2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcec/ELXL/RvEfhL7JPNa2t3e6dbXZ8yTbJGTOdpJXgEjjb0x8uea7q2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/Eay7m3XU3uLTUrDSLy3ktLJZLe51B3jYCSTqpjI9cjHy9RnNEmOVGTU0uy6ruvMxvhjrl9rOpeNjdzzXdta66ba0Ikk2xxhwQgKrzyTy3zZORzXW6ezfYLj91MPnv/wDlrN/z3b1Xt3zwf4sGqulW40u1Nppun6PZ2kboEht9SeJFHnMeAsYGO+ew+bqaLG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTii+oqdGSg0+66rs/Mta8zf2Fqf7qb/j0vOss3r/ALvbvng/xYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNZGtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NW764vCtxiLTzmRsY1aV8/ucd4+fTPc/L0oT1KVJ8q06y6ry8ye+dv7V079xP/wAf54864z/x6ycfdznvnrjjGOap6z5jaO4iuLuxkFqpW5hlkDoQkmGXcjAfkR1xwSQt5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1HPE2owQWmo2OkXVpLDGksNxqTtGw2ycMDGQO3HQcD+I0J7kypPkWn2e67vzOO+B2o3+q+E4NR1W/vdSvLqC2d3lkYeVieZQiiNAAuFBAOSCSQT0HoqMd0v7qb/WJ/y1m/57N/s/hzznkfNkVzXh7TrbRJ7iDRtK0TT45IbOWWK1vmhRn8x8sQsYG7A54+UAEE9tlLi83S/utP/wBYn/MWlH/LZj/zz545z2HzdTRF6DlRktH/AHeq7LzDT2b7Bcfuph89/wD8tZv+e7eq9u+eD/Fg0a8zf2Fqf7qb/j0vOss3r/u9u+eD/Fg1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mlf3TVUn7ZO32n1Xd+Zr3zErcfuphmRussxx+591/HnnHH3eaivnb+1dO/cT/wDH+ePOuM/8esnH3c575644xjmoL64vCtxiLTzmRsY1aV8/ucd4+fTPc/L0qO8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9OabehjTpO232X1Xb1NC2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcU7Vm/tKX91Mf9Esf+Ws3/PWX/Z79scD+HJotri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGqltPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNDepapP3tOi6rv6mujHdL+6m/1if8tZv+ezf7P4c855HzZFU9PZvsFx+6mHz3/wDy1m/57t6r2754P8WDQlxebpf3Wn/6xP8AmLSj/lsx/wCefPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFF9RKk7PTquq7PzLWvM39han+6m/49LzrLN6/wC72754P8WDVy+Ylbj91MMyN1lmOP3Puv48844+7zWRrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KE9QVJ8q06y6ry8zmPjNfXmneEL2/027vNNvLWZ54p4pZCwZbVyF/eIQc456Ng44HNa/w/lnl8L+HZrm4vNQnmtIZnnllk3MzJIxHyIAAM7QAOAvU/MaPEVpDrM1pZ6zp2i31m9/uMFzqTzRORbPgndHjAP8WCcgL05qfRIP7LhsLTTtP0eztI0QrDBqTwohIlLcLHhSWYkgdCf9o0J7mcqMrJ/wB3+Zd35lm1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyauIx3S/upv9Yn/LWb/ns3+z+HPOeR82RWRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTQmaVaTu9O3Vdl5hp7N9guP3Uw+e/wD+Ws3/AD3b1Xt3zwf4sGjXmb+wtT/dTf8AHpedZZvX/d7d88H+LBqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUmtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NK/umipP2ydvtPqu78zXvmJW4/dTDMjdZZjj9z7r+PPOOPu81FfO39q6d+4n/AOP88edcZ/49ZOPu5z3z1xxjHNQX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c029DGnSdtvsvqu3qaFszedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOaG9S1SfvadF1Xf1NdGO6X91N/rE/5azf8APZv9n8Oec8j5siqens32C4/dTD57/wD5azf8929V7d88H+LBoS4vN0v7rT/9Yn/MWlH/AC2Y/wDPPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTii+olSdnp1XVdn5nMfHPVtQ0f4b6hd6ZJcWswcxvKHkbEb3CK4O5cYwSD9ecHAp2ja/e6l8UPGlgLmWfSbOG1aCJZZGSJ3t33fNtyScZ+bsMdMmuh8QtNcaBqcVzBpzwvaXiup1SR8gn+6Y8N7A/e6mktdOg0WzuLbRNJ0KwtjKzeVZ37IhJhPO0RAHnv3Py9KL6mf1ed1K+mvVf5+a+41r52/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnGfeXFz/AGpYFk08f6cSuNYlIP8AozjlvL4HX5uufl6c1JbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNCe5UqT5Fp9nuu78wtWb+0pf3Ux/0Sx/5azf89Zf9nv2xwP4cmriMd0v7qb/AFif8tZv+ezf7P4c855HzZFZFtPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNW0uLzdL+60//AFif8xaUf8tmP/PPnjnPYfN1NCZVWk7vTt1XZeYaezfYLj91MPnv/wDlrN/z3b1Xt3zwf4sGjXmb+wtT/dTf8el51lm9f93t3zwf4sGqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU0r+6aKk/bJ2+0+q7vzNe+Ylbj91MMyN1lmOP3Puv48844+7zUV87f2rp37if/j/PHnXGf+PWTj7uc989ccYxzUF9cXhW4xFp5zI2MatK+f3OO8fPpnufl6VHeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNNvQxp0nbb7L6rt6nD6/qGpQ/GPwXptvrWo22n3tq009pHLhWMS5UAmMuA2SCFzwTtI6jvLVm/tKX91Mf9Esf+Ws3/AD1l/wBnv2xwP4cmsp9E0+81nT9SvdB8Oz6hEkLJdTXhMqMquVIcxZQgheh+UgY61atp7oX8n7uw3/ZbIEHVZABiST/Y69cj+HqM5ob1CFGS579bdV3Xma6Md0v7qb/WJ/y1m/57N/s/hzznkfNkVT09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNCXF5ul/daf/rE/wCYtKP+WzH/AJ588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUX1KVJ2enVdV2fmWteZv7C1P91N/x6XnWWb1/3e3fPB/iwaKqa3cXR0XUA8diFNreAldVkY8nsPL5OOg/i6misKz1R9Nw7Fxpzv3737+bLenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KNenkOhamPtkJzaXgx56c5PI+536j17belR2VretYXB+3aqozqAI222P9edxPyZ68tjv93ijXLW9XRNSZr/AFVlFpekqy22CM8g4TOPXHP92tr+7sfNqMPbLWPxPv3fkaF9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNU77VIz4jsLMavZfbluzOYftce8IbWQCQjZnb23YxnjGean1G0vtlzu1HVv9a2d62vX7OeuE649OMe9cTrXwn8OXOqaWi6dNbBdQCMlta2MSyoIhN5ciLHscFoYyQwIwCONzZG9NjmslG8XF+6/y9EauoeM4tP8c+EfDkN3C97qUTSufOTbbwxwTEFjs+Vi3AGG4D5Odpq1d+ItO0fUsatr+mWHm2lmIxdX0UW7bLJwNy87cgnrjIznpXJ6T4E0nwNrPhRPDp1GwW/1ON5W3xSF3+w3oXBcH1IAPHzNnBwaf8LNAa5s4fEV4ko1zU4bbVHu0jt5ZEE8jhI0klUuqLGkSKgIUFTxg0N67GcH704Nxvp3sldeXn+fzsP8RtRuYbjUPDvh3VNU0aJkmluzLHbNOnmLIGtoZEEkxxIxHyoCVOCcgDf8IeI7LxBoM15pWqwXEDPfBl80K6lpidrI0YZWIIIUgEjkbRWzHaX2+f8A4mOrf62POFtev2h+vydc59s5zxiuG1z4W+H/ABVJLqWt2uoy3qG+BmjkihZgszD5ygBYcnOc9cLxxRfXY1VOybUovVd+z8v8/kdlr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0qS+1SBr24sTqtk96Q0/2cXcZkMflbd+0ICVz8u7gZ46815pcfDvXND0vVdF0LWb/AE7wR9lubkRRyq16ki5DxJIeEhYiN3xliQwUAOxNHxloUHgDV73VbDUtWXUjoWqM9/qU8VzcTSpHaLEHdgdwywGOgyAuCTTvrsZ+0SjqkkubXvttp+dj0Xxj4mGh3mlP5zX97NqQWCytLiEzzkwFCyhlVdq7xuckKozn1pvhzxdHqWvtpci3OlahZwQSCDUJrdXeIpIBInlmRSoOVPJKkgHkjGfongVtE8TwatPqev3+vXd0IJr27ktpZI1+zyOY4srhE3Mx2D5cY4yq40Na8IQ+I/7KXUp9See3WCW1uUjtBPbMu6QNC5jynzRqfcKQ2eBST30Bq9NS934dvLXy+7Zd+4nhnxLYa5qWqDStWt5jYC1sbhDKEeKWOWTI2tGDgZ+8MrwcM+CB0Cyyq0hN3ENzowJmUbv378j5OQDk5/HkcDhNM8D3+lTwQeGfEOs6ZHHY2CTEwWc5nHnXDhiWThjJIzbupywYcgjNks7vwZe/EPV7G91K41KLSrXVbme7EDC5nSa9CmRVAwoESKFj29D7GmnoTOo1K1RLpr02VvO5sePNXtrH4a+JBqGrWcIuLTVoI1e7jUyu7yfIgKcs3YDk9RjpVTQpbayuPiRpNisVpHBJJOI0YLG0ctpCo2kr82WhccYztPQ5y7wJ4V1M6fHrviLV9WvvEDQXytJiFYYA0o8xY4iCqZZfmYAMc4HHFaPi7wh9rN3ra6nr9tqkOn3sPnwvbKJIgXzHImza6ZdiQRkNgqRip6GqV6yq2V+bbru/lf5/M6G51q0nv77To9ZsJr+JjJLbR3kbyqDBgMVCAgEEDPHUDqQ1VPFXiOx0K4srzWNcsbSFL15N8t3GN2LV8lR5eW7LwDkkDGTmvEdZs/EHgbxvqupalq73nifUNBl+0XJjQK1y0sUMeFAICqJYwABzt6DJFezDwxPa+MbPV5tV8QXeqvMbETzmzBSLyGkKqqRqmSVBJIOQBzlVw29DGlPm92yT5Xvslb+tir4c8d22o+IbPS5Vv9LuXjJsm1JVt1u0i81WaPKkjHXZIFfa6naQcroxaxaweIlsJdYsIr2aysjDbPeRrI6rJKflQpk7cEnrjGST0qLXvCNt4q0610vX21C+sZI4T5brbZBCS4ZDtBU4LYOQcFvasOH4e2zF4Uv/ABA10g02+ivbm4iupo5UnmMRUzBtqruZVUY4Zg2cklt6mrTjzW5Xovz9O53CTybpf9MhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Vwumy+PtJ1fQh4v1+Fl1LUEsJLfTreEKGC3MgcO6ZLmWMf3VAyMHIIf4Nt/EXjHwxHq2savqFlo98k15bWGmvHFIYzKsjLNcBVkILcMIxGcEgEg8F/e2EqsbNKKvdfk/6+86jX/EGn/Z9S0s69pn9pNZ3mLP7dF5xBG4/Jt3HI+Yeo5G0Vt308jLcZvIXzIx4nQ5/c4zwgzxx25468157rfwn8NQ+FLq3t9MltzbWlw0NxDb2iTo0LAo3nBPMJBUZO4k89QTk1ex+LdvHcwQatot8El/4/LqNbdpP9H+bdCiOA2MnKvggdATwJ67Giskk+XeW1/LyO9vrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmpbaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcgjg9Tt/inPq8Pk3Wk2BEshgEjreM119nYqGIjhCoY9wLYbGRhSaki8SatomvaRbeMruPRrO5tTJBepqVu6ZQYVCZbaNVLCRiAWJwjdeMJPfQUnT5Fdx28+78tjqLe+VNaa3Oo2yzPY2bJEblAxVJXyQNmcKWXP93cMk5Aq5Jei3iup59QtooYyJZJHuEVVVZnYsSUxgcsTwAOTxwPFIdRvX8c+EPEmrazeRWdxFPEk0oijSCyVrh4pEXZ0aO3RyzDJz6BQOv8OeHbzxp4f0vWfFWq63dfalivBp0b26WiiS4MiK8flr5pXCgeZuG4McAEU09DOVRTb0XT02jZvTr94h+J2mWf2qJHurzTY7iaCfVrZ4XsoWuJ2Kgy4G4Y2FigIXeuShyB2Oq3y3Xhq+mt9Rtp4JbG7dHjuUZZFbnKkJyG6jHUcgjpRZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eK5XWvCHiDSvCJsPDfizVbPT7Kwu4BBeWVncqIEwuxSoRgQAAWJY+gNK/umrbhWT0l7z206vv/n8zs9X1KK3DC71S0Qz3BijD3UY81zAcKvyDcSARgdcYxn5qo+K/ENnoLWupaxrNpa2kN8ztK9ynJFpJ90CPLEgEAAEk8AE81xvxT8MPZ6W3iDUNU13UL6y1OxCS30sAjhVpoFYrHEgQOQcbwpO04JI4pnw70WPW9Ts/Hk76hNrur6lMqXm22LR26wzLCsYKAKfKVcnGGyTycYG/IwpVFJ8qUU+V79reSFk8VeJdHu7bxTqP25PC+ESXTnW3NzYweSoW4KxozYV/P3qWZlSRSVypAuWnxFsZ/iFp+haXdw38V7ZWyte215E8UDoZZEjOEOTtDE/3cDO7OB3FpaX3n2G3UdWz5UW3atrnGyXGMp064zzjOecV5T4q0iy8Ga5pmtWCtbmOX+1ZiyRqJJFsL1iQEXaAwgUHjcSSTknNDepU4KmpSUk1pfq915fM9Ti1OFrWa7TVbM2u5ZDOLqPZtEzktu2YwOWJ6Ac9OBx+jfEPTbm9fT1nuBazzX0Fvqb7RZXUzTsfJjl2fMzYJXHyvghWyNtZXgz4XwN4O0a01XUNfuLWKK3lk0wXEX2IzNNufMZUeYvmKSqyblBLcAGu0l0Y6rol3a6lJe3Vm7X2+C4htJI223JOSrIc/MAx9GxtwKbeuxUE5RveK1X32f8AX9a3/EUk0ei6okt1GrfZLwFTMueecY2d+o9e23pVq+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmvNPEXwZ8JSQahqLaZepMkNxP5cLxQwloj8uYo9q4GBuAHJ6Vr3vwys7bSxZWGteNbCG2do4xFrbgKgtsKm0sVAUDjaPu8c9KE9ditor4Xvs/S+6/U6++uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGeax/Eni+z8Jx6Jc6reCOC6ubaxWVZowsDOkuGkJXCooB3HnGec9Rz2radrfgb+zZNP1bxhrsH9oSobW78m8uDKbKRoysojLKSyhCWDIFkzwRmpPDPw2wtnceItT8Q6tql3YLBP9qu4p4ohNFJ56W6Ou1I2xgcZCrjjOCX3Od1VOKjFJNLW+3f9TpZtWt9MuJ7nUNWsrO2S0sA0txdxxqv72TAJZMDBPTPHfd0rKg8c/a7nUP7EsNQ1m0gmVDe6fdWRgkcP5mEaSRC4G8ZZRgHOem0cd8MtBj8RTadqOoxXc76FpGi2VjK6QOIJGiWdyiuu0HEkG1sFxjBIBIr1aO0vt8//Ex1b/Wx5wtr1+0P1+TrnPtnOeMUJ+RopKv76cUtPXSy7GB4K8UWniLQpZrK/jSf/TGuLKeZFubUvOx8uWPZlHJB4PXBIIFaHiXVYINNurS41ayjubq0vhDC93GHmxywRdmW45wOo5+XpWFq/gaDxBHJfT6h4hsdRiW/hF7p9xDbTGMXJYozIAXTcMlWyASSoGaz734T+GNO8O3C2mlzRG0gnnimVLdZ1aFwyN56qJRgqMkNk844JpX93Y2SarW926l56u78tD0G+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmsqbxDaXHi+HSoNYtX1G0u1nnjWdT5Ye1lCkt5e3kDGOoyMjkMeQ/sjxnpniGXw5Z6vr03hyMG7fWL+S3muULQSA2+542Ej5Abdn5Yztxnaazrzw6fA/xOude/tbVJjPY6hqd5PeSQtcu0EcPC7Y/LACzHChThc4HAFNvTY5o1Yq10krNfgeq2s8gms8XkIIjjAPnoNvyScH5OMZxznGR1yCMXQdfsNWv7ltJ13Tb1IrWxVzbX0UgTEkpAO1Tgjrg9O+7pWPZ+Db7xDo/h+Lxdq+uX+YLS4uLB47JYHlEch2lRCCyBskK5P3fmBIFGp+C5NQ1m31DT9S1TTdbsNOtYrO+hjtSEV2kUI8e0CSIEKQpwcjqOCBvVGkZc0ZTSVrLTruvkdkk8m6X/AEyEZkQ/69Of3zHP3PXn6HPIOBT0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pXLWFh8Trpp5L7XdI06QzLmC108XSA+ZwQzvGf9b5mFwcALlm60Wek+Pms7o/8JXaRxhrwY/sRDuAmYSk/6RxlueM4zgcCi+uxrHkcXtuvyfkdN4jvPL0HUPNv7dQ9vdRLuuEG5nYKqj5OS7EADqxIxjpVvVb4QxTvcajbKjTbMtcphmaLYoHyDJJIQdMkhQM81wXiLwLqms6Lqj+NtevNZjitr6S1t4rG2t4LdyMGTYS5Z1+bDk7l3Hb1Jql4x8P+O7Hwtrd5rPjifUIrANqSINHtoGNxbQ+dF8yuRtDIjEbWyExxk0X1OaVVxgpcit73Vd1e/wDwD0m+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGeaa+pRWC2txeapaWsCJCplmuo41TKuqgsUwDlsYOeWA5JGOHutc8Sa/rdlpvhu8eK6litdQOoTGGRbVp4JcbYPLG8+XHJjdIvVSQT1118AWOoX1jca5Lqut3XlKEfURazqiPEQVjiZPKQfugchAx+bcT8uBPfQ0lKMopRS+Hfp18jctZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VLd6nFYW9zdX2qWdrbI6M8011GiD9+2CWKYxk5zx1B5B2jz++0/xV4OtI5vD2qXOo6Npmj2puLO/FvFMIovNMIgljibOSuMOhPTLc8Lpzn4i61NJpviLUb7wvYy2Us0SQ25juLgyzSBGbaMlN1s+PmTdlWH90T6WFVqRfRJu2nyXlbp37Ha6Lfrd6O1xbajbTW832143S4Rg6tOTkYTnd1HqORjpXNeIPGlxdtq+maDZzatFaLc2+oXkd3BHBBuDM6KXAMsowvyLgZcAumCBynw+n1DWvD2geHNP1XVtNsbfw3dteGw8j7wnFuNryRl0DNFOxIO7I+XaAK9E/sAaD4Nm03S5tSg06z0+8iigxbbQinkE7dx/wBo53E8g96V/d2LpTjiKicWo67+uvZ7dbl6x12217RU1PTdSgurK7zLG6zKSwMBHI2AgjlSOCGBUgEZq1fXMv8Aaunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzXJ6x4e8S6LqF/N4WuJJbG9uLi4vLW+mt4Aty0EeJEMdu55USl14BJBBDFsrO3xDW/sBNY2jXH2zgrrEY/efZnzj/QuPlz6jHGM/MBvTYKXLb3uX4X37emx2FtPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VycfifVG8Oade2Mt4+szXiaTBZmaDyzcLLNCwEggJCKqSSZZAdqtnBK1znhG48Q6X4Z1m0i1C5XVbPWLTTftj20JhmkuL/zPM8shT926D7FbqeW24wN67D56S5tVsu/deR6RrPibTNBG/Wde0+xE0qBPPvI0MhE55UFMkAsGJHABDHjgGh6lFf6NJcWWp2lzbStflJIbqN1cG4bOCE5yemDz229KoaD4Wv7XUbjVdV1a+v9edY7Z7yO0tIQsX2uRxGilWKruOfvNlhliQFxHoPhb+zrvW9TsL3WbeTUWvWuoVNt5MkizFTLtKHDkAByuM4GBwMO+uwoK6bfLa69dn5G1r08h0LUx9shObS8GPPTnJ5H3O/Uevbb0oqPXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/wB2isK2rR9Zw4oqnU5Wt+nz8kSafaKLC4P2eYYe/OSkPG2dh29O+OR/DxRr1oo0LUz9nmGLS8OdkPG047enfuP4eKqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8ACODRreladHouovHp1grra3jKy6YVIIPBB7Edj/D0NbXfKfPJx9stX8T+z5vzNe+swi3H+jzLtkYcpCMfud3b8+OMf7VRX1iv9q6ev2Wf/j/K48u3z/x6yHHpnv6Y96gvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpUd5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6m27GNNxtu/hf2fL1OS+Kc8Ojw+DtSuEeK3g1ezeV3WPGxobhSeAeuf4v+Bdq0vhrahvCmgMbeUltB0huI4MfNvHp37f+PcVi/GPwY/iH4dXVh4d0q3k1d0tXgjgtfJdyHO4byQD8u4knhscdK6+20fSlv5IotOsvIS1stitppOMySDJPckAZP8AFjApO9zGC/fTd3ay6ea8zWS0BaX/AEeY4kQfch4zMw/pjjjI5+XFU9PtFFhcH7PMMPfnJSHjbOw7enfHI/h4oTR9M3S/8SzT/wDWJ/zDCf8Alsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBp3dzoTjyvV7r7Pk/Mt69aKNC1M/Z5hi0vDnZDxtOO3p37j+HivPfjLY27+I9EtrlJIoJSYnVljBdTfaWGUbOM7Wb2/Emu31vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6GvMfjpp/2Xxj4FOn6fFFY3GqfZbp4bIwRnMlpIqNkY58piFPPyselLW5jXcXRSu9W+nnHzPYL6xX+1dPX7LP8A8f5XHl2+f+PWQ49M9/THvUttaK01mPs8x3RxnASHnKSHjP0788HPOKz7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JppvU0k48i1fw/y+b8wtbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFed/EOCOXW9a0gieJ9Zj0fTFCrFvYSX94JFGBx+6WXkYxg84ArubbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVw2sfYLX4z6RpkdpApuWtpfKSz2xlVXVkYsmPm/1ijHXoOopa2McdZqye7S27peZ6Jp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFGvWijQtTP2eYYtLw52Q8bTjt6d+4/h4qpZaVpz2NwzadYFg18ATphyMTkDntgcA/wjg0a3pWnR6LqLx6dYK62t4ysumFSCDwQexHY/w9DRd8p2Jx9stX8T+z5vzOB+Mix2njjwvE0PzXcvkLHJtU/JeadKeEIH3Vbp2z9R6hfWK/2rp6/ZZ/8Aj/K48u3z/wAeshx6Z7+mPevNfiHodjN8V/AsUVlbxwr/AGnLIILIxAhbaIrkem4jr0ySeGrv7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1DucWH5VObu9n0/u+vmaFtaK01mPs8x3RxnASHnKSHjP0788HPOKp2toDqUp+zzHNpYnISHndLKO/r27n+Lii20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgU23c6U4+9q9l9nz9TnPjCqaX4UGuNbMf7F1OzvfnWIDAumjYHHqrFfTr2C1e+FmmyWnwx0GC4t5RPDp8qvhYsBkbB5PzYH5+lN8e+CrXxN4U1PR7OGxsZbqWBPtCacwaNBd5crjkHYCAO/C5GCa2bXTLCa0uZJrCykkL32XfTiWOJ2A+Y+nY/w9DRrzGUUueTu7XXTyfmWdetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VZGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8AD0NW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6UJu5qnHlWr3l9n08ye+sV/tXT1+yz/8AH+Vx5dvn/j1kOPTPf0x71Q13wxY+JtGbRtTtbl7S+t40fyxCHGVkIZSR1BUMCe688gVJeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNCb1Jnyumk2/h/l835nmnxttZ7kaBa2wmin1S+sNPaYrGTsuor2GTGPVXOCeeOT0r1ZLNcyj7PNgSIPuQ8fvmX+mOOMjn5cVyereDdH1zUdPFzbpCmnPp2oItvYbRI6vMNr8HcpyN2Mb9qgEYroU0fTN0v/Es0/8A1if8wwn/AJbMPw9Mdx8vUUK5E4xVWUr78vTyXmGn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HiqllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODRreladHouovHp1grra3jKy6YVIIPBB7Edj/AA9DSu+U6U4+2Wr+J/Z835nPfHi0MXwy16WKGaN7eaGZSyxDHlmOTHyjP8PbjHvV3wBZo3gvwHtguHVoLYAlISSP7PLd/wA8HjHvVrxx4btNQ8K6/ZWFhZRXdxb3EMLR6eYSHa1YKN38IyRkfVulWLfw/pWnnRbKDS7GOKK5WAIdNZ/lW0bCknlhkA4PJI3UO5yU0vauV38D+z6+Zs21orTWY+zzHdHGcBIecpIeM/Tvzwc84rx/4/yxaboEFxKjxo8KRlm8tdxlstRTAI55JAGeT3zxXqlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/Ca83+K/hdNYg0ewsNMVkkvdK8/wCy6fICkTPOruxUH5fu5bgHAx0pyuOvZ0qiTey6efqeqJaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxQmj6Zul/4lmn/6xP8AmGE/8tmH4emO4+XqKqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NF3c2TjyvV7r7Pk/Mt69aKNC1M/Z5hi0vDnZDxtOO3p37j+Hirl9ZhFuP9HmXbIw5SEY/c7u358cY/2qyNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehq3faPpgW4xpmnjEjdNMKY/c579Oecdj83ShN3BOPKtXvL7Pp5k99Yr/aunr9ln/wCP8rjy7fP/AB6yHHpnv6Y96ltrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xWfeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNCb1Jk48i1fw/y+b8zzP8AZ7li1XS9XvIIHMTDS412LEQClrDE45/20YD6fNXrCWgLS/6PMcSIPuQ8ZmYf0xxxkc/LiuG+GfhCPw94a0/RtVhsbu4tLO2Jc2TzKDJczudrMAcfNjoNwGB0zXWpo+mbpf8AiWaf/rE/5hhP/LZh+HpjuPl6iiN7ExsoJSbT93p5LzDT7RRYXB+zzDD35yUh42zsO3p3xyP4eKNetFGhamfs8wxaXhzsh42nHb079x/DxVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Gld8p0Jx9stX8T+z5vzNe+swi3H+jzLtkYcpCMfud3b8+OMf7VeYfHXRZptQ8LeR59vHfasNBuBiJWaG7SPeo28ZIjOOR1GOSa9DvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpWR4r8IaNrF9osU1nBALfWorpTb6YU3GKBnCMMHKEjBTgnOc4ptuxxVoKpT5U29O3az7nR21orTWY+zzHdHGcBIecpIeM/Tvzwc84qna2gOpSn7PMc2lichIed0so7+vbuf4uKLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E1UttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBQ27nSnH3tXsvs+fqa6WgLS/wCjzHEiD7kPGZmH9MccZHPy4qnp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFCaPpm6X/iWaf8A6xP+YYT/AMtmH4emO4+XqKqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8ACODRd3BOPK9Xuvs+T8y3r1oo0LUz9nmGLS8OdkPG047enfuP4eKTxRo4v9E1exFtKDcJNbjfHBgbrc8ED65x0x/tVV1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grl5pOmJ57LpmnArK2P+JXt/5Y579BnnB7/N0o1uTJRlTS5n9r7Pp5nm/wEtmv/BHh7VbmF5J72+8ncnlMBHBZtCq/N3/dFz2y5zk16nbWitNZj7PMd0cZwEh5ykh4z9O/PBzziuU8LeCtL8K6T4f0SO3trsW10YpJ5tMctMTbSOxYEk4LEnZnjg9BW/baPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmlG6uZwUY0Yq7+Ht5vzC1tAdSlP2eY5tLE5CQ87pZR39e3c/xcVbiskXzES2lCo8aKojgwo85lxjtwMcccYPy4rJttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVtNH0zdL/xLNP/ANYn/MMJ/wCWzD8PTHcfL1FNXNqvLzXu+n2fJeZ5j8B7KaUeNr2eSSZI7+6sY0UIVRYZGl3ZI5+a6fkc+lena9aKNC1M/Z5hi0vDnZDxtOO3p37j+HiuO+HHhEaZp3iKfV7GzafUNU1G9jSS0MzxIXVFUvyAfkJ6nbu55JA6bW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+HoaWvKY4FKKpptp37evma99ZhFuP9HmXbIw5SEY/c7u358cY/2qivrFf7V09fss//AB/lceXb5/49ZDj0z39Me9QX2j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdTbdjSm423fwv7Pl6mPo/gKys/GNvrMDX7JMrT/YmWBoknmQB5YwRwSIj97P33PBPPDYvbr41t4ekhkexkubLX2X5M+WlqsHpg5lEJwTj5RkE5r1W20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNc9ZeH7CTx3d3U2nW7JFo2mww7tPcxjfc3DSAD7pPyoSR97OBjJyO5zVqUOZKN91fT18zrUtAWl/0eY4kQfch4zMw/pjjjI5+XFU9PtFFhcH7PMMPfnJSHjbOw7enfHI/h4oTR9M3S/wDEs0//AFif8wwn/lsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBou7nWnHler3X2fJ+Zb160UaFqZ+zzDFpeHOyHjacdvTv3H8PFFVNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehorCte6ufTcO29nOz69rdwsbu2SxuAbd87r45XSZ/wDnu2OccEev8HQ80a3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3p7N9guP3Uw+e/8A+Ws3/PdvVe3fPB/iwaNeZv7C1P8AdTf8el51lm9f93t3zwf4sGtteU+dTXtlo/ifVd35BfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpWhfMStx+6mGZG6yzHH7n3X8eeccfd5qK+dv7V079xP8A8f54864z/wAesnH3c575644xjmm72MabVtn8L6rt6EFte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1rWzN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTinas39pS/upj/olj/y1m/56y/7Pftjgfw5NDvdFJx97R7Lqu/oCXtrul/0eT/WJ/wAwec/8tmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/z3bHOOCPX+Doea10Y7pf3U3+sT/lrN/wA9m/2fw55zyPmyKp6ezfYLj91MPnv/APlrN/z3b1Xt3zwf4sGjW4Jx5Xo911XZ+RU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6Ua8zf2Fqf7qb/j0vOss3r/u9u+eD/Fg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu80K9wTjyrR7y6ry8jPvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpUlte2plswbeQ5jjznR52z8knUY+b6jrwf4TU987f2rp37if/j/ADx51xn/AI9ZOPu5z3z1xxjHNS2zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTgV9SZNci0fw913fkZNtd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhrOl0bRLjxlD4le2uv7StoPsSY0u48so1wTyuOowwHqHK8kAjbtWb+0pf3Ux/wBEsf8AlrN/z1l/2e/bHA/hyauIx3S/upv9Yn/LWb/ns3+z+HPOeR82RQkyq3K3qn9nquy8jIsbu2SxuAbd87r45XSZ/wDnu2OccEev8HQ80a3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3p7N9guP3Uw+e/8A+Ws3/PdvVe3fPB/iwaNeZv7C1P8AdTf8el51lm9f93t3zwf4sGlrymia9stH8T6ru/Ip6rDpU2pJqUllKby086KCQaVcpsWSFSwxjHJReoJGNwwCc2Ly6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VoXzErcfuphmRussxx+591/HnnHH3eaivnb+1dO/cT/APH+ePOuM/8AHrJx93Oe+euOMY5pu9jGny9E/hfVdvQgtr21MtmDbyHMcec6PO2fkk6jHzfUdeD/AAmqttd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhrWtmbzrP91Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/RLH/lrN/wA9Zf8AZ79scD+HJod7opOPvaPZdV39AS9td0v+jyf6xP8AmDzn/lsw9OOOMdx8vUVUsbu2SxuAbd87r45XSZ/+e7Y5xwR6/wAHQ81rox3S/upv9Yn/AC1m/wCezf7P4c855HzZFU9PZvsFx+6mHz3/APy1m/57t6r2754P8WDRrcE48r0e66rs/Iqa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKNeZv7C1P8AdTf8el51lm9f93t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93mhXuCceVaPeXVeXkZ95dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/wAXSpLa9tTLZg28hzHHnOjztn5JOox831HXg/wmp752/tXTv3E//H+ePOuM/wDHrJx93Oe+euOMY5qW2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcCvqTJrkWj+Huu78jJtru2+3yOYHwbWyH/ACCZyc+ZJnPHfPXo/QdDVpL213S/6PJ/rE/5g85/5bMPTjjjHcfL1FFqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk1cRjul/dTf6xP+Ws3/PZv9n8Oec8j5sihXKqtXej6dV2XkZFjd2yWNwDbvndfHK6TP/z3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1b09m+wXH7qYfPf/8ALWb/AJ7t6r2754P8WDRrzN/YWp/upv8Aj0vOss3r/u9u+eD/ABYNLXlNE17ZaP4n1Xd+QX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VoXzErcfuphmRussxx+591/HnnHH3eaivnb+1dO/cT/8f54864z/AMesnH3c575644xjmm72MabVtn8L6rt6EFte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1rWzN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTinas39pS/upj/olj/wAtZv8AnrL/ALPftjgfw5NDvdFJx97R7Lqu/oCXtrul/wBHk/1if8wec/8ALZh6cccY7j5eoqpY3dsljcA2753Xxyukz/8APdsc44I9f4Oh5rXRjul/dTf6xP8AlrN/z2b/AGfw55zyPmyKp6ezfYLj91MPnv8A/lrN/wA929V7d88H+LBo1uCceV6PddV2fkVNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1bvr21C3GLeQYkbpo86Y/c57rx647H5ulGvM39han+6m/49LzrLN6/7vbvng/xYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNCvcE48q0e8uq8vIz7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1PfO39q6d+4n/4/zx51xn/j1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOBX1Jk1yLR/D3Xd+Rk213bfb5HMD4NrZD/AJBM5OfMkznjvnr0foOhq0l7a7pf9Hk/1if8wec/8tmHpxxxjuPl6ii1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyauIx3S/upv9Yn/LWb/ns3+z+HPOeR82RQrlVWrvR9Oq7LyMixu7ZLG4Bt3zuvjldJn/57tjnHBHr/AAdDzRrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grens32C4/dTD57//AJazf8929V7d88H+LBo15m/sLU/3U3/HpedZZvX/AHe3fPB/iwaWvKaJr2y0fxPqu78gvr21C3GLeQYkbpo86Y/c57rx647H5ulR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0rQvmJW4/dTDMjdZZjj9z7r+PPOOPu81FfO39q6d+4n/4/zx51xn/j1k4+7nPfPXHGMc03exjTats/hfVdvQgtr21MtmDbyHMcec6PO2fkk6jHzfUdeD/Caq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6Gta2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/AESx/wCWs3/PWX/Z79scD+HJod7opOPvaPZdV39AS9td0v8Ao8n+sT/mDzn/AJbMPTjjjHcfL1FVLG7tksbgG3fO6+OV0mf/AJ7tjnHBHr/B0PNa6Md0v7qb/WJ/y1m/57N/s/hzznkfNkVT09m+wXH7qYfPf/8ALWb/AJ7t6r2754P8WDRrcE48r0e66rs/Iqa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKNeZv7C1P91N/wAel51lm9f93t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93mhXuCceVaPeXVeXkZ95dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKktr21MtmDbyHMcec6PO2fkk6jHzfUdeD/AAmp752/tXTv3E//AB/njzrjP/HrJx93Oe+euOMY5qW2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnAr6kya5Fo/h7ru/Iyba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDVpL213S/6PJ/rE/5g85/5bMPTjjjHcfL1FFqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk1cRjul/dTf6xP+Ws3/AD2b/Z/DnnPI+bIoVyqrV3o+nVdl5GLpc1la6XJDDaGOOP7aESPR5gqgTHaBgYGBwP7nQ80/W7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NW9PZvsFx+6mHz3/wDy1m/57t6r2754P8WDRrzN/YWp/upv+PS86yzev+72754P8WDS15TROPtlo/ifVd35BfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpWhfMStx+6mGZG6yzHH7n3X8eeccfd5qK+dv7V079xP8A8f54864z/wAesnH3c575644xjmm72MabVtn8L6rt6EFte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1rWzN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTinas39pS/upj/olj/y1m/56y/7Pftjgfw5NDvdFJx97R7Lqu/oCXtrul/0eT/WJ/wAwec/8tmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/z3bHOOCPX+Doea10Y7pf3U3+sT/lrN/wA9m/2fw55zyPmyKp6ezfYLj91MPnv/APlrN/z3b1Xt3zwf4sGjW4Jx5Xo911XZ+RU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DRVvXmb+wtT/AHU3/HpedZZvX/d7d88H+LBorCte6ufTcOtezna+/W3n2KtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0raz5T51P98vdXxPq+7C+uLwrcYi085kbGNWlfP7nHePn0z3Py9KjvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmtC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ptO25jTenwr4X1l2ILa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RqpbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzWvbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEU7WeQalKBeQjFpYjHnpxiWXA+526n077ulDTvuUn8XurZdX3BLi83S/utP/wBYn/MWlH/LZj/zz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4rWSeTdL/pkIzIh/16c/vmOfuevP0OeQcCnp88hsLgG8hOXvxjz0Ocztkfc79R69tvSizuCfuv3Vuur7Mqa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1bvbm92XIWPTzmRvu6tK+R5PvHzz39fl6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254680JO4J+6vdW8ur8jPvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmpLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rqe+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCBJ66kyfuL3V8PeXdmRbT3Qv5P3dhv8AstkCDqsgAxJJ/sdeuR/D1Gc1bS4vN0v7rT/9Yn/MWlH/AC2Y/wDPPnjnPYfN1NFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf8ATIRmRD/r05/fMc/c9efoc8g4Akyqr1furp1fZGTY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUmtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NW9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KVnymif75e6vifV92F9cXhW4xFp5zI2MatK+f3OO8fPpnufl6VHeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNaF9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNRX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzTadtzGm9PhXwvrLsQW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jVS2nuhfyfu7Df9lsgQdVkAGJJP9jr1yP4eozmte2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKGnfcpP4vdWy6vuCXF5ul/daf/AKxP+YtKP+WzH/nnzxznsPm6mqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxWsk8m6X/AEyEZkQ/69Of3zHP3PXn6HPIOBT0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRZ3BP3X7q3XV9mVNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat31xeFbjEWnnMjYxq0r5/c47x8+me5+XpRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0q5fTyMtxm8hfMjHidDn9zjPCDPHHbnjrzQk7gn7q91by6vyM+8uLn+1LAsmnj/AE4lcaxKQf8ARnHLeXwOvzdc/L05qS2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EanvrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmpbaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcggSeupMn7i91fD3l3ZkW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc1bS4vN0v7rT/wDWJ/zFpR/y2Y/88+eOc9h83U0Ws8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/0yEZkQ/69Of3zHP3PXn6HPIOAJMqq9X7q6dX2Rk2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVvT55DYXAN5CcvfjHnoc5nbI+536j17belGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSlZ8pon++Xur4n1fdhfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elR3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzWhfTyMtxm8hfMjHidDn9zjPCDPHHbnjrzUV9cy/wBq6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNNp23Mab0+FfC+suxBbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/wBlsgQdVkAGJJP9jr1yP4eozmte2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKGnfcpP4vdWy6vuCXF5ul/daf/rE/wCYtKP+WzH/AJ588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycVrJPJul/0yEZkQ/69Of3zHP3PXn6HPIOBT0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRZ3BP3X7q3XV9mVNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat31xeFbjEWnnMjYxq0r5/c47x8+me5+XpRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0q5fTyMtxm8hfMjHidDn9zjPCDPHHbnjrzQk7gn7q91by6vyM+8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGp765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qW2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIEnrqTJ+4vdXw95d2ZFtPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzVtLi83S/utP/1if8xaUf8ALZj/AM8+eOc9h83U0Ws8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/wBMhGZEP+vTn98xz9z15+hzyDgCTKqvV+6unV9kZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pWfKaJ/vl7q+J9X3YX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1oX08jLcZvIXzIx4nQ5/c4zwgzxx254681FfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNNp23Mab0+FfC+suxBbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOa17aeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0oad9yk/i91bLq+4JcXm6X91p/8ArE/5i0o/5bMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFayTybpf8ATIRmRD/r05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belFncE/dfurddX2ZU1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSrl9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNCTuCfur3VvLq/Iz7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmpLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rqe+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCBJ66kyfuL3V8PeXdmRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTRazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0q4k8m6X/TIRmRD/r05/fMc/c9efoc8g4Akyqr1furp1fZGTY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUmtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NW9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KVnymif75e6vifV92F9cXhW4xFp5zI2MatK+f3OO8fPpnufl6VHeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNaF9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNRX1zL/AGrp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM802nbcxpvT4V8L6y7EFtcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1Utp7oX8n7uw3/AGWyBB1WQAYkk/2OvXI/h6jOa17aeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0oad9yk/i91bLq+4JcXm6X91p/+sT/AJi0o/5bMf8AnnzxznsPm6mqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxWsk8m6X/TIRmRD/r05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belFncE/dfurddX2ZU1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upoq3r08h0LUx9shObS8GPPTnJ5H3O/Uevbb0orCstUfTcO/w56W17t9+55ZH418QJE8a6hhH83I8mPnzG3P8Aw9yc+3bFFx418QXFvLBNqG6KVJI3XyYxlZDlx93v/wDqoorLmfc9j6hhb39lH7l/kPm8deI5g4k1HIdizfuI+SU2H+H+7xQ/jnxFJPHM+o5kjl85T5EfD7DHn7v90kf/AF6KKHJ9xf2fhV/y6j/4Cv8AII/HXiONomTUcGJVVP3EfAUMB/D6M350xPGviBH3rqGGMcUefJj+7GSyD7vYsfrnmiijmfcf1DC/8+o/+Ar/ACHjx14jBYjUeWYMf3EfUMXH8P8AeJNMj8a+IEieNdQwj+bkeTHz5jbn/h7k59u2KKKOZ9w+oYX/AJ9R/wDAV/kFx418QXFvLBNqG6KVJI3XyYxlZDlx93v/APqp83jrxHMHEmo5DsWb9xHySmw/w/3eKKKOZ9w+oYX/AJ9R/wDAV/kD+OfEUk8cz6jmSOXzlPkR8PsMefu/3SR/9eiPx14jjaJk1HBiVVT9xHwFDAfw+jN+dFFCk+4v7Pwtreyj/wCAr/IYnjXxAj711DDGOKPPkx/djJZB93sWP1zzTx468RgsRqPLMGP7iPqGLj+H+8SaKKOZ9xvAYV70o/8AgK/yGR+NfECRPGuoYR/NyPJj58xtz/w9yc+3bFFx418QXFvLBNqG6KVJI3XyYxlZDlx93v8A/qooo5n3D6hhb39lH7l/kPm8deI5g4k1HIdizfuI+SU2H+H+7xQ/jnxFJPHM+o5kjl85T5EfD7DHn7v90kf/AF6KKHJ9xf2fhV/y6j/4Cv8AII/HXiONomTUcGJVVP3EfAUMB/D6M350xPGviBH3rqGGMcUefJj+7GSyD7vYsfrnmiijmfcf1DC/8+o/+Ar/ACHjx14jBYjUeWYMf3EfUMXH8P8AeJNMj8a+IEieNdQwj+bkeTHz5jbn/h7k59u2KKKOZ9w+oYX/AJ9R/wDAV/kFx418QXFvLBNqG6KVJI3XyYxlZDlx93v/APqp83jrxHMHEmo5DsWb9xHySmw/w/3eKKKOZ9w+oYX/AJ9R/wDAV/kD+OfEUk8cz6jmSOXzlPkR8PsMefu/3SR/9eiPx14jjaJk1HBiVVT9xHwFDAfw+jN+dFFCk+4v7Pwtreyj/wCAr/IYnjXxAj711DDGOKPPkx/djJZB93sWP1zzTx468RgsRqPLMGP7iPqGLj+H+8SaKKOZ9xvAYV70o/8AgK/yGR+NfECRPGuoYR/NyPJj58xtz/w9yc+3bFFx418QXFvLBNqG6KVJI3XyYxlZDlx93v8A/qooo5n3D6hhb39lH7l/kPm8deI5g4k1HIdizfuI+SU2H+H+7xQ/jnxFJPHM+o5kjl85T5EfD7DHn7v90kf/AF6KKHJ9xf2fhV/y6j/4Cv8AII/HXiONomTUcGJVVP3EfAUMB/D6M350xPGviBH3rqGGMcUefJj+7GSyD7vYsfrnmiijmfcf1DC/8+o/+Ar/ACHjx14jBYjUeWYMf3EfUMXH8P8AeJNMj8a+IEieNdQwj+bkeTHz5jbn/h7k59u2KKKOZ9w+oYX/AJ9R/wDAV/kFx418QXFvLBNqG6KVJI3XyYxlZDlx93v/APqp83jrxHMHEmo5DsWb9xHySmw/w/3eKKKOZ9w+oYX/AJ9R/wDAV/kD+OfEUk8cz6jmSOXzlPkR8PsMefu/3SR/9eiPx14jjaJk1HBiVVT9xHwFDAfw+jN+dFFCk+4v7Pwtreyj/wCAr/IYnjXxAj711DDGOKPPkx/djJZB93sWP1zzTx468RgsRqPLMGP7iPqGLj+H+8SaKKOZ9xvAYV70o/8AgK/yGR+NfECRPGuoYR/NyPJj58xtz/w9yc+3bFFx418QXFvLBNqG6KVJI3XyYxlZDlx93v8A/qooo5n3D6hhb39lH7l/kPm8deI5g4k1HIdizfuI+SU2H+H+7xQ/jnxFJPHM+o5kjl85T5EfD7DHn7v90kf/AF6KKHJ9xf2fhV/y6j/4Cv8AII/HXiONomTUcGJVVP3EfAUMB/D6M350xPGviBH3rqGGMcUefJj+7GSyD7vYsfrnmiijmfcf1DC/8+o/+Ar/ACHjx14jBYjUeWYMf3EfUMXH8P8AeJNMj8a+IEieNdQwj+bkeTHz5jbn/h7k59u2KKKOZ9w+oYX/AJ9R/wDAV/kFx418QXFvLBNqG6KVJI3XyYxlZDlx93v/APqp83jrxHMHEmo5DsWb9xHySmw/w/3eKKKOZ9w+oYX/AJ9R/wDAV/kD+OfEUk8cz6jmSOXzlPkR8PsMefu/3SR/9eiPx14jjaJk1HBiVVT9xHwFDAfw+jN+dFFCk+4v7Pwtreyj/wCAr/IYnjXxAj711DDGOKPPkx/djJZB93sWP1zzTx468RgsRqPLMGP7iPqGLj+H+8SaKKOZ9xvAYV70o/8AgK/yGR+NfECRPGuoYR/NyPJj58xtz/w9yc+3bFFx418QXFvLBNqG6KVJI3XyYxlZDlx93v8A/qooo5n3D6hhb39lH7l/kPm8deI5g4k1HIdizfuI+SU2H+H+7xQ/jnxFJPHM+o5kjl85T5EfD7DHn7v90kf/AF6KKHJ9xf2fhV/y6j/4Cv8AII/HXiONomTUcGJVVP3EfAUMB/D6M350xPGviBH3rqGGMcUefJj+7GSyD7vYsfrnmiijmfcf1DC/8+o/+Ar/ACHjx14jBYjUeWYMf3EfUMXH8P8AeJNMj8a+IEieNdQwj+bkeTHz5jbn/h7k59u2KKKOZ9w+oYX/AJ9R/wDAV/kFx418QXFvLBNqG6KVJI3XyYxlZDlx93v/APqooopNt7m1KhSoq1KKjfskj//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram showing multifocal atrial tachycardia in a woman with severe pulmonary disease. The diagnostic criteria include an average atrial rate above 100 beats/min and at least three different consecutive non-sinus P waves in the same lead. Note the multiple P wave morphologies - inverted (I), upright (U), and biphasic (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39922=[""].join("\n");
var outline_f38_63_39922=null;
var title_f38_63_39923="Eptifibatide: Patient drug information";
var content_f38_63_39923=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Eptifibatide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     see \"Eptifibatide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Integrilin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Integrilin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during a heart treatment to protect the arteries.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the number of heart attacks in patients who have unstable angina or mild heart attacks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702037",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to eptifibatide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems, low platelet count, on dialysis, recent surgery, stroke, or very high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fall or crash when you hit your head. Talk with your doctor even if you feel fine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11943 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39923=[""].join("\n");
var outline_f38_63_39923=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166052\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166053\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014315\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014314\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014319\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014320\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014322\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014317\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014318\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014323\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014324\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=related_link\">",
"      Eptifibatide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_63_39924="Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients";
var content_f38_63_39924=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39924/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39924/contributors\">",
"     John W Baddley, MD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39924/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39924/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39924/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39924/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/63/39924/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acquired immunodeficiency syndrome (AIDS) are susceptible to both infection and to disseminated disease from the endemic fungi, which are localized to specific geographic regions. The endemic mycoses (ie, Histoplasma capsulatum, Coccidioides immitis, and Blastomyces dermatitidis) are a diverse group of fungi that occupy a specific niche in the environment and cause infections in healthy and immunocompromised hosts, particularly those with T-cell immune deficiencies.",
"   </p>",
"   <p>",
"    Histoplasmosis is an important infectious disease among patients with advanced AIDS and continues to cause severe morbidity and mortality in endemic areas, particularly in resource-limited settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/1\">",
"     1",
"    </a>",
"    ]. Histoplasmosis is the AIDS-defining illness in up to 50 percent of affected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. In resource-rich settings, disseminated disease usually occurs in patients who are not taking antiretroviral therapy at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology and clinical manifestations of histoplasmosis will be reviewed here. The diagnosis and treatment of histoplasmosis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1449?source=see_link\">",
"     \"Diagnosis and treatment of histoplasmosis in HIV-infected patients\"",
"    </a>",
"    .) The other major endemic fungi (ie, Coccidioides immitis and Blastomyces dermatitidis) are discussed in separate topics.",
"   </p>",
"   <p>",
"    An overview of the use of prophylactic antifungal agents in patients with AIDS is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasmosis is found in temperate zones worldwide; specific endemic areas include the Mississippi, Ohio, and St. Lawrence River valleys, the Caribbean, southern Mexico, and certain parts of Central and South America, Africa, and Asia. In these regions, the fungus is found in high concentrations in soil contaminated with bird or bat excreta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/8\">",
"     8",
"    </a>",
"    ]. Transmission occurs via inhalation of H. capsulatum spores from the soil.",
"   </p>",
"   <p>",
"    Histoplasmosis is the most common endemic mycosis in AIDS patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In the early HIV epidemic, histoplasmosis occurred in 5 to 27 percent of patients with AIDS living in endemic areas of the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/11\">",
"     11",
"    </a>",
"    ]. Most of these cases were caused by exogenous exposure, with progressive disseminated disease occurring shortly after initial infection. Disseminated infection has also been described in patients who were living outside of endemic areas; these cases probably represent endogenous reactivation of latent foci of infection acquired from previous travel or residence in areas of risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/7\">",
"     7",
"    </a>",
"    ]. Infection may be acquired through a multitude of activities (eg, construction, spelunking, bird handling), which may lead to inhalation of the pathogen through contaminated soil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. capsulatum acts as an opportunistic pathogen, causing disseminated disease in patients with AIDS and in hosts with impaired cellular immunity. Histoplasmosis generally occurs late in the course of HIV infection, when CD4 lymphocyte counts are below 100",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    importance of cellular immunity was demonstrated in one study of T-cell proliferative responses to histoplasma antigens; in vitro data showed that T-cell proliferative responses were depressed in HIV-infected patients with a history of histoplasmosis and CD4 counts ranging from 200 to 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    compared with HIV-seronegative controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endemic fungi are thermally dimorphic; they exist as moulds in the environment, and as yeasts at body temperatures. Microscopically, Histoplasma capsulatum has hyaline, septate hyphae, with spherical, thick-walled conidia and smaller microconidia (",
"    <a class=\"graphic graphic_picture graphicRef68444 \" href=\"mobipreview.htm?30/44/31427\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the immunocompetent host, histoplasmosis can present as a mild self-limiting pulmonary illness. However, patients with advanced AIDS usually develop progressive disseminated histoplasmosis (PDH), a febrile, wasting illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common symptoms include fever, night sweats, fatigue, weight loss, nausea, vomiting, and dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/3-5,11,14\">",
"     3-5,11,14",
"    </a>",
"    ]. Physical examination may demonstrate hepatosplenomegaly and adenopathy. Skin and mucosal lesions can occur (",
"    <a class=\"graphic graphic_picture graphicRef78902 \" href=\"mobipreview.htm?41/9/42132\">",
"     picture 2",
"    </a>",
"    ), although cutaneous lesions appear to be more common in Brazil than in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. These variant clinical manifestations may be related to genetic differences in the causative organisms from the respective geographic locations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 40 to 50 percent of AIDS patients with PDH have pulmonary involvement. Cough and dyspnea are common, although such patients may rarely be asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/11\">",
"     11",
"    </a>",
"    ]. Isolated pulmonary involvement without dissemination occurs in less than 5 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characteristics of severe disease include a sepsis-like syndrome with multi-organ failure (including respiratory or renal failure) or concomitant meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/3,4,11,14\">",
"     3,4,11,14",
"    </a>",
"    ]. Mortality can be as high as 50 percent in patients with AIDS, despite appropriate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancytopenia secondary to bone marrow involvement with histoplasmosis is highly prevalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/5\">",
"     5",
"    </a>",
"    ]. Elevated aminotransferases, lactate dehydrogenase, and ferritin are commonly seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/1\">",
"     1",
"    </a>",
"    ]. Elevation of creatinine is a poor prognostic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1449?source=see_link\">",
"     \"Diagnosis and treatment of histoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histoplasmosis usually occurs in patients with untreated advanced AIDS, so the CD4 cell count is typically less than 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and HIV RNA levels are usually high due to lack of antiretroviral therapy (ART) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographic abnormalities have been reported in 50 to 70 percent of patients with disseminated infection, although the initial x-ray may be normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/3\">",
"     3",
"    </a>",
"    ]. The most common radiographic findings are diffuse interstitial or reticulonodular infiltrates, which can be misdiagnosed as pneumocystosis or tuberculosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79439 \" href=\"mobipreview.htm?15/35/15935\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/7\">",
"     7",
"    </a>",
"    ]. &nbsp;Focal infiltrates are rare. Other findings include pleural effusions, mediastinal adenopathy, cavitary disease, and calcified granulomas; however, the initial x-ray is frequently normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39924/abstract/3,11\">",
"     3,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progression to an acute respiratory distress syndrome-like disease may also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/5/13393?source=see_link\">",
"       \"Patient information: Histoplasmosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histoplasmosis is an important cause of morbidity and mortality in patients living in endemic areas who are not taking antiretroviral therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transmission of Histoplasma occurs via inhalation of spores from the soil of endemic areas, which can lead to acute infection; in contrast, some patients develop disease many years after travel to an endemic area, consistent with reactivation of latent foci. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AIDS patients with histoplasmosis usually develop progressive disseminated histoplasmosis (PDH), a febrile, wasting illness, characterized by fever, night sweats, and weight loss. Physical examination is notable for hepatosplenomegaly and adenopathy. Supportive laboratory data include pancytopenia and elevated lactate dehydrogenase. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common radiographic abnormalities are diffuse interstitial or reticulonodular infiltrates. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Radiographic manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/1\">",
"      Mora DJ, dos Santos CT, Silva-Vergara ML. Disseminated histoplasmosis in acquired immunodeficiency syndrome patients in Uberaba, MG, Brazil. Mycoses 2008; 51:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/2\">",
"      Nightingale SD, Parks JM, Pounders SM, et al. Disseminated histoplasmosis in patients with AIDS. South Med J 1990; 83:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/3\">",
"      Sarosi GA, Johnson PC. Disseminated histoplasmosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1992; 14 Suppl 1:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/4\">",
"      Johnson PC, Khardori N, Najjar AF, et al. Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/5\">",
"      Baddley JW, Sankara IR, Rodriquez JM, et al. Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy. Diagn Microbiol Infect Dis 2008; 62:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/6\">",
"      Couppi&eacute; P, Aznar C, Carme B, Nacher M. American histoplasmosis in developing countries with a special focus on patients with HIV: diagnosis, treatment, and prognosis. Curr Opin Infect Dis 2006; 19:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/7\">",
"      Antinori S, Magni C, Nebuloni M, et al. Histoplasmosis among human immunodeficiency virus-infected people in Europe: report of 4 cases and review of the literature. Medicine (Baltimore) 2006; 85:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/8\">",
"      Murray JF, Mills J. Pulmonary infectious complications of human immunodeficiency virus infection. Part II. Am Rev Respir Dis 1990; 141:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/9\">",
"      Wheat LJ, Chetchotisakd P, Williams B, et al. Factors associated with severe manifestations of histoplasmosis in AIDS. Clin Infect Dis 2000; 30:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/10\">",
"      Hage CA, Wheat LJ, Loyd J, et al. Pulmonary histoplasmosis. Semin Respir Crit Care Med 2008; 29:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/11\">",
"      Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990; 69:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/12\">",
"      Hajjeh RA. Disseminated histoplasmosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 1:S108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/13\">",
"      Vail GM, Mocherla S, Wheat LJ, et al. Cellular immune response in HIV-infected patients with histoplasmosis. J Acquir Immune Defic Syndr 2002; 29:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/14\">",
"      Wheat LJ, Slama TG, Zeckel ML. Histoplasmosis in the acquired immune deficiency syndrome. Am J Med 1985; 78:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39924/abstract/15\">",
"      Karimi K, Wheat LJ, Connolly P, et al. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. J Infect Dis 2002; 186:1655.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6991 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39924=[""].join("\n");
var outline_f38_63_39924=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RADIOGRAPHIC MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/6991\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6991|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/35/15935\" title=\"diagnostic image 1\">",
"      Histo in AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6991|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/44/31427\" title=\"picture 1\">",
"      Histoplasma from culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/9/42132\" title=\"picture 2\">",
"      Disseminated histoplasmosis - papules",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1449?source=related_link\">",
"      Diagnosis and treatment of histoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/5/13393?source=related_link\">",
"      Patient information: Histoplasmosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_63_39925="Asthma treatment in adolescents and adults";
var content_f38_63_39925=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/63/39925/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39925/contributors\" id=\"au677\">",
"       Christopher H Fanta, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/63/39925/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39925/contributors\" id=\"se560\">",
"       Bruce S Bochner, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/63/39925/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39925/contributors\" id=\"de1810\">",
"       Helen Hollingsworth, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/63/39925?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ASTHMA TREATMENT OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Asthma is a common lung disease affecting millions of people worldwide. It is caused by narrowing of the airways (breathing tubes) in the lungs. This narrowing is partially or completely reversible. Symptoms of asthma include wheezing, coughing, chest tightness, and shortness of breath. These symptoms tend to come and go, and are related to the degree of airway narrowing in the lungs. The airways are sensitive to a variety of stimuli, which may include viral illnesses (eg, the common cold), allergens, exercise, medicines, or environmental conditions.",
"    </p>",
"    <p>",
"     Asthma can usually be treated successfully. This requires being well informed about the disease and being an active player in managing it.",
"    </p>",
"    <p>",
"     This topic will review asthma treatment in adolescents and adults (adolescents defined as children 12 years and older). Other topics about asthma are also available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=see_link\">",
"      \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/20/14660?source=see_link\">",
"      \"Patient information: Asthma and pregnancy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/26/1442?source=see_link\">",
"      \"Patient information: Exercise-induced asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Topics about asthma in children are also available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/0/37892?source=see_link\">",
"      \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=see_link\">",
"      \"Patient information: Asthma treatment in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=see_link\">",
"      \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CONTROLLING ASTHMA TRIGGERS",
"     </span>",
"    </p>",
"    <p>",
"     The factors that set off and worsen asthma symptoms are called \"triggers.\" Identifying and avoiding asthma triggers are essential steps in preventing asthma flare-ups. Common asthma triggers generally fall into several categories:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Allergens (including dust, pollen, and furred animals)",
"      </li>",
"      <li>",
"       Respiratory infections",
"      </li>",
"      <li>",
"       Irritants (such as tobacco smoke or chemicals)",
"      </li>",
"      <li>",
"       Physical activity",
"      </li>",
"      <li>",
"       Certain medicines, known as beta blockers",
"      </li>",
"      <li>",
"       Emotional stress",
"      </li>",
"      <li>",
"       Menstrual cycle in some women",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A small number of patients will develop asthmatic symptoms after exposure to aspirin or other nonsteroidal antiinflammatory medications, like ibuprofen or naproxen. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=see_link\">",
"      \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=see_link\">",
"      \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     After identifying potential asthma triggers, you and your clinician should develop a plan to deal with the triggers. There are three main options:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid the trigger entirely (eg, if allergic to animals, do not own pets, if sensitive to aspirin or related medications, avoid all forms of these medications).",
"      </li>",
"      <li>",
"       Limit exposure to the asthma trigger if it cannot be completely avoided (eg, move to another seat if someone with strong perfume is seated nearby, have someone else do house cleaning if allergic to dust mites).",
"      </li>",
"      <li>",
"       Take an extra dose of bronchodilator medication before exposure to an asthma trigger. Talk with a healthcare provider before using this approach; it should only be used if the first two options are not possible. Be careful not to use more than twice the amount of medication normally used.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Special approaches to unavoidable allergic triggers include allergy desensitization injections (&ldquo;allergy shots&rdquo;) and an injected medication targeting allergy proteins in the blood (anti-immunoglobulin E antibody, called omalizumab).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      MONITORING SYMPTOMS AND LUNG FUNCTION",
"     </span>",
"    </p>",
"    <p>",
"     Successful asthma treatment relies on your ability to monitor your condition over time. This is done by recording the frequency and severity of symptoms (such as wheezing, coughing, and shortness of breath) and by measuring lung function with a peak flow meter",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Asthma diary",
"     </span>",
"     &nbsp;&mdash;&nbsp;A healthcare provider may recommend keeping a daily asthma diary when symptoms are not well controlled or when starting a new treatment. In the diary, your peak flow readings, asthma symptoms (eg, coughing, wheezing), and medications are recorded (",
"     <a class=\"graphic graphic_figure graphicRef74684 \" href=\"mobipreview.htm?4/25/4498\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     A periodic diary may be recommended if you have stable symptoms and your medications have not changed recently. This type of diary can be completed before visiting the healthcare provider and helps you and your healthcare provider to determine whether the asthma treatment plan needs to be adjusted (",
"     <a class=\"graphic graphic_form graphicRef54723 \" href=\"mobipreview.htm?14/58/15266\">",
"      form 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Peak expiratory flow (PEF)",
"     </span>",
"     &nbsp;&mdash;&nbsp;PEF measures the rate at which you can exhale. This rate is dependent on the degree of airway narrowing. PEF monitoring can be used to monitor your lung function and response to treatment, assess the severity of asthma attacks, and guide decisions regarding treatment.",
"    </p>",
"    <p>",
"     Peak flow meters are inexpensive and easy to use. Adults with persistent asthma may, at times, use a peak flow meter once or twice daily to monitor their lung function. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=see_link\">",
"      \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Review of treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Adolescents and adults with asthma are usually seen by their healthcare provider once or twice a year if their asthma is well-controlled or more often if their asthma is not well-controlled. At these visits, the healthcare provider will evaluate the severity and frequency of your asthma symptoms and response to treatment. If your asthma control has been adequate for at least three months, your medication dose may be decreased. If control is not adequate, your medication schedule, delivery technique, and trigger avoidance will be reviewed, and your medication dose may be increased.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      CATEGORIES OF ASTHMA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The medications used for asthma treatment vary according to your age, the severity of asthma, and the level of symptom control. The asthma treatment plan must be reviewed and adjusted on a regular basis. If symptoms are well controlled, medication can often be reduced. As symptoms worsen, medication should be increased.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Intermittent asthma",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with intermittent asthma are defined as those who have the following characteristics (see",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18154?source=see_link\">",
"      \"Treatment of intermittent and mild persistent asthma in adolescents and adults\"",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Symptoms of asthma occur two or fewer days per week",
"      </li>",
"      <li>",
"       Asthma does not interfere with daily activities",
"      </li>",
"      <li>",
"       Nighttime symptoms awaken you two or fewer nights per month",
"      </li>",
"      <li>",
"       Oral steroid treatment (eg, prednisone) is needed no more than once per year to treat increased asthma symptoms",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If your asthma is triggered only by vigorous exercise (exercise-induced bronchoconstriction), you might fit into this category, even if you have episodes of asthma with exercise more than twice per week. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/26/1442?source=see_link\">",
"      \"Patient information: Exercise-induced asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Persistent asthma",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with persistent asthma have symptoms regularly. There may be days when your activities are limited due to symptoms, and you may be awakened from sleep.",
"    </p>",
"    <p>",
"     Based on how frequently you have symptoms and the severity of your asthma flares, the clinician will determine whether your persistent asthma is mild, moderate, or severe. Treatment plans will vary based upon the severity of your asthma, as well as your level of symptom control. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26745?source=see_link\">",
"      \"Treatment of moderate persistent asthma in adolescents and adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The symptoms that are used to determine your asthma severity include the number of days per week that you have one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Symptoms such as cough, wheeze, and shortness of breath",
"      </li>",
"      <li>",
"       Nighttime symptoms that awaken you from sleep",
"      </li>",
"      <li>",
"       Symptoms that need treatment with a bronchodilator (reliever medication)",
"      </li>",
"      <li>",
"       Symptoms that affect your ability to participate in normal activities",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      ASTHMA RELIEVER MEDICATIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Bronchodilators",
"     </span>",
"     &nbsp;&mdash;&nbsp;Short-acting bronchodilators (usually beta-2 agonists) relieve asthma symptoms rapidly, by temporarily relaxing the muscles around narrowed airways. In the United States, albuterol (Ventolin&reg;, Proventil&reg;, and ProAir&reg; plus generic albuterol) is the most commonly used short-acting bronchodilator. These medications are sometimes referred to as \"quick-acting relievers.\" People with intermittent asthma, the mildest form of asthma, will require these symptom-relieving medications only occasionally.",
"    </p>",
"    <p>",
"     The preferred way of taking medication for mild intermittent asthma is by inhalation with a metered dose inhaler. This method allows the medication to take effect rapidly with maximum strength and minimal side effects. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     There is no benefit to using short-acting bronchodilators on a regular basis. If your asthma symptoms are consistently occurring more than two days per week, you should review your treatment plan with a healthcare provider. Other medications are more effective for persistent symptoms in this situation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Side effects of bronchodilators",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people feel shaky, have a rapid heart rate,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     feel anxious after using an inhaled short-acting bronchodilator. Using a single puff rather than the usual two puffs may limit these side effects and only minimally decrease their benefit. In addition, these side effects usually become less noticeable over time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      ASTHMA CONTROLLER MEDICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     People with persistent asthma need to take medication on a daily basis to keep their asthma under control, even if there are no symptoms of active asthma on a given day. Medications taken daily for asthma are called \"long-term controller\" medicines.",
"    </p>",
"    <p>",
"     Some controller medicines are delivered by inhaler, while others are taken as a tablet. The doses and types of controller medications prescribed depend upon your asthma severity and level of symptom control.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Inhaled steroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Inhaled steroids (also known as glucocorticoids) act to decrease inflammation (swelling) of the airways over time. The steroids used to treat asthma are different from the ones athletes take to build muscle. Regular treatment with an inhaled steroid reduces the frequency of symptoms (and the need for inhaled bronchodilators for symptom relief), improves quality of life, and decreases the risk of serious attacks.",
"    </p>",
"    <p>",
"     A number of inhaled steroid medications are available, most of which are taken once or twice a day. An inhaled bronchodilator is still used as needed for relief of symptoms and before exposure to asthma triggers. There is no need to take the inhaled bronchodilator before each daily dose of inhaled steroid.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Side effects of inhaled steroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Unlike steroids that are taken as tablet or liquid by mouth, very little of the inhaled steroid is absorbed into the bloodstream, and there are few side effects. However, as the dose of inhaled steroid is increased, more of the medication is absorbed into the bloodstream, and the risk of side effects increases.",
"    </p>",
"    <p>",
"     The most common side effect of",
"     <strong>",
"      low-dose",
"     </strong>",
"     inhaled steroid is oral candidiasis (thrush). This can usually be prevented by taking inhaled steroids from a metered dose inhaler with a spacer (which helps to deliver medication to the lungs, rather than the mouth) (",
"     <a class=\"graphic graphic_picture graphicRef56533 \" href=\"mobipreview.htm?21/27/21951\">",
"      picture 1",
"     </a>",
"     ). You should rinse your mouth or brush your teeth and tongue immediately after inhalation. A hoarse voice and sore throat (without thrush) are less common side effects that are usually managed by changing to a different inhaled steroid preparation.",
"    </p>",
"    <p>",
"     Rare but possible side effects of long-term",
"     <strong>",
"      high-dose",
"     </strong>",
"     inhaled steroid treatments, besides oral candidiasis, include cataracts, increased pressure in the eye (glaucoma), easy bruising of the skin, and increased bone loss (osteoporosis).",
"    </p>",
"    <p>",
"     The risk of these complications is far less with inhaled glucocorticoids compared with oral glucocorticoids (eg, prednisone). Nevertheless, every effort should be made to use the lowest possible dose that controls asthma and minimizes the risk of an asthma attack.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Long-acting bronchodilators",
"     </span>",
"     &nbsp;&mdash;&nbsp;A long-acting inhaled bronchodilator is often recommended, in combination with an inhaled steroid, for adults with persistent asthma. Long-acting bronchodilators (salmeterol, formoterol) are recommended because they work for a longer period than short-acting bronchodilators (for 12 or more hours). A device that contains both an inhaled steroid and a long-acting bronchodilator is usually preferred (Advair&reg;, Symbicort&reg;, Seretide&reg; in Europe, and Dulera&reg;). A short-acting bronchodilator is still used as needed for immediate relief of asthma symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Cromolyn and nedocromil",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cromolyn (Intal&reg;) and nedocromil may be recommended as an alternative to low-dose inhaled glucocorticoids; however, only the cromolyn nebulizer solution is available in the United States. These medicines work by decreasing the activity of allergy cells. They are generally less effective than inhaled glucocorticoids. They are also less convenient because they must be used three or four times daily.",
"    </p>",
"    <p>",
"     Cromolyn can be used to prevent symptoms before exposure to an asthma trigger or before exercising. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/26/1442?source=see_link\">",
"      \"Patient information: Exercise-induced asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Leukotriene modifiers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Leukotriene modifiers, such as montelukast (Singulair&reg;), zafirlukast (Accolate&reg;), or zileuton (Zyflo&reg;) are an alternative to inhaled glucocorticoids. Leukotriene modifiers work by opening narrowed airways, decreasing inflammation, and decreasing mucus production. They are taken by mouth as a pill once or twice daily and have very few side effects. Mood alteration and depression are rare side effects. However, compared with inhaled glucocorticoids, leukotriene modifiers are generally somewhat less effective in controlling asthma.",
"    </p>",
"    <p>",
"     Leukotriene modifiers can be used to prevent symptoms before exposure to a trigger or before exercising. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/26/1442?source=see_link\">",
"      \"Patient information: Exercise-induced asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Oral steroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;If symptoms are not controlled with the above medications, an oral steroid (eg, prednisone) may be added to the treatment regimen. Steroids used to treat asthma are in a class called glucocorticoids and are different from the ones athletes take to build muscle. Most healthcare providers recommend a 5 to 10 day course of oral glucocorticoids for flares of asthma.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      EXERCISE-INDUCED ASTHMA",
"     </span>",
"    </p>",
"    <p>",
"     If exercise is a trigger for asthma, an extra dose of bronchodilator medication, leukotriene modifier, or cromolyn taken before exercise can be used to prevent asthma symptoms. A topic review that discusses exercise-induced asthma is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/26/1442?source=see_link\">",
"      \"Patient information: Exercise-induced asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      ASTHMA IN PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     Asthma is the most common chronic medical condition that affects the lungs during pregnancy. About 4 percent of pregnant women have asthma. With good asthma treatment during pregnancy, most women can breathe easily, have a normal pregnancy, and give birth to a healthy baby. It is essential to keep asthma well controlled during pregnancy to ensure that optimal levels of oxygen reach the baby.",
"    </p>",
"    <p>",
"     Before becoming pregnant, women with asthma should learn as much as they can about the condition and talk with their healthcare providers about asthma treatment during pregnancy. More information about asthma during pregnancy is presented separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/20/14660?source=see_link\">",
"      \"Patient information: Asthma and pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      ASTHMA ATTACK TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The term \"asthma attack\" is somewhat confusing because it does not distinguish between a mild increase in symptoms and a life-threatening episode. Symptoms may be aggravated by changes in air quality, the common cold, exercise, exposure to allergens, or changes in the weather. These triggers can cause mild, moderate, or severe symptoms to develop. Any of these changes could be considered an asthma \"attack.\"",
"    </p>",
"    <p>",
"     Some people have periodic, mild asthma attacks that never require emergency care, while others have severe and sudden asthma attacks that require a call for emergency medical services.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Asthma action plan",
"     </span>",
"     &nbsp;&mdash;&nbsp;You should work with your healthcare provider to develop personalized directions (also called an asthma action plan) to follow when symptoms increase or your peak flow begins to decrease. Asthma action plans for adolescents and adults and school asthma action plans are available (",
"     <a class=\"graphic graphic_form graphicRef53142 \" href=\"mobipreview.htm?36/38/37482\">",
"      form 2",
"     </a>",
"     and",
"     <a class=\"graphic graphic_form graphicRef59053 graphicRef71869 graphicRef51794 \" href=\"mobipreview.htm?43/42/44714\">",
"      form 3A-C",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Peak expiratory flow rates can be divided into three zones, which are assigned colors similar to those of a traffic light. These zones can be used to make decisions about the need for treatment:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      Green",
"     </span>",
"     &nbsp;&mdash;&nbsp;Green signals that the lungs are functioning well. When symptoms are not present or are well controlled, you should continue your regular medicines and activities.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Yellow",
"     </span>",
"     &nbsp;&mdash;&nbsp;Yellow is a sign that the airways in the lungs are somewhat narrowed, making it difficult to move air in and out; asthma symptoms may be more frequent or more severe. A short-term change or increase in medication is generally required. You should change or increase your medication according to the plan that was discussed with your provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h3\">",
"      Red",
"     </span>",
"     &nbsp;&mdash;&nbsp;Red is a sign that the airways are severely narrowed and require immediate treatment. Symptoms are usually more severe and frequent. In addition to using 2 to 4 puffs of the quick-acting reliever inhaler (eg, albuterol), steroid tablets are often required to bring relief, according to the plan discussed with your provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Emergency care plan",
"     </span>",
"     &nbsp;&mdash;&nbsp;You should work with your healthcare provider to formulate an emergency care plan that explains exactly what to do if symptoms worsen. This may include more frequent use of a reliever medication (eg, albuterol) and starting or increasing the dose of a long-term controller medication (eg, prednisone).",
"    </p>",
"    <p>",
"     However, if symptoms are severe and worsen or do not improve after use of a quick-acting reliever medication, someone should immediately call for emergency medical assistance. Severe asthma attacks can be fatal if not treated promptly. In most areas of the United States, emergency medical assistance is available by calling 911. You should",
"     <strong>",
"      not",
"     </strong>",
"     attempt to drive yourself to the hospital, and you should not ask someone else to drive. Calling 911 is safer than driving for two reasons:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       From the moment EMS personnel arrive, they can begin evaluating and treating your asthma. When driving in a car, treatment cannot begin until you arrive in the emergency department.",
"      </li>",
"      <li>",
"       If a dangerous complication of asthma occurs on the way to the hospital, EMS personnel may be able to treat the problem immediately.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Following an asthma attack, most people are given a 5 to 10 day course of an oral steroid medication (eg, prednisone). This treatment helps to reduce the risk of a second asthma attack.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Wear medical identification",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with medical conditions wear a bracelet, necklace, or similar alert tag at all times. If an accident occurs and you cannot explain your condition, the identification will help responders provide appropriate care.",
"    </p>",
"    <p>",
"     The alert tag should include a list of major medical conditions and allergies, as well as the name and phone number of an emergency contact. One device, Medic Alert&reg; (",
"     <a class=\"external\" href=\"file://www.medicalert.com/\">",
"      www.medicalert.com",
"     </a>",
"     ), provides a toll-free number that emergency medical workers can call to find out a person's medical history, list of medications, family emergency contact numbers, and healthcare provider names and numbers.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H29\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H291\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21386774\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/11/4275?source=see_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/2/16419?source=see_link\">",
"      Patient information: Avoiding asthma triggers (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/34/41506?source=see_link\">",
"      Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/47/9970?source=see_link\">",
"      Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/22/30052?source=see_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/21/18770?source=see_link\">",
"      Patient information: Asthma and pregnancy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21386782\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=see_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/20/14660?source=see_link\">",
"      Patient information: Asthma and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/26/1442?source=see_link\">",
"      Patient information: Exercise-induced asthma (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/0/37892?source=see_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=see_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=see_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=see_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=see_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=see_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"      An overview of asthma management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14105?source=see_link\">",
"      Evaluation of severe asthma in adolescents and adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13735?source=see_link\">",
"      Identifying patients at risk for fatal asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7383?source=see_link\">",
"      Natural history of asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36278?source=see_link\">",
"      Severe asthma: Evidence for heterogeneity of the disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/56/5002?source=see_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18154?source=see_link\">",
"      Treatment of intermittent and mild persistent asthma in adolescents and adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26745?source=see_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3354?source=see_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungusa.org/\">",
"      www.lungusa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Allergy, Asthma, and Immunology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aaaai.org/patients.stm\">",
"      www.aaaai.org/patients.stm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American College of Allergy, Asthma, and Immunology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acaai.org/allergist/Pages/default.aspx\">",
"      www.acaai.org/allergist",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/63/39925/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18236310\">",
"     <span class=\"h1\">",
"      ACKNOWLEDGMENT",
"     </span>",
"    </p>",
"    <p>",
"     The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Suzanne Fletcher, who contributed to an earlier version of this topic review.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/63/39925?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39925/abstract/1\">",
"      Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998; 351:1225.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 01, 2007).",
"    </li>",
"    <li>",
"     Fanta CH, Haver KH, Cristiano LM. Harvard Medical School guide to taking control of asthma, Free Press (Simon &amp; Schuster), New York 2004.",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f38_63_39925=[""].join("\n");
var outline_f38_63_39925=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ASTHMA TREATMENT OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CONTROLLING ASTHMA TRIGGERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           MONITORING SYMPTOMS AND LUNG FUNCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           CATEGORIES OF ASTHMA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           ASTHMA RELIEVER MEDICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           ASTHMA CONTROLLER MEDICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           EXERCISE-INDUCED ASTHMA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           ASTHMA IN PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           ASTHMA ATTACK TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H29\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18236310\">",
"           ACKNOWLEDGMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/25/4498\" title=\"figure 1\">",
"           Asthma daily diary PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          FORMS",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"mobipreview.htm?14/58/15266\" title=\"form 1\">",
"           Asthma self assess PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"mobipreview.htm?36/38/37482\" title=\"form 2\">",
"           Asthma action plan PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"mobipreview.htm?28/14/28905\" title=\"form 3A\">",
"           School action plan A",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"mobipreview.htm?38/31/39416\" title=\"form 3B\">",
"           School action plan B",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"mobipreview.htm?35/59/36794\" title=\"form 3C\">",
"           School action plan C",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/27/21951\" title=\"picture 1\">",
"           MDI spacers PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f38_63_39926="Tubal preg vs corpus luteum";
var content_f38_63_39926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tubal pregnancy versus corpus luteum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two examples of an ectopic pregnancy next to corpus luteal cysts. Note in both cases the ring around the ectopic pregnancy is more echogenic than the surrounding tissues of the corpus luteum.",
"    <div class=\"footnotes\">",
"     E: ectopic pregnancy; O: ovary.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tejas S Mehta, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39926=[""].join("\n");
var outline_f38_63_39926=null;
var title_f38_63_39927="Management of brain metastases in melanoma";
var content_f38_63_39927=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of brain metastases in melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39927/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39927/contributors\">",
"     Marc H Friedberg, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39927/contributors\">",
"     Eric T Wong, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39927/contributors\">",
"     Julian K Wu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39927/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39927/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39927/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39927/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39927/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39927/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39927/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/63/39927/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma is the third most common cancer causing brain metastases in the United States, after cancers of the lung and breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/1\">",
"     1",
"    </a>",
"    ], which appears to reflect the relative propensity of melanoma to metastasize to the central nervous system (CNS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/2\">",
"     2",
"    </a>",
"    ]. Brain metastases are responsible for 20 to 54 percent of deaths in patients with melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/3\">",
"     3",
"    </a>",
"    ], and among those with documented brain metastases, these lesions contribute to death in up to 95 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with other primary tumors, patients with melanoma metastatic to brain typically present with symptoms of increased intracranial pressure (eg, headache), focal neurologic deficits,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures. Brain metastases from melanoma may have a particularly high propensity for spontaneous hemorrhage.",
"   </p>",
"   <p>",
"    The risk factors, prognosis, and management of brain metastases will be reviewed here. The general clinical manifestations and diagnosis of brain metastases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although all patients with melanoma are at risk for metastasis to the brain, certain characteristics that are associated with increased risk of systemic metastases also correlate with the subsequent development of brain metastasis. These factors include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Melanomas arising on mucosal surfaces or the skin of the trunk, head, or neck",
"     </li>",
"     <li>",
"      Wide, thick, deeply invasive, or ulcerated primary lesions",
"     </li>",
"     <li>",
"      Acral lentiginous or nodular lesions on histologic examination",
"     </li>",
"     <li>",
"      Involvement of more than three regional lymph nodes, either at diagnosis or relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Visceral metastasis at the time of diagnosis, especially if the visceral metastasis is disseminated to more than one organ",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma patients with brain metastases in general have a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/4,9-11\">",
"     4,9-11",
"    </a>",
"    ]. In a combined analysis of two series totaling almost 1400 patients, the median survival was four months, and one year survival rates were 9 and 19 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/4,9\">",
"     4,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the general grim prognosis, occasional patients do well. Favorable prognostic signs include the presence of a single brain metastasis without other visceral metastatic disease, and an initial presentation with a metastasis to the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast, multiple brain lesions, extensive visceral metastases, or a primary lesion of the head and neck region carry an unfavorable prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/4,12-14\">",
"     4,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with brain metastases from other primary tumors, good performance status and limited intra- and extracranial disease are associated with a favorable prognosis. The Radiation Therapy Oncology Group (RTOG) used recursive partitioning analysis (RPA) to analyze over 1200 patients with brain metastases and develop a prognostic index to predict the outcome following palliative whole brain radiation therapy (WBRT) (",
"    <a class=\"graphic graphic_table graphicRef77561 \" href=\"mobipreview.htm?7/63/8187\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 2",
"    </a>",
"    ). When RPA was applied to 74 patients with brain metastases from melanoma, the median survival durations for patients in RPA classes I, II, and III were 10.5, 5.9, and 1.8 months, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link&amp;anchor=H12085144#H12085144\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\", section on 'Recursive partitioning analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More recently, a diagnosis-specific graded prognostic assessment tool has been developed to estimate prognosis in patients with brain metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/16\">",
"     16",
"    </a>",
"    ]. When a multivariate analysis was applied to 481 patients with melanoma and brain metastases, the only statistically significant factors were the Karnofsky performance status (&lt;70, 70 to 80, versus 90 to 100) and the number of brain metastases (&gt;3, 2 to 3, or 1) (",
"    <a class=\"graphic graphic_table graphicRef68091 \" href=\"mobipreview.htm?29/57/30619\">",
"     table 3",
"    </a>",
"    ). Median survival based upon these parameters ranged from 3.4 to 13.2 months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link&amp;anchor=H12085237#H12085237\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\", section on 'Diagnosis-specific graded prognostic assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FAVORABLE PROGNOSIS PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In favorable prognosis patients (ie, limited or no extracranial disease, a good performance status [(",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 2",
"    </a>",
"    )], and a single or limited number of brain metastases), aggressive treatment to eradicate metastases in the brain is associated with an improved outcome. Surgery traditionally was used to treat patients with a single or limited number of lesions, often supplemented with WBRT. Subsequent advances have made stereotactic radiosurgery (SRS) an alternative, particularly when lesions are not surgically accessible or when multiple lesions are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection appears to be more effective than WBRT in favorable prognosis patients with melanoma metastatic to brain. Most data supporting the use of surgery in this setting were generated from patients with a single lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. However, patients with multiple surgically-accessible lesions and little or no extracranial disease may also have an improved prognosis when treated with surgical resection, rather than WBRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/4,12,17-20\">",
"     4,12,17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials comparing surgery plus WBRT to WBRT alone in patients with brain metastases from diverse primary tumors support a survival benefit associated with the use of surgery. The results of these trials are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Surgery plus WBRT versus WBRT alone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective analysis of 686 patients treated for brain metastases between 1985 and 2000 at the Melanoma Institute Australia, the median survival for those undergoing surgery with or without RT (8.9 and 8.7 months, respectively) was significantly greater than that of patients treated with RT alone or supportive care (3.4 and 2.1 months, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/9\">",
"     9",
"    </a>",
"    ]. These results suggest that there is a benefit for surgery as a component of the initial treatment, although much of the observed difference may reflect a patient selection bias.",
"   </p>",
"   <p>",
"    In patients who are not candidates for surgical resection because of the size or location of the lesion, biopsy is indicated when the diagnosis is in doubt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Stereotactic radiosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;SRS utilizes multiple convergent radiation beams to deliver a high single dose to a radiographically discrete treatment volume. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Stereotactic radiosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is substantial experience with SRS in patients with melanoma brain metastases suggesting that outcomes are similar to those with other malignancies metastatic to the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/13,21-24\">",
"     13,21-24",
"    </a>",
"    ]. Freedom from progression is achieved in approximately 90 to 95 percent of lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/13,21\">",
"     13,21",
"    </a>",
"    ], with disappearance or a reduction in size occurring in about 55 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/13\">",
"     13",
"    </a>",
"    ]. Local control is primarily influenced by the dose and lesion size, while an increasing number of lesions predict a higher likelihood of relapse at other sites in the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of SRS compared to conventional surgery remains uncertain. In general, our first choice is surgery if a single metastatic lesion is causing neurologic symptoms and is easily accessible. Large posterior fossa tumors or those with large amounts of surrounding edema causing significant effacement of the fourth ventricle or cerebral aqueduct should be resected to prevent the development of obstructive hydrocephalus. SRS is preferred for lesions in eloquent or relatively inaccessible areas of the brain and in patients who have previously received WBRT and have new, progressive, or symptomatic lesions. Evidence from one series suggests that SRS may be more effective than conventional radiation therapy in prolonging survival, but this observation requires confirmation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adjuvant WBRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both surgical resection and SRS are generally followed by postoperative radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/9,12,13,25\">",
"     9,12,13,25",
"    </a>",
"    ]. The goal of WBRT is to treat any residual cancer cells at the site of resection and elsewhere within the brain.",
"   </p>",
"   <p>",
"    When WBRT is used as an adjuvant, there is the potential for delayed complications. This risk must be weighed against the potential benefits and long-term prognosis. The late effects of WBRT are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Adjuvant WBRT after surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have been conducted specifically in melanoma patients to assess the effectiveness of postoperative WBRT, but randomized trials in patients with diverse tumor types support the use of this approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'WBRT after definitive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although extrapolation of such results to radioresistant tumor types may not be appropriate, observational studies in melanoma patients who had a resection of a solitary brain metastasis suggest that WBRT improves the outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/3,17,26\">",
"     3,17,26",
"    </a>",
"    ]. In one study of 35 patients, the likelihood of dying from neurologic causes was much lower in the 19 patients who received radiation group (24 versus 85 percent, compared to those who were treated with surgery alone), although overall survival was similar and depended upon control of systemic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective studies of radiosurgery to the tumor bed after resection of the metastasis in lieu of WBRT have shown local control rates of greater than 70 percent, which is comparable to that of surgery with postoperative WBRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Patient survival also did not appear to be adversely affected compared to surgery plus WBRT. For favorable prognosis patients, resection of large or symptomatic metastasis followed by radiosurgery to the resection cavity, instead of WBRT, is an option. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Stereotactic radiosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adjuvant WBRT after SRS",
"    </span>",
"    &nbsp;&mdash;&nbsp;WBRT is often given after SRS in patients with brain metastases from a variety of tumor types. The data from randomized trials supporting this approach are derived from studies in patients with multiple tumor types, and are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'SRS plus WBRT versus SRS alone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the role of WBRT after resection or SRS has been questioned by the neurooncology community due to the relative radioresistance of melanoma to fractionated radiation. Decisions about adjuvant WBRT after SRS in patients with melanoma need to be individualized, taking into account the size and number of CNS lesions and the status of the systemic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POOR PROGNOSIS PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor prognosis patients are generally treated with WBRT rather than surgery or SRS (",
"    <a class=\"graphic graphic_table graphicRef77561 \" href=\"mobipreview.htm?7/63/8187\">",
"     table 1",
"    </a>",
"    ). However, surgery is occasionally performed to resect a large symptomatic or life-threatening lesion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36486?source=see_link\">",
"     \"Treatment of brain metastases in poor prognosis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;WBRT is widely used as the treatment for poor prognosis patients with melanoma metastatic to the brain. Even with treatment, the prognosis for these patients is poor. In the Melanoma Institute Australia study, 234 patients treated with WBRT alone had a median survival of 3.4 months, compared to 2.1 months in 210 who received supportive care only [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/9\">",
"     9",
"    </a>",
"    ]. The optimal dose and schedule for WBRT is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36486?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of brain metastases in poor prognosis patients\", section on 'WBRT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Craniospinal radiation occasionally may have a palliative role in controlling the symptoms from leptomeningeal metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SYSTEMIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical results from the development of immunotherapy agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    and targeted therapies such as dabrafenib and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    suggest that systemic therapy may have a role in carefully selected patients with brain metastases not amenable to surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15558?source=see_link\">",
"     \"Overview of the management of advanced melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional studies will be required to define the role of immunotherapy and targeted therapy in patients with melanoma brain metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13565191\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy both with high-dose interleukin-2 and the anti-CTLA4 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    have clinically useful activity in the treatment of disseminated melanoma. Both ipilimumab and IL-2 in the context of adoptive cell therapy may have clinically useful activity against brain metastases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In phase II studies and case reports,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      , a human monoclonal antibody that blocks CTLA-4, has demonstrated activity against brain metastases in patients with advanced melanoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/30\">",
"       30",
"      </a>",
"      ]. In the largest experience, 12 of 51 patients (24 percent) with asymptomatic brain metastases not on steroids had either a partial response or stable disease for their brain lesions. In a cohort of 21 patients with minimally symptomatic brain metastases on a stable dose of steroids, one patient had a complete response and another had stable disease (overall rate of disease control 10 percent) during treatment. Results from that study and from other phase II studies indicate that the safety profile and level of activity against brain metastases is similar to that seen at non-CNS sites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=see_link\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adoptive cell therapy (ACT) using autologous antitumor lymphocytes plus interleukin-2 following a lymphocyte-depleting preparative regimen has antitumor activity in carefully selected patients with metastatic melanoma. An analysis of the experience at the National Cancer Institute found 7 of 17 evaluable patients (44 percent) with brain metastases had a complete response in the brain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=see_link&amp;anchor=H531559843#H531559843\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\", section on 'IL-2, TILs, and lymphodepletion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13565198\">",
"    <span class=\"h2\">",
"     Targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in understanding the pathogenesis of melanoma have identified the MAPK pathway as a target for treatment in many patients with metastatic melanoma. Dabrafenib and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    target mutations in BRAF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dabrafenib has activity in melanoma patients with brain metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. In a multicenter phase II study, 172 patients with asymptomatic brain metastases containing either the V600E or V600K mutation were treated with dabrafenib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 139 patients whose tumor contained a V600E mutation, objective responses were observed in 29 of 74 patients (39 percent) in those whose brain metastases were treatment na&iuml;ve and 20 of 65 (31 percent) in those who had received prior local treatment.",
"     </li>",
"     <li>",
"      Objective responses were observed in 5 of 33 patients (15 percent) with a V600K mutation.",
"     </li>",
"     <li>",
"      One patient had an intracranial hemorrhage that was considered treatment-related.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Case reports indicate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    , another small molecule inhibitor of BRAF, also has activity in patients with multiple brain metastases who received prior",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    whole brain radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neither",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    nor dabrafenib has been compared directly with radiation for treatment of brain metastases. Until further studies are performed, we do not recommend withholding brain radiation in most patients with BRAF-mutant melanoma. This is based on the higher rates of local control associated with SRS and the uncertain durability of brain responses associated with BRAF inhibition. In carefully selected patients with symptomatic systemic disease and small, asymptomatic brain metastases, a closely monitored trial of a BRAF inhibitor might be considered. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13565330\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy for patients with metastatic melanoma has generally had only limited activity, and this approach has been replaced by immunotherapy and targeted therapy for the initial treatment of metastatic disease. Although chemotherapy agents such as fotemustine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    have shown evidence of some activity against brain metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39927/abstract/38-41\">",
"     38-41",
"    </a>",
"    ], cytotoxic chemotherapy does not have an established role in the management of patients with melanoma brain metastases.",
"   </p>",
"   <p>",
"    Patients with leptomeningeal metastases from melanoma have a poor prognosis, with a median survival less than two months. Intrathecal chemotherapy may delay the progression of neurologic signs and symptoms, but benefits are limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/6/28772?source=see_link\">",
"       \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/8/39042?source=see_link\">",
"       \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain metastases are frequent in patients with metastatic melanoma and when present are an important cause of both morbidity and mortality (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the approach to patients with melanoma metastatic to brain is similar to that for patients with other types of tumors. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link\">",
"       \"Treatment of brain metastases in favorable prognosis patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36486?source=see_link\">",
"       \"Treatment of brain metastases in poor prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a relatively favorable prognosis (RPA class I or II) (",
"      <a class=\"graphic graphic_table graphicRef77561 \" href=\"mobipreview.htm?7/63/8187\">",
"       table 1",
"      </a>",
"      ) have a single or limited number of brain metastases, good performance status (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ), and limited or no extracranial disease (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Prognosis'",
"      </a>",
"      above).In this setting, aggressive treatment directed against the brain metastases is warranted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend surgical resection for patients with a single or limited number of surgically accessible metastases (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend stereotactic radiosurgery (SRS) for patients with lesions in surgically inaccessible locations and those who are not surgical candidates or refuse surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Stereotactic radiosurgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with extensive extracranial disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a poor performance status have a very poor prognosis (RPA class II or III) (",
"      <a class=\"graphic graphic_table graphicRef77561 \" href=\"mobipreview.htm?7/63/8187\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ) and are less likely to benefit from aggressive treatment directed against their brain metastases. In this setting we suggest WBRT or best supportive care (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical results from the development of immunotherapy agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      and targeted therapies such as dabrafenib and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      suggest that systemic therapy may have a role in carefully selected patients with brain metastases not amenable to surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy. (See",
"      <a class=\"local\" href=\"#H13565191\">",
"       'Immunotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13565198\">",
"       'Targeted therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/1\">",
"      Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am 1996; 7:337.",
"     </a>",
"    </li>",
"    <li>",
"     Sawaya R, Bindal RK. Metastatic brain tumors. In: Brain Tumors, Kaye AH, Laws ER Jr (Eds), Churchill Livingstone, New York 1995. p.923.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/3\">",
"      Skibber JM, Soong SJ, Austin L, et al. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 1996; 3:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/4\">",
"      Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/5\">",
"      Othus M, Moon J, Margolin K. Melanoma's deadly march to the brain: by what route, and can it be stopped? Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/6\">",
"      Zakrzewski J, Geraghty LN, Rose AE, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/7\">",
"      Bedikian AY, Wei C, Detry M, et al. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol 2011; 34:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/8\">",
"      Ballo MT, Ross MI, Cormier JN, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 2006; 64:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/9\">",
"      Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/10\">",
"      Carlino MS, Atkins MB, Warneke CL, et al. Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases: analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ and the US) study (abstract #8516). Society for Melanoma Research 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/11\">",
"      Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011; 117:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/12\">",
"      Ewend MG, Carey LA, Brem H. Treatment of melanoma metastases in the brain. Semin Surg Oncol 1996; 12:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/13\">",
"      Mori Y, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 1998; 42:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/14\">",
"      Gupta G, Robertson AG, MacKie RM. Cerebral metastases of cutaneous melanoma. Br J Cancer 1997; 76:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/15\">",
"      Buchsbaum JC, Suh JH, Lee SY, et al. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 2002; 94:2265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/16\">",
"      Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/17\">",
"      Wroski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 2000; 93:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/18\">",
"      Konstadoulakis MM, Messaris E, Zografos G, et al. Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? J Neurosurg Sci 2000; 44:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/19\">",
"      Zacest AC, Besser M, Stevens G, et al. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg 2002; 96:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/20\">",
"      McWilliams RR, Brown PD, Buckner JC, et al. Treatment of brain metastases from melanoma. Mayo Clin Proc 2003; 78:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/21\">",
"      Yu C, Chen JC, Apuzzo ML, et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 2002; 52:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/22\">",
"      Selek U, Chang EL, Hassenbusch SJ 3rd, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 2004; 59:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/23\">",
"      Radbill AE, Fiveash JF, Falkenberg ET, et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 2004; 101:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/24\">",
"      Stone A, Cooper J, Koenig KL, et al. A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer Invest 2004; 22:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/25\">",
"      Salvati M, Cervoni L, Caruso R, Gagliardi FM. Solitary cerebral metastasis from melanoma: value of the 'en bloc' resection. Clin Neurol Neurosurg 1996; 98:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/26\">",
"      Hagen NA, Cirrincione C, Thaler HT, DeAngelis LM. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 1990; 40:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/27\">",
"      Mathieu D, Kondziolka D, Flickinger JC, et al. Tumor bed radiosurgery after resection of cerebral metastases. Neurosurgery 2008; 62:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/28\">",
"      Soltys SG, Adler JR, Lipani JD, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 2008; 70:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/29\">",
"      Hwang SW, Abozed MM, Hale A, et al. Adjuvant Gamma Knife radiosurgery following surgical resection of brain metastases: a 9-year retrospective cohort study. J Neurooncol 2010; 98:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/30\">",
"      Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/31\">",
"      Weber JS, Amin A, Minor D, et al. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 2011; 21:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/32\">",
"      Hong JJ, Rosenberg SA, Dudley ME, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 2010; 16:4892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/33\">",
"      Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/34\">",
"      Long GV, Kefford RF, Carr PJ, et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600E mutatn BRAF kinase: evidence of activity melanoma brain metastases. Ann Oncol 2010; 21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/35\">",
"      Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patietns with VAl600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/36\">",
"      Dummer R, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol 2011; 29:537s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/37\">",
"      Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011; 365:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/38\">",
"      Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/39\">",
"      Giorgio CG, Giuffrida D, Pappalardo A, et al. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 2005; 50:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/40\">",
"      Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004; 22:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39927/abstract/41\">",
"      Schadendorf D, Hauschild A, Ugurel S, et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol 2006; 17:1592.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7611 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39927=[""].join("\n");
var outline_f38_63_39927=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FAVORABLE PROGNOSIS PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adjuvant WBRT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Adjuvant WBRT after surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adjuvant WBRT after SRS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POOR PROGNOSIS PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SYSTEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13565191\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13565198\">",
"      Targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13565330\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7611\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7611|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/63/8187\" title=\"table 1\">",
"      Brain mets prognosis RTOG RPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/57/30619\" title=\"table 3\">",
"      Graded prognostic assessment for brain metastases from melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=related_link\">",
"      Interleukin-2 and other immunotherapies for advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15558?source=related_link\">",
"      Overview of the management of advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/8/39042?source=related_link\">",
"      Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36486?source=related_link\">",
"      Treatment of brain metastases in poor prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_63_39928="Malignancy-related ascites";
var content_f38_63_39928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignancy-related ascites",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39928/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39928/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39928/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39928/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39928/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/63/39928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority (85 percent) of ascites in the United States is found in the setting of cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/1\">",
"     1",
"    </a>",
"    ]. Cancer is the sole cause of ascites formation or contributes to ascites formation in approximately 7 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/1\">",
"     1",
"    </a>",
"    ]. Some patients have two causes for ascites formation (eg, cirrhosis plus peritoneal carcinomatosis).",
"   </p>",
"   <p>",
"    This topic review will provide an overview of malignancy-related ascites. A general approach to patients with ascites is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=see_link\">",
"     \"Evaluation of adults with ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a common misconception that malignant ascites is synonymous with peritoneal carcinomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/2\">",
"     2",
"    </a>",
"    ]. Malignant disease can cause ascites by at least six mechanisms (",
"    <a class=\"graphic graphic_table graphicRef65840 \" href=\"mobipreview.htm?7/11/7355\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, the phrase \"malignancy-related ascites\" is a more appropriate descriptor than \"malignant ascites\" since it includes all of these causes.",
"   </p>",
"   <p>",
"    Ascites typically develops in the setting of recurrent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    advanced cancer. Patients may have a history of metastases to the peritoneum or liver, enlarged abdominal lymph nodes, or a large tumor burden prior to the development of ascites. The origin of the primary tumor has an impact on the sites of abdominal metastases, and the etiology of the ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignancies of ovarian and urinary bladder origin as well as peritoneal mesothelioma tend to cause peritoneal carcinomatosis. In such cases, the accumulation of fluid is the result of blockage of the draining lymphatic channels (which normally keep the amount of intraperitoneal fluid low) and increased vascular permeability.",
"     </li>",
"     <li>",
"      Colonic, gastric, breast, pancreatic, and lung cancers may cause peritoneal carcinomatosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      massive liver metastases, which leads to ascites either because they",
"      <span class=\"nowrap\">",
"       obstruct/compress",
"      </span>",
"      portal veins or because they cause liver failure.",
"     </li>",
"     <li>",
"      Most lymphomas tend to cause lymph node obstruction and the accumulation of chylous ascites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/4\">",
"       4",
"      </a>",
"      ]. The malignant cells of primary effusion lymphoma involve the serosal surface leading to symptomatic serous effusions containing high-grade, malignant lymphocytes, but with no detectable mass lesion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30969?source=see_link\">",
"       \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patients with underlying liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy-related ascites in patients with underlying liver disease is usually due to hepatocellular carcinoma (HCC) rather than liver metastases. The development of ascites may be the first indication of a primary HCC.",
"   </p>",
"   <p>",
"    The four most common settings in which HCC-related ascites develops are in patients with chronic hepatitis B acquired in infancy or childhood (most common in Asia), in patients with nonalcoholic fatty liver disease, in patients with chronic hepatitis C, and in patients with alcoholic cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/5\">",
"     5",
"    </a>",
"    ]. In these settings, ascites often develops when the tumor volume grows to an extent that it replaces a critical portion of functional liver mass or that it invades the portal vein leading to portal vein thrombosis.",
"   </p>",
"   <p>",
"    HCC that develops in the setting of alcoholic liver disease is often seen in patients with compensated cirrhosis who have stopped drinking and lived long enough to develop HCC. HCC can develop in cirrhosis due to other causes but in these settings it is frequently detected during surveillance, when the tumor is not large enough to cause ascites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients often first seek medical attention because of abdominal pain, shortness of breath, or early satiety. Abdominal pain may be due to a combination of factors including nerve invasion by the tumor, stretching of the liver capsule, or (in those with tense ascites) stretching of the abdominal wall.",
"   </p>",
"   <p>",
"    Because ascites usually develops in the setting of a large tumor burden, patients have typically lost a large amount of weight before the development of ascites (and despite the added weight from the ascites itself).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single laboratory test (other than a positive ascitic fluid cytology) that can establish the diagnosis of malignancy-related ascites. The diagnosis is based upon the clinical setting, ascitic fluid analysis, and imaging tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a known malignancy who develop ascites frequently undergo an extensive and typically futile inpatient evaluation; not infrequently, they die while hospitalized. Once a patient develops ascites in the setting of a nonovarian cancer (including effusion lymphomas), the prognosis is usually poor, often less than three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, the approach should focus on rapid evaluation and discharge, with treatment aimed at improving quality of life (",
"    <a class=\"graphic graphic_algorithm graphicRef78972 \" href=\"mobipreview.htm?18/4/18501\">",
"     algorithm 1",
"    </a>",
"    ). On the other hand, the presence of ascites in a woman with epithelial ovarian cancer is not necessarily associated with a severely limited prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of bulging flanks should lead to percussion of the flanks for dullness followed by testing for shifting dullness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=see_link\">",
"     \"Evaluation of adults with ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although rarely present, an umbilical nodule that does not represent herniating bowel or omentum (ie, a Sister Mary Joseph nodule) provides supportive evidence for malignancy as the cause of the ascites. A fine needle aspiration of the nodule can provide a rapid tissue diagnosis. Gastric or colon cancer, HCC, lymphoma, and rarely peritoneal mesothelioma can cause ascites accompanied by an umbilical nodule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ascites should undergo imaging to confirm the presence of ascites, visualize the liver, and examine for other findings that might support the diagnosis of malignancy. Ultrasound is probably the most cost-effective initial imaging modality, and it does not require exposure to radiation or contrast. CT or MRI may also be performed depending upon the clinical setting and the status of renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ABDOMINAL PARACENTESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal paracentesis with appropriate ascitic fluid analysis is the most efficient way to confirm the presence of ascites, diagnose its cause, and determine if the fluid is infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=see_link\">",
"     \"Evaluation of adults with ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gross appearance of the ascitic fluid can be helpful in the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clear fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uninfected ascites in the setting of cirrhosis or massive liver metastases is usually translucent and yellow; it can be water clear if the ascitic fluid bilirubin concentration is normal and the protein concentration is very low (eg, &lt;1",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Turbid or cloudy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascitic",
"    fluid in the setting of peritoneal carcinomatosis may be turbid or cloudy due to the presence of cells. In general, high protein concentrations do not make ascitic fluid turbid or cloudy. An elevated triglyceride concentration of as little as 50 to 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    makes the fluid \"opalescent\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Milky",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milky fluid usually has a triglyceride concentration greater than serum and greater than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.26",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and often greater than 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.3",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    such specimens are referred to as chylous ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/10\">",
"     10",
"    </a>",
"    ]. A study performed in a tertiary referral center reported that malignancy was the most common cause of chylous ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/4\">",
"     4",
"    </a>",
"    ]; however, the results could be due to selection bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, a prospective study performed in large general hospitals documented that cirrhosis caused 10 times as many cases of chylous ascites as malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/11\">",
"     11",
"    </a>",
"    ]. Approximately 1 out of 200 patients (0.5 percent) with cirrhosis has chylous ascites in the absence of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/168?source=see_link\">",
"     \"Chylous, bloody, and pancreatic ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pink or bloody",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pink fluid usually has a red cell concentration of &gt;10,000",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"    In contrast, frankly bloody fluid typically has a red cell count of tens of thousands of cells per mm3. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/168?source=see_link\">",
"     \"Chylous, bloody, and pancreatic ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ascitic fluid is bloody in about one-half of patients with HCC and in about 20 percent of malignancy-related ascites overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"     3",
"    </a>",
"    ]. Ascitic fluid is bloody in less than 10 percent of patients who have peritoneal carcinomatosis as the sole cause of ascites formation, but it is bloody in about two-thirds of patients with peritoneal carcinomatosis plus massive liver metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ascitic fluid tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cell count and differential",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total WBC count is &ge;500",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    in approximately 75 percent of patients with peritoneal carcinomatosis, 80 percent of those with peritoneal carcinomatosis plus massive liver metastases, and two-thirds of those with cirrhosis and HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritoneal carcinomatosis can mimic spontaneous bacterial peritonitis; about 8 percent of patients have an absolute neutrophil counts &ge;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"     3",
"    </a>",
"    ]. The tip-off that the fluid is not infected is the predominance of lymphocytes. The presence of neutrophils may reflect a response to dying tumor cells.",
"   </p>",
"   <p>",
"    Antibiotics can be given initially when an elevated fluid neutrophil count is detected. They can be discontinued when it becomes clear (by positive cytology and absence of growth on bacterial culture) that ascites is related to malignancy and that infection has been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Serum-to-ascites albumin gradient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum-to-ascites albumin gradient (SAAG) accurately identifies the presence of portal hypertension and is more useful than the older protein-based",
"    <span class=\"nowrap\">",
"     exudate/transudate",
"    </span>",
"    concept for identifying portal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of a gradient &ge;1.1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (11",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      is an indicator of portal hypertension with 97 percent accuracy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/1\">",
"       1",
"      </a>",
"      ]. Patients with HCC complicating cirrhosis and patients with massive liver metastases (with or without peritoneal carcinomatosis) almost always (94 percent) have a SAAG &ge;1.1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A gradient &lt;1.1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (&lt;11",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      indicates that the patient does not have portal hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/1\">",
"       1",
"      </a>",
"      ]. Patients with peritoneal carcinomatosis in the absence of cirrhosis or the absence of massive liver metastases almost always (95 percent) have a SAAG &lt;1.1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial cultures of ascitic fluid should be obtained on specimens from patients with new onset ascites as well as those with fever or abdominal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. An adequate volume of ascitic fluid (generally 10 mL per bottle but varying according to the manufacturer of the bottle) should be inoculated into blood culture bottles at the bedside. It is unusual to detect spontaneous bacterial peritonitis in patients with ascites due solely to peritoneal carcinomatosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12296?source=see_link\">",
"     \"Diagnosis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ascitic fluid protein concentration may provide a clue as to the cause of the malignancy-related ascites. In one series, the mean ascitic fluid total protein in patients with peritoneal carcinomatosis was 4.0",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and 95 percent of patients had a value &ge;2.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    when ascites was due solely to peritoneal carcinomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"     3",
"    </a>",
"    ]. By contrast, it was always &lt;2.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in patients with massive liver metastases and in patients with HCC complicating cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ascitic fluid glucose concentration is similar to that in serum unless glucose is being consumed in the peritoneal cavity by white blood cells or bacteria. Malignant cells also consume glucose; thus, the concentration of glucose may be low in the setting of peritoneal carcinomatosis. In one series, 70 percent of patients with malignancy-related ascites had a serum glucose level of &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and 17 percent had a level &lt;50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Lactate dehydrogenase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because lactate dehydrogenase (LDH) is a much larger molecule than glucose, it enters ascitic fluid less readily. If the fluid to serum LDH ratio is more than 1.0, LDH is being produced in or released into the peritoneal cavity, usually because of the presence of tumor cells or infection. In one series, when ascites was due solely to peritoneal carcinomatosis, the LDH of the fluid was greater than the upper limit of normal for serum in 74 percent of samples, and was greater than the simultaneous serum value in 54 percent of samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall sensitivity of cytology smears for the detection of malignancy-related ascites is 58 to 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The sensitivity of cytology depends upon the number of specimens processed, the quality of processing, and the cause of the malignancy-related ascites. A sample of 50 mL is sufficient if processed properly. This should be coordinated with the local laboratory; some laboratories prefer a hand-carried specimen, while others prefer a specimen that is fixed in alcohol at the bedside. When the processing of the specimen is coordinated with the laboratory, 83 percent of first specimens are positive or suspicious for malignancy (93 percent if two specimens are sent and 97 percent if three specimens are sent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with ascites related to peritoneal carcinomatosis, viable malignant cells are exfoliated into the ascitic fluid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"       3",
"      </a>",
"      ]. In most cases, cytology will be positive if the fluid is processed optimally and if enough specimens are examined. In one series, 97 percent of patients with peritoneal carcinomatosis had at least one positive ascitic fluid cytology after testing three samples; in 83 percent the first cytology specimen was positive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, only about two-thirds of patients with malignancy-related ascites have peritoneal carcinomatosis. The remaining one-third have massive liver metastases, chylous ascites due to lymphoma, HCC, or malignant Budd-Chiari syndrome; these patients almost always have negative cytologies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"       3",
"      </a>",
"      ]. With increases in the prevalence of HCC, more malignancy-related ascites could be due to HCC. HCC causes ascites by increasing portal pressure by replacing parenchyma with tumor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      leading to benign or malignant thrombosis of the portal vein [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Peritoneal mesothelioma may be difficult to diagnose cytologically, even in experienced hands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. It may be especially difficult to differentiate between peritoneal mesothelioma and a serous ovarian carcinoma. In some cases, peritoneoscopy may be needed with tissue biopsy in order to perform immunohistochemistry and electron microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32552?source=see_link&amp;anchor=H1568139510#H1568139510\">",
"     \"Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma\", section on 'Mesothelin'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H24\">",
"     'Laparoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hepatocellular carcinomas metastasize to the peritoneum infrequently enough to be the subject of few reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Ordering an ascitic fluid cytology in an attempt to confirm the diagnosis of an HCC is almost always futile.",
"   </p>",
"   <p>",
"    We suggest that at least 50 mL of ascitic fluid be submitted and either hand-carried to the laboratory or placed immediately into a fixative of the laboratory's choice. It is best to coordinate this with the local laboratory to assure proper processing and thereby maximize sensitivity. The clinical utility of newer more sensitive and specific cytologic techniques including cytometry to detect aneuploidy and magnetic enrichment is not yet established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/12,13,21,22\">",
"     12,13,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Tumor markers CEA and CA 125",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoembryonic antigen (CEA) is a glycoprotein that is shed from the surface of malignant cells; detectable levels of this tumor marker can be measured in the serum, and serve as indicators of disease activity. CEA is elevated in a variety of malignancies, predominantly those affecting the gastrointestinal tract.",
"   </p>",
"   <p>",
"    Measurement of CEA in ascitic fluid has been proposed as a helpful test in detecting malignancy-related ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/14,23\">",
"     14,23",
"    </a>",
"    ]. However, both sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/26\">",
"     26",
"    </a>",
"    ] are limited, and as a result, the precise value of ascitic fluid CEA levels in the diagnosis and differential diagnosis of malignancy-related ascites is uncertain.",
"   </p>",
"   <p>",
"    The cancer antigen 125 (CA 125) warrants particular attention since it can lead to misleading results when levels are found to be elevated in serum. Virtually all patients, including men, with ascites or pleural fluid of any cause have elevated serum level of CA 125, presumed to reflect shear forces on mesothelial cells, and hence, elevated serum levels are nonspecific. In one study, the values in patients with chronic liver disease and ascites averaged 321",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/17\">",
"     17",
"    </a>",
"    ]. When ascites is controlled, the serum CA 125 level decreases dramatically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/7,17\">",
"     7,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, assay of ascitic fluid CA 125 levels is not a helpful test to differentiate between ascites that is due to ovarian cancer from ascites due to tumors or benign causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, we suggest",
"    <strong>",
"     against",
"    </strong>",
"    testing patients with ascites for CA 125 either in serum or in the ascitic fluid. It is predictably elevated, and uninformed clinicians may inappropriately pursue the diagnosis of ovarian cancer. The diagnosis of ascites due to ovarian cancer should be made only on the basis of cytology and not upon CA 125 levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Ascitic fluid \"humoral tests of malignancy\"",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, only approximately two-thirds of patients with malignancy-related ascites have peritoneal carcinomatosis, a virtual requirement for having positive cytology. This has led to the misconception that cytology is insensitive for detecting malignancy-related ascites. In truth, cytology is almost 100 percent sensitive in detecting peritoneal carcinomatosis, but one-third of patients with malignancy-related ascites have other mechanisms of ascites formation. In such patients viable tumor cells are not found lining the peritoneum, and the cytology would not be expected to be positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple ascitic fluid tests (eg, fibronectin, glycosaminoglycans) have been proposed to replace or supplement the cytology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/8,29\">",
"     8,29",
"    </a>",
"    ]. However, none of these tests has stood the \"test of time\", and their use should be discouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopy with biopsy of peritoneal implants has a sensitivity for detecting peritoneal carcinomatosis that approaches 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"     3",
"    </a>",
"    ]. However, optimally processed cytology of the fluid from a simple, minimally invasive paracentesis almost always precludes the need for this invasive procedure, with the possible exception of peritoneal mesothelioma, as noted above. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Cytology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Omental biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful diagnosis of the cause of ascites has been described using transabdominal ultrasound-guided biopsy of the greater omentum in patients with a radiologically thickened greater omentum in whom the cause of ascites remained unclear after a more conventional evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/30\">",
"     30",
"    </a>",
"    ]. A particular sonographic feature of the greater omentum (the \"cerebral fissure\" sign) was suggestive of tuberculous peritonitis. Such an approach is uncommonly used in the United States. Omental biopsy has also been reported using CT guidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic paracentesis is the mainstay of treatment for peritoneal carcinomatosis other than that caused by ovarian cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/32\">",
"     32",
"    </a>",
"    ]. As will be discussed below, optimal treatment of advanced ovarian cancer involves surgical debulking and chemotherapy. Abdominal paracentesis is usually needed every one to two weeks, although the frequency should be guided by the patient's symptoms (ie, distension, shortness of breath, and early satiety).",
"   </p>",
"   <p>",
"    In the absence of successful treatment of the tumor itself, peritoneal implants continue to form and can make successful paracentesis more and more difficult, as the implants adhere to previously successful tap sites. Image guidance can help in this situation. Eventually the fluid becomes more solid and the patient may expire from bowel obstruction.",
"   </p>",
"   <p>",
"    Large volumes of fluid (up to 21 liters) can be removed without fear of hemodynamic sequelae including circulatory failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/20,33\">",
"     20,33",
"    </a>",
"    ]. Therapeutic paracentesis can be performed in the clinic office, endoscopy unit, or interventional radiology suite. Hospitalization is not required and intravenous fluid infusion is not needed following paracentesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adoption of guidelines to minimize the need for image guidance, the length of time needed to accomplish paracentesis, and elimination of albumin infusion post-tap led to a more efficient procedure with no hypotension in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/34\">",
"     34",
"    </a>",
"    ]. The authors changed their policies after they realized that \"some practices were placing unnecessary burdens on patients whose life expectancy was short\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/34\">",
"     34",
"    </a>",
"    ]. These patients are almost always too ill to drive. The patient and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    family want the most efficient paracentesis and want to leave as soon as possible. As much fluid should be removed as is readily removable to increase the amount of time before the next tap is required.",
"   </p>",
"   <p>",
"    The need for colloid replacement to prevent hemodynamic deterioration after large volume paracentesis remains controversial. However, the available data and clinical experience suggest that intravenous albumin infusion is generally",
"    <strong>",
"     not",
"    </strong>",
"    necessary. Furthermore, it increases the time that the patient spends undergoing paracentesis, especially if they have to go to an infusion center to receive the albumin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35465?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of diuretic-resistant ascites in patients with cirrhosis\", section on 'Colloid replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peritoneal ports and catheters can also be placed to facilitate repeated paracentesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. These techniques permit removal of the fluid at home by a visiting nurse or the patient or a family member. However, infection remains a potential complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/35-39\">",
"     35-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritoneovenous shunts, such as the Denver shunt, can be placed to minimize the need for paracentesis, if a surgeon can be found who is experienced in this technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/40\">",
"     40",
"    </a>",
"    ]. Unfortunately, these shunts can be associated with several complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/50/29482?source=see_link&amp;anchor=H18#H18\">",
"     \"Hepatorenal syndrome\", section on 'Peritoneovenous shunt'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with portal hypertension due to massive liver metastases, cirrhosis with HCC, or malignant Budd-Chiari syndrome may respond to diuretics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/41\">",
"     41",
"    </a>",
"    ]. A serum-ascites albumin gradient &ge;1.1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is suggestive of the presence of portal hypertension, and diuretic treatment should be attempted in this setting. Starting diuretic doses are 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    . These doses should be adjusted upward (while maintaining this ratio) to achieve natriuresis and weight loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients often have a poor appetite and thus a diet or nutritional supplements should be suggested to maximize caloric intake. We generally do not suggest a sodium restricted diet (despite its benefit in ascites due to portal hypertension) since it may adversely affect quality of life. Patients with malignancy-related ascites have a short life expectancy. Diuretic doses can be adjusted to compensate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Tumor-targeted treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending in part upon the tumor type, specific tumor-targeted treatments may be appropriate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with ovarian cancer, the most common cause of peritoneal carcinomatosis, the treatment of choice is surgical debulking followed by chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/42\">",
"       42",
"      </a>",
"      ]. Intraperitoneal chemotherapy may provide better outcomes than all-IV systemic therapy for selected women with optimally debulked stage III disease. However, even so, more than one-half of patients with advanced ovarian cancer will have a complete remission from initial therapy, although only 10 to 30 percent will remain progression-free long-term. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=see_link\">",
"       \"Epithelial ovarian cancer: Initial surgical management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with peritoneal mesothelioma, diffuse peritoneal adenomucinosis (pseudomyxoma peritonei), and possibly selected patients with isolated peritoneal carcinomatosis from of appendiceal or colorectal adenocarcinoma may benefit from aggressive cytoreductive therapy combined with intraperitoneal hyperthermic chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=see_link\">",
"       \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link\">",
"       \"Cancer of the appendix and pseudomyxoma peritonei\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19930?source=see_link&amp;anchor=H15#H15\">",
"       \"Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer\", section on 'Aggressive cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For other solid tumors with malignant ascites, prognosis is poor, the role of surgery is not established, and palliative systemic therapy is appropriate. The specific regimen is chosen based upon the primary site. Unfortunately, many patients with enough tumor burden to have ascites have already failed standard chemotherapy. Treatment of many of the underlying tumors that cause peritoneal carcinomatosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      massive liver metastases, chylous ascites, or malignant Budd-Chiari syndrome is beyond the scope of this topic review. (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      Intraperitoneal administration of anticancer drugs enables direct contact of extremely high drug concentrations with the malignant lesions within the peritoneal cavity. However, while some studies suggest promise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/43-45\">",
"       43-45",
"      </a>",
"      ], the role of intraperitoneal rather than intravenous administration of chemotherapy for patients with malignant ascites and a tumor other than epithelial ovarian cancer is not established.",
"     </li>",
"     <li>",
"      Vascular endothelial growth factor (VEGF) appears to have an important role in permitting tumors to attach to the peritoneum; some VEGF inhibitors have been reported to provide some palliation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/46\">",
"       46",
"      </a>",
"      ]. There is limited experience with commercially available anti-VEGF strategies, such as the anti-VEGF monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (Avastin) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/47\">",
"       47",
"      </a>",
"      ]. However, some data suggest that bevacizumab can provide symptomatic relief of ascites in women with refractory epithelial ovarian cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with ascites from pancreatic cancer, benefit from systemic administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    appears to correlate with ascitic fluid VEGF levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39928/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/40/16002?source=see_link\">",
"       \"Patient information: Fluid in the belly (ascites) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ascites is a common complication of certain malignancies including cancer of the ovary, breast, colon, lung, pancreas, and liver. Lymphoma can be complicated by chylous ascites.",
"     </li>",
"     <li>",
"      There is a common misconception that \"malignant ascites\" is synonymous with peritoneal carcinomatosis. By contrast, malignancies can cause ascites by at least six mechanisms making the term \"malignancy-related ascites\" preferable (",
"      <a class=\"graphic graphic_table graphicRef65840 \" href=\"mobipreview.htm?7/11/7355\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients often first seek medical attention because of abdominal pain, shortness of breath, or early satiety. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no single laboratory test (other than positive ascitic fluid cytology) that can establish the diagnosis of malignancy-related ascites. The diagnosis is based upon the clinical setting, ascitic fluid analysis, and imaging tests. We suggest the following approach (",
"      <a class=\"graphic graphic_algorithm graphicRef78972 \" href=\"mobipreview.htm?18/4/18501\">",
"       algorithm 1",
"      </a>",
"      ). It emphasizes rapid evaluation and discharge, with treatment aimed at improving quality of life. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       against",
"      </strong>",
"      testing serum for CA 125 levels since the results may be misleading and result in unnecessary evaluation. Instead, the diagnosis of ovarian cancer should be made based upon cytology. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Tumor markers CEA and CA 125'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest large volume therapeutic paracentesis for most patients with non-ovarian causes of peritoneal carcinomatosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Peritoneal ports, catheters, and shunts can be considered if the expertise is available and patients are intolerant of paracenteses. However, survival is so short that usually not many paracenteses are required. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with portal hypertension due to massive liver metastases, cirrhosis with hepatocellular carcinoma, or malignant Budd-Chiari syndrome, we suggest a trial of diuretics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such patients can be identified by a serum-ascites albumin gradient &ge;1.1",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Several specific antineoplastic treatments may be useful, depending in part upon the tumor type. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Tumor-targeted treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Palliative care should be considered because of the very short life expectancy of patients with malignancy-related ascites and their generally poor functional status.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/1\">",
"      Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/2\">",
"      Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 2003; 15:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/3\">",
"      Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988; 8:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/4\">",
"      Press OW, Press NO, Kaufman SD. Evaluation and management of chylous ascites. Ann Intern Med 1982; 96:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/5\">",
"      Giannini EG, Marabotto E, Savarino V, et al. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol 2009; 7:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/6\">",
"      Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998; 27:264.",
"     </a>",
"    </li>",
"    <li>",
"     Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/ Management, 8th ed, Feldman M, Friedman LS, Brandt LJ (Eds), WB Saunders, Philadelphia 2006. p.1935.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/8\">",
"      Runyon BA. Malignancy-related ascites and ascitic fluid \"humoral tests of malignancy\". J Clin Gastroenterol 1994; 18:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/9\">",
"      Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007; 18:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/10\">",
"      Rector WG Jr. Spontaneous chylous ascites of cirrhosis. J Clin Gastroenterol 1984; 6:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/11\">",
"      Cardozo PL. A critical evaluation of 3000 cytologic analyses of pleural fluid, ascitic fluid, and pericardial fluid. Acta Cyto 1966; 10:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/12\">",
"      Decker D, Stratmann H, Springer W, et al. Benign and malignant cells in effusions: diagnostic value of image DNA cytometry in comparison to cytological analysis. Pathol Res Pract 1998; 194:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/13\">",
"      Kielhorn E, Schofield K, Rimm DL. Use of magnetic enrichment for detection of carcinoma cells in fluid specimens. Cancer 2002; 94:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/14\">",
"      Loewenstein MS, Rittgers RA, Feinerman AE, et al. Carcinoembryonic antigen assay of ascites and detection of malignancy. Ann Intern Med 1978; 88:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/15\">",
"      Patel NP, Taylor CA, Levine EA, et al. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol 2007; 128:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/16\">",
"      Hassan R, Alexander R, Antman K, et al. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol 2006; 17:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/17\">",
"      Zuckerman E, Lanir A, Sabo E, et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999; 94:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/18\">",
"      Chetty R, Learmonth GM, Taylor DA. Giant cell hepatocellular carcinoma. Cytopathology 1990; 1:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/19\">",
"      Falconieri G, Zanconati F, Colautti I, et al. Effusion cytology of hepatocellular carcinoma. Acta Cytol 1995; 39:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/20\">",
"      Cruikshank DP, Buchsbaum HJ. Effects of rapid paracentesis. Cardiovascular dynamics and body fluid composition. JAMA 1973; 225:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/21\">",
"      Barker SD, Casado E, Gomez-Navarro J, et al. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol 2001; 82:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/22\">",
"      Pinto MM. DNA analysis of malignant effusions. Comparison with cytologic diagnosis and carcinoembryonic antigen content. Anal Quant Cytol Histol 1992; 14:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/23\">",
"      Guly&aacute;s M, Kaposi AD, Elek G, et al. Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology. J Clin Pathol 2001; 54:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/24\">",
"      Sari R, Yildirim B, Sevinc A, et al. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology. Hepatogastroenterology 2001; 48:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/25\">",
"      Chen SJ, Wang SS, Lu CW, et al. Clinical value of tumour markers and serum-ascites albumin gradient in the diagnosis of malignancy-related ascites. J Gastroenterol Hepatol 1994; 9:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/26\">",
"      Torresini RJ, Prolla JC, Diehl AR, et al. Combined carcinoembryonic antigen and cytopathologic examination in ascites. Acta Cytol 2000; 44:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/27\">",
"      Pinto MM. CA-15.3 assay in effusions: comparison with carcinoembryonic antigen and CA-125 assay and cytologic diagnosis. Acta Cytol 1996; 40:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/28\">",
"      Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006; 102:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/29\">",
"      Lee CM, Changchien CS, Shyu WC, Liaw YF. Serum-ascites albumin concentration gradient and ascites fibronectin in the diagnosis of malignant ascites. Cancer 1992; 70:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/30\">",
"      Que Y, Wang X, Liu Y, et al. Ultrasound-guided biopsy of greater omentum: an effective method to trace the origin of unclear ascites. Eur J Radiol 2009; 70:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/31\">",
"      Pombo F, Rodriguez E, Martin R, Lago M. CT-guided core-needle biopsy in omental pathology. Acta Radiol 1997; 38:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/32\">",
"      Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006; 42:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/33\">",
"      Halpin TF, McCann TO. Dynamics of body fluids following the rapid removal of large volumes of ascites. Am J Obstet Gynecol 1971; 110:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/34\">",
"      Stephenson J, Gilbert J. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med 2002; 16:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/35\">",
"      O'Neill MJ, Weissleder R, Gervais DA, et al. Tunneled peritoneal catheter placement under sonographic and fluoroscopic guidance in the palliative treatment of malignant ascites. AJR Am J Roentgenol 2001; 177:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/36\">",
"      Barnett TD, Rubins J. Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites: a simplified percutaneous approach. J Vasc Interv Radiol 2002; 13:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/37\">",
"      Rosenberg S, Courtney A, Nemcek AA Jr, Omary RA. Comparison of percutaneous management techniques for recurrent malignant ascites. J Vasc Interv Radiol 2004; 15:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/38\">",
"      Savin MA, Kirsch MJ, Romano WJ, et al. Peritoneal ports for treatment of intractable ascites. J Vasc Interv Radiol 2005; 16:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/39\">",
"      Brooks RA, Herzog TJ. Long-term semi-permanent catheter use for the palliation of malignant ascites. Gynecol Oncol 2006; 101:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/40\">",
"      Tomiyama K, Takahashi M, Fujii T, et al. Improved quality of life for malignant ascites patients by Denver peritoneovenous shunts. Anticancer Res 2006; 26:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/41\">",
"      Pockros PJ, Esrason KT, Nguyen C, et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 1992; 103:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/42\">",
"      Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/43\">",
"      Aleem A, Siddiqui N. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate. Leuk Lymphoma 2005; 46:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/44\">",
"      Ng T, Pagliuca A, Mufti GJ. Intraperitoneal rituximab: an effective measure to control recurrent abdominal ascites due to non-Hodgkin's lymphoma. Ann Hematol 2002; 81:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/45\">",
"      Kitayama J, Ishigami H, Kaisaki S, et al. Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology 2010; 78:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/46\">",
"      Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003; 9:5721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/47\">",
"      Kobold S, Hegewisch-Becker S, Oechsle K, et al. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 2009; 14:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39928/abstract/48\">",
"      Kuwahara K, Sasaki T, Kobayashi K, et al. Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites. Oncol Rep 2004; 11:73.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1240 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39928=[""].join("\n");
var outline_f38_63_39928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patients with underlying liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ABDOMINAL PARACENTESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clear fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Turbid or cloudy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Milky",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pink or bloody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ascitic fluid tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cell count and differential",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Serum-to-ascites albumin gradient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Glucose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Lactate dehydrogenase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Tumor markers CEA and CA 125",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Ascitic fluid \"humoral tests of malignancy\"",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Omental biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Tumor-targeted treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1240\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1240|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?18/4/18501\" title=\"algorithm 1\">",
"      Eval Rx malignancy ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1240|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/11/7355\" title=\"table 1\">",
"      Causes malignancy ascites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/168?source=related_link\">",
"      Chylous, bloody, and pancreatic ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32552?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12296?source=related_link\">",
"      Diagnosis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19930?source=related_link\">",
"      Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=related_link\">",
"      Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/40/16002?source=related_link\">",
"      Patient information: Fluid in the belly (ascites) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35465?source=related_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_63_39929="Biliary atresia";
var content_f38_63_39929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biliary atresia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39929/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39929/contributors\">",
"     Jessi Erlichman, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39929/contributors\">",
"     Kathleen M Loomes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39929/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/63/39929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/63/39929/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/63/39929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19842378\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary atresia (BA) is a progressive, idiopathic, fibro-obliterative disease of the extrahepatic biliary tree that presents with biliary obstruction exclusively in the neonatal period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the overall incidence is low (about one in 10,000 to 20,000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]), BA is the most common cause of neonatal jaundice for which surgery is indicated and the most common indication for liver transplantation in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2535778\">",
"    <span class=\"h1\">",
"     TYPES OF BILIARY ATRESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with biliary atresia (BA) can be grouped into three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Biliary atresia without any other anomalies or malformations",
"      </strong>",
"      &ndash; This pattern is sometimes referred to as perinatal BA, and occurs in approximately 70 percent of infants with BA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/1,6\">",
"       1,6",
"      </a>",
"      ]. Typically, these children are born without jaundice, but within the first two months of life, jaundice develops and stools become progressively acholic.",
"     </li>",
"     <li>",
"      <strong>",
"       Biliary atresia in association with laterality malformations",
"      </strong>",
"      &ndash; This pattern is also known as Biliary Atresia Splenic Malformation (BASM) or \"embryonal\" biliary atresia, and occurs 10 to 15 percent of infants with BA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. The laterality malformations include situs inversus, asplenia or polysplenia, malrotation, interrupted inferior vena cava, and cardiac anomalies. Data suggest that children with BASM have poorer outcomes compared to those with perinatal BA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Biliary atresia in association with other congenital malformations",
"      </strong>",
"      &ndash; This occurs in the remaining 10 to 15 percent of BA cases; associated congenital malformations include choledochal cyst, kidney anomalies,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      heart malformations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the type of BA, in each case, the histology and cholangiogram are characteristic: the histology typically shows inflammation, portal tract fibrosis, cholestasis, and bile duct proliferation; the cholangiogram demonstrates loss of patency of the extrahepatic bile ducts.",
"   </p>",
"   <p>",
"    Because of the cholangiographic findings, BA was previously termed &ldquo;extrahepatic biliary atresia,&rdquo; to distinguish it from &ldquo;intrahepatic biliary atresia,&rdquo; which was a histopathologic grouping of disorders in which the intrahepatic bile ducts are primarily affected. However, disorders primarily affecting the intrahepatic bile ducts are now categorized by the genetic, metabolic or infectious cause, rather than by the histologic finding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19842386\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of biliary atresia (BA) is unknown, although several mechanisms have been implicated, as outlined below. In some patients, several of these mechanisms may contribute to the development of BA. Conversely, BA may be the common phenotype that can be caused by a variety of injuries to the biliary system occurring in the perinatal period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19842393\">",
"    <span class=\"h2\">",
"     Viral etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clustering of cases of BA in time and space suggest a possible viral etiology. As an example, an analysis of 249 cases of BA over a 16-year period in New York State demonstrated seasonal patterns of incidence that varied by region in the state; in New York City, the risk of BA was highest for infants born during the Spring months, whereas outside of New York City infants born in the Fall months had a higher risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/11\">",
"     11",
"    </a>",
"    ]. To date, a specific virus has not been implicated; investigations have failed to identify associations with several specific viral infections including cytomegalovirus, reovirus, and group C rotavirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19842400\">",
"    <span class=\"h2\">",
"     Toxic etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clustering of cases of BA is also consistent with the possibility of a toxin-mediated inflammatory response. The strongest evidence for this hypothesis comes from three reported outbreaks of BA in lambs in Australia in 1964, 1988, and 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/16\">",
"     16",
"    </a>",
"    ]. In each outbreak, in a time of drought ewes that gave birth to affected lambs had grazed on lands that had previously been flooded. A significant number of offspring were thin, jaundiced, had acholic stools, and eventually died, and autopsy revealed a diagnosis of BA. The hypothesized mechanism is that the pregnant ewes ingested a toxin when grazing on lands previously submerged. To date, a specific toxin has not been implicated in the development of BA in either animals or humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19842407\">",
"    <span class=\"h2\">",
"     Genetic etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors may play a causative role in the small subgroup of patients with BASM malformations, as suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations in the CFC1 gene, which encodes cryptic protein and is involved in determining laterality during fetal development, have been associated with BASM syndrome. A heterozygous mutation in CFC1 was found in five out of ten infants with BASM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/17\">",
"       17",
"      </a>",
"      ]. The frequency of this mutation in infants with BASM is twice that found in a population of healthy individuals. Thus, CFC1 gene mutations may predispose to BASM but are not sufficient to cause the disease.",
"     </li>",
"     <li>",
"      A transgenic mouse with a recessive deletion of the inversin gene provides an animal model for BASM, displaying situs inversus and extrahepatic biliary obstruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other than these subgroups of patients with BASM, genetic factors may not play a direct causative role in the development of most cases of BA; this is suggested by the observation that monozygotic twins usually have a discordant phenotype. Nonetheless, genetics may still play a role in disease susceptibility. Association studies have identified a few genomic loci with increased susceptibility to BA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In addition, mutations in the human Jagged1 gene, which are responsible for Alagille syndrome, have been found in a few cases of biliary atresia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/21\">",
"     21",
"    </a>",
"    ]. The Jagged1 gene encodes a ligand in the Notch signaling pathway, which is critical in the determination of cell fate during development and may also alter production of inflammatory cytokines. Epigenetic factors have also been postulated as important factors impacting biliary development and the pathogenesis of BA. Both microRNA and DNA methylation have been studied in animal models and humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/50/16169?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of neonatal cholestasis\", section on 'Alagille syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19842414\">",
"    <span class=\"h2\">",
"     Immunologic etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune dysregulation, either as a primary disorder or as the result of infectious or genetic triggers, has been implicated in various studies.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A high concentration of maternal chimeric cells have been found in the portal and sinusoidal areas of patients with biliary atresia, suggesting that maternal lymphocytes cause bile duct injury through a graft-versus-host immune response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"     <li>",
"      Coordinated activation of genes involved with lymphocyte differentiation, particularly those associated with T helper 1 immunity, has been identified in liver samples from infants with biliary atresia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polymorphisms that enhance expression of the CD14 gene, which plays a role in the recognition of bacterial endotoxin, have been associated with biliary atresia and idiopathic neonatal cholestasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19842421\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infants with biliary atresia (BA) are born at full term, have a normal birth weight and initially thrive and seem healthy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9952373\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jaundice is the first sign of BA. Initially, the jaundice may be seen only in the sclerae. The onset of jaundice occurs any time from birth up to eight weeks of age, and it is highly unlikely to appear later.",
"     </li>",
"     <li>",
"      Some infants have acholic stools (",
"      <a class=\"graphic graphic_figure graphicRef74099 \" href=\"mobipreview.htm?34/51/35639\">",
"       figure 1",
"      </a>",
"      ). Acholic stools often go unrecognized because the stools are pale but not white and the stool color can vary on a daily basis.",
"     </li>",
"     <li>",
"      Most infants have dark urine because of bilirubin excretion into the urine. This often is not recognized by parents, who may not realize that infant urine should not stain a diaper yellow.",
"     </li>",
"     <li>",
"      If the jaundice has gone unnoticed and the child&rsquo;s disease has progressed, there may be a firm, enlarged liver and splenomegaly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9952381\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When laboratory studies are performed in infants after they come to attention because of one of the above symptoms, they reveal elevations in bilirubin (conjugated bilirubin &ge;2",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      and mild or moderate elevations in serum aminotransferases, with a disproportionately increased GGTP.",
"     </li>",
"     <li>",
"      If laboratory studies are performed shortly after birth (before the infant becomes symptomatic), mild elevations of conjugated bilirubin are seen. As an example, one study reported mild elevations in conjugated bilirubin (&gt;0.3",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      or direct bilirubin (&gt;0.5",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      at 24 to 48 hours of life in each of 34 infants who were later diagnosed with BA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/27\">",
"       27",
"      </a>",
"      ]. The mean serum direct bilirubin level was 1.4 &plusmn; 0.43",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      as compared with 0.19 &plusmn; 0.075 in control infants. The total bilirubin was not elevated at that time and conjugated bilirubin did not exceed 20 percent of the total bilirubin level.",
"      <br/>",
"      <br/>",
"      These observations suggest that infants with mildly elevated conjugated or direct bilirubin levels in the perinatal period should be followed closely and evaluated for the possibility of BA. Furthermore, they raise the possibility that measurements of conjugated or direct bilirubin during the first few days of life could be used as a screening tool for BA, if this approach is supported by additional studies of the sensitivity and cost-effectiveness of this measure and its potential effect on patient outcome. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19842428\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with suspected biliary atresia (BA) should be evaluated as rapidly as possible because the success of the surgical intervention (hepatoportoenterostomy, the Kasai procedure) diminishes progressively with older age at surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7032591\">",
"     'Predictors of the need for transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evaluation process involves a series of serologic, laboratory, urine, and imaging tests. The order of diagnostic tests is prioritized based on testing for treatable diseases first, such as biliary obstruction, infections, and some metabolic diseases. Because the timing of surgery is crucial for infants with BA, it is often appropriate to proceed with surgical exploration, even if all of the test results have not returned. In our practice, we typically proceed with each of the steps below if the infant is less than six weeks of age. For those patients six weeks and older, we still try to complete a full evaluation as rapidly as possible (eg, three to four days). Our rationale is that some diseases, such as Alagille Syndrome or alpha-1-antitrypsin deficiency, can mimic many of the findings of BA. &nbsp;",
"   </p>",
"   <p>",
"    Additional detail about the evaluation of an infant with cholestasis is given in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24519?source=see_link\">",
"     \"Approach to neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19845734\">",
"    <span class=\"h2\">",
"     Abdominal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of biliary anatomy begins with an ultrasound. The main utility of the ultrasound is to exclude other anatomic causes of cholestasis (ie, choledochal cyst) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/50/16169?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of neonatal cholestasis\", section on 'Biliary cysts'",
"    </a>",
"    ). In infants with BA, the gallbladder is usually either absent or irregular in shape. When a detailed ultrasonographic protocol is used, additional features can be identified to support the diagnosis of biliary atresia, including abnormal gallbladder size and shape, the \"triangular cord\" sign, gallbladder contractility, and absence of the common bile duct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. The triangular cord sign is a triangular echogenic density seen just above the porta hepatis on US scan. Its presence is highly suggestive of biliary atresia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19845741\">",
"    <span class=\"h2\">",
"     Hepatobiliary scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patency of the extrahepatic biliary tree can be further assessed by hepatobiliary scintigraphy. Although some centers may use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    to enhance radioisotope excretion, we do not use phenobarbital because it will delay diagnosis and does not obviate the need for liver biopsy. Failure of tracer excretion suggests BA, but does not exclude other diseases. Conversely, if scintigraphy demonstrates definite excretion of the tracer from the liver to the small bowel, patency is established, and BA is very unlikely. However, if excretion is noted on a scan that is performed when the infant is very young (ie, less than six weeks old), and cholestasis persists, the scan should be repeated one to two weeks later because the disease process may progress during the neonatal period. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19845787\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform a liver biopsy in virtually all infants with suspected biliary atresia for two reasons. One purpose is to identify histologic changes consistent with obstruction that warrant surgical exploration. The other is to differentiate BA from other causes of intrahepatic cholestasis, which would not need surgical exploration.",
"   </p>",
"   <p>",
"    Biopsy findings that indicate another etiology include bile duct paucity (Alagille syndrome), PAS positive diastase resistant granules (consistent with alpha-one antitrypsin deficiency), loss of MDR3 staining (suggestive of PFIC3), or giant cell hepatitis without proliferation of ducts. Characteristic histologic features of BA include expanded portal tracts with bile duct proliferation, portal tract edema, fibrosis and inflammation, and canalicular and bile duct bile plugs. The earliest histological changes associated with BA may be relatively nonspecific, and biopsies done too early may result in a false negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/34\">",
"     34",
"    </a>",
"    ]. At times it is necessary to repeat a liver biopsy at an older age (eg, two to three weeks later).",
"   </p>",
"   <p>",
"    Histologic findings alone cannot help to distinguish BA from other causes of obstruction, such as choledochal cyst or external compression. Therefore, any evidence of obstruction mandates imaging exploration and a definitive cholangiogram. In some cases, imaging cannot be performed because the biliary tree is atretic; in this case the surgeon makes the diagnostic decision based on visual inspection of the biliary tree.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19845794\">",
"    <span class=\"h2\">",
"     Cholangiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the above steps in the evaluation support the diagnosis of BA, the infant should be taken to the operating room.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first step is an intraoperative cholangiogram, which is the gold standard in the diagnosis of BA. It is essential that patency be investigated both proximally into the liver and distally into the bowel to determine whether BA is present.",
"     </li>",
"     <li>",
"      If the intraoperative cholangiogram demonstrates biliary obstruction (ie, if the contrast does not fill the biliary tree or reach the intestine), the surgeon should perform a hepatoportoenterostomy (Kasai HPE) at that time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An alternative yet valid approach at some centers is to perform a percutaneous gallbladder cholangiogram or an ERCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. These procedures are less invasive than intraoperative cholangiogram, but performance of these procedures in infants requires special expertise and equipment. Moreover, if BA is confirmed, the infant will still need to undergo an operation for treatment. The percutaneous gallbladder cholangiogram can only be performed in an infant with an identified gallbladder; the procedure is performed by an interventional radiologist. Alternatively, an endoscopic retrograde cholangiopancreatography (ERCP) can be used to demonstrate biliary patency in an infant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20536?source=see_link&amp;anchor=H2#H2\">",
"     \"ERCP for biliary disease in children\", section on 'Neonatal cholestasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19843985\">",
"    <span class=\"h1\">",
"     KASAI PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;If biliary atresia (BA) is confirmed by cholangiogram, a Kasai procedure (hepatoportoenterostomy [HPE]) should be performed promptly. This operation is undertaken in the attempt to restore bile flow from the liver to the proximal small bowel (",
"    <a class=\"graphic graphic_figure graphicRef67547 \" href=\"mobipreview.htm?18/55/19318\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/38\">",
"     38",
"    </a>",
"    ]. For this procedure, a roux-en-Y loop of bowel is created by the surgeon and directly anastomosed to the hilum of the liver, following excision of the biliary remnant and portal fibrous plate.",
"   </p>",
"   <p>",
"    If successful, the remaining small patent bile ducts will drain into the roux limb and jaundice will start to resolve in the weeks following surgery. If unsuccessful, bile drainage is not achieved, and the child remains jaundiced. If there is persistent jaundice three months after the Kasai, the patient should be referred for liver transplant evaluation. (See",
"    <a class=\"local\" href=\"#H19844768\">",
"     'Liver transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Revision of a non-functioning HPE generally is not recommended. This is because a revisional procedure is unlikely to be effective if the original HPE did not achieve bile drainage, and because the revisional procedure is likely to cause adhesions that increase the technical difficulty of a subsequent transplant procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/39\">",
"     39",
"    </a>",
"    ]. However, in patients in whom the initial HPE was successful, revisional HPE may be appropriate if the patient abruptly develops jaundice, or experiences recurrent episodes of cholangitis but has no other evidence of chronic liver disease. In one report of 24 patients who underwent revisional HPE for these indications, 75 percent achieved bile drainage and 46 percent survived with their native liver (mean follow-up 92 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even if bile flow is established and cholestasis improves, many patients will have slowly progressive liver disease despite undergoing the Kasai procedure, and the majority of patients with BA will ultimately require liver transplantation. At least 50 percent of patients who undergo HPE will require liver transplantation by two years of age as a result of primary failure of the Kasai HPE",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    growth failure. The patient&rsquo;s age at the time of HPE can predict native liver survival at later time points. As an example, among those patients who undergo HPE &le;30 days of life, the chance of native liver survival at four years of age is nearly 50 percent, whereas among those who underwent HPE between 31 and 90 days of life, the chance of native liver survival at four years of age is 36 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19844244\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus, the vast majority of individuals with BA will eventually require liver transplantation. Nonetheless, the Kasai HPE obviates the need for liver transplantation in a substantial minority and significantly delays the liver transplantation for many others. Pre-emptive transplant is avoided because of the&nbsp;advantages of transplanting older, larger patients and because of the potential for improved transplantation therapies in the future. At one time pre-emptive transplantation was used to avoid the difficulties of performing surgery on a patient with a prior HPE. With modern transplantation techniques, there is no surgical advantage to pre-emptive transplantation. Therefore, HPE is almost always&nbsp;performed first. If bile drainage is achieved, it is likely that transplantation will not be needed for years or decades. Historical series from before the Kasai procedure was introduced in 1968 report a 10 percent survival rate at age three years of age, as compared with the 35 to 50 percent survival rates with native liver at age four years of age, as cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19844768\">",
"     'Liver transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19844500\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical care following Kasai hepatoportoenterostomy (HPE) consists of the following interventions, as detailed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Choleretics and possible use of anti-inflammatory medications",
"     </li>",
"     <li>",
"      Nutritional rehabilitation",
"     </li>",
"     <li>",
"      Fat-soluble vitamin supplementation",
"     </li>",
"     <li>",
"      Prevention of cholangitis",
"     </li>",
"     <li>",
"      Management of portal hypertension and its sequelae",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19844509\">",
"    <span class=\"h2\">",
"     Choleretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of choleretics such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/19/13621?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA) is standard practice in biliary atresia (BA), although its clinical utility has not been definitively established. UDCA is a hydrophilic bile acid; when given by mouth it shifts the balance of bile acids towards hydrophilic forms. This is thought to stabilize membranes and the reduce generation of free radicals, thus protecting mitochondria from damage.",
"   </p>",
"   <p>",
"    The recommended dose of UDCA in BA ranges from 15 to 30",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    and should not exceed 30",
"    <span class=\"nowrap\">",
"     mg/kg/day.",
"    </span>",
"    To avoid potential toxicity, UDCA therapy should be discontinued if the total bilirubin level rises above 15",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"   </p>",
"   <p>",
"    The most clear human data regarding benefits of UDCA come from the group of patients with primary biliary cirrhosis (PBC). In several large randomized double blind placebo-controlled trials in patients with PBC, UDCA decreased plasma levels of aminotransferases, improved liver histology and quality of life, and decreased risk of death and need for liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43526?source=see_link\">",
"     \"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis\"",
"    </a>",
"    .) However, in patients with primary sclerosing cholangitis (PSC) a randomized trial suggested negative effects of long-term, high-dose UDCA therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In BA, observational studies suggest a number of possible benefits of UDCA treatment, ranging from enhanced weight gain to reduced episodes of cholangitis and improved bile flow, but definitive evidence from randomized trials is lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19844516\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether adjuvant treatment with glucocorticoids after HPE improves outcomes has not been established. This question has been addressed with several retrospective studies and with open-label prospective trials, using a variety of treatment protocols, with inconsistent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. As an example, a randomized placebo-controlled trial found that adjuvant treatment with glucocorticoids improved bilirubin levels at one month postoperatively, but not at the 6- or 12-month time points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/49\">",
"     49",
"    </a>",
"    ]. The study protocol used a relatively low dose and duration of glucocorticoid treatment, and was somewhat underpowered. This question will be addressed in a prospective randomized placebo-controlled trial designed by the",
"    <a class=\"external\" href=\"file://www.childrennetwork.org/about.html\">",
"     Childhood Liver Disease Research and Education Network",
"    </a>",
"    (ChiLDREN).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19844523\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional problems in BA are common and difficult to overcome. Poor nutrition is a significant clinical problem and is one of the most common indications for liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19844888\">",
"    <span class=\"h3\">",
"     Caloric needs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors contribute to malnutrition in patients with BA, including malabsorption due to cholestasis, chronic liver inflammation, and lack of gall bladder. Because of malabsorption and metabolic alterations, the total caloric needs in infants with BA are approximately 150 percent of the recommended energy intake for healthy infants and children (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30985?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of failure to thrive (undernutrition) in children younger than two years\", section on 'Requirements'",
"    </a>",
"    ). To compensate for losses and catabolism, the expected protein needs are 3 to 4",
"    <span class=\"nowrap\">",
"     g/kg/day",
"    </span>",
"    in infants and 2 to 3",
"    <span class=\"nowrap\">",
"     g/kg/day",
"    </span>",
"    in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/50-52\">",
"     50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to meet these nutritional requirements, several strategies are utilized. These strategies are similar to those used for infants with other causes of growth failure, except that they should be implemented proactively because of the high rates of growth failure in patients with BA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30985?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of failure to thrive (undernutrition) in children younger than two years\", section on 'Nutritional therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants, formulas are concentrated or expressed breast milk is fortified to provide additional energy. After Kasai HPE, the feed is typically designed to provide 24 kcal per ounce. If growth is inadequate, the feed may be increased to 27 kcal per ounce; additional energy content can be added in solid foods when the infant is old enough.",
"     </li>",
"     <li>",
"      High-energy supplements, such as glucose polymers (which provide 8",
"      <span class=\"nowrap\">",
"       cal/teaspoon)",
"      </span>",
"      or medium chain triglyceride oil (which provides 7.7",
"      <span class=\"nowrap\">",
"       cal/mL),",
"      </span>",
"      are used to fortify formula or solid foods [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/53\">",
"       53",
"      </a>",
"      ]. MCT oil is useful because it is calorically rich, and it is readily absorbed by patients with cholestasis because it does not require micellar solubilization.",
"     </li>",
"     <li>",
"      Despite these measures, many infants and children with BA require supplemental feeding by nasogastric tube because they are unable to take enough energy by mouth to meet their increased nutritional needs. Gastrostomy tubes are not recommended because many patients develop portal hypertension, leading to gastric varices and the propensity to develop varices around the gastrostomy tube site. Candidates for nasogastric feeds are identified by poor weight gain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor linear growth. Proactive management is recommended because the malnutrition may worsen the overall prognosis, with or without liver transplantation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11529?source=see_link\">",
"       \"Enteral nutrition in infants and children\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19844897\">",
"    <span class=\"h3\">",
"     Fat-soluble vitamin supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;All jaundiced infants and children with BA should be given supplements of fat-soluble vitamins. Once jaundice resolves and vitamins are replete, children can be transitioned to standard multi-vitamins. Nevertheless, routine monitoring of vitamin levels should continue (",
"    <a class=\"graphic graphic_table graphicRef51569 \" href=\"mobipreview.htm?7/57/8093\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Deficiencies of fat-soluble vitamins are common in patients with BA. In a series of 29 patients with BA, serologic deficiencies of vitamins A and E and radiographic evidence of vitamin D deficiency were reported despite establishment of bile flow by hepatoportoenterostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/54\">",
"     54",
"    </a>",
"    ]. Vitamin deficiencies occur despite recommended supplementation and are particularly common among patients with residual cholestasis after Kasai HPE (serum bilirubin &ge;2",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Therefore, vitamin levels should be monitored frequently (ie, several times in the first year), starting at the first month after HPE, in order to adjust supplements appropriately for deficiencies or toxicities (",
"    <a class=\"graphic graphic_table graphicRef51569 \" href=\"mobipreview.htm?7/57/8093\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19844697\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with successful bile drainage following HPE must be followed closely for complications including ascending cholangitis and portal hypertension. In addition, all patients should be routinely monitored for fat-soluble vitamin deficiencies as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19844706\">",
"    <span class=\"h3\">",
"     Ascending cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangitis is a common complication in patients with BA who have undergone a Kasai HPE (excluding post-surgical complications). The incidence of cholangitis in these patients is between 40 and 90 percent, with the majority of patients experiencing at least one episode prior to two years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/43,57\">",
"     43,57",
"    </a>",
"    ]. These patients are at risk for cholangitis because of the abnormal anatomy and bacterial stasis in the region of the roux limb.",
"   </p>",
"   <p>",
"    Because cholangitis can be life threatening and may impact long- and short-term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], most clinicians prescribe prophylactic antibiotics in the first year of life. Small nonrandomized trials suggest that the benefits of antibiotic prophylaxis outweigh the risks of antibiotic resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. As an example, in one series infants treated with prophylactic antibiotics had half the rate of cholangitis as compared with infants in a historical control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/59\">",
"     59",
"    </a>",
"    ]. Either",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/8/5255?source=see_link\">",
"      trimethoprim",
"     </a>",
"     /sulfamethoxazole",
"    </span>",
"    (4",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    trimethoprim and 20",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    sulfamethoxazole, divided twice daily) or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/42/29348?source=see_link\">",
"     neomycin",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    divided four times daily) appear to be equally effective in decreasing the incidence of cholangitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent cholangitis may predict the need for liver transplantation as it can lead to progressive cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/57\">",
"     57",
"    </a>",
"    ]; however, one episode of cholangitis does not predict early transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/6\">",
"     6",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19844713\">",
"    <span class=\"h3\">",
"     Portal hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic hepatobiliary inflammation characteristic of BA leads to progressive biliary cirrhosis. Biliary cirrhosis causes portal hypertension, which can lead to variceal bleeding and ascites. In a registry study of 163 children with BA in North America who had not undergone liver transplantation (average age 9.2 years), half had definite portal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/61\">",
"     61",
"    </a>",
"    ]. Among those with portal hypertension, 53 percent had a history of variceal bleeding, 17 percent had ascites, and 34 percent had reduced hepatic synthetic function (PT &gt;15 seconds or albumin &lt;3",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"    Recurrent variceal bleeding and refractory ascites are indications for liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19844768\">",
"     'Liver transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If portal hypertension leads to variceal bleeding, this complication is often controlled with sclerotherapy or banding. After the first variceal bleed, sclerotherapy or band ligation is instituted on a repeat basis with the ultimate goal of complete variceal obliteration. Some centers perform surveillance endoscopy to gauge the size and status of developing varices in patients who demonstrate clinical and ultrasonographic signs of portal hypertension following the Kasai procedure. In a series of 47 children with BA managed with endoscopic surveillance, varices developed in about half of the children, at a mean of 19 months (range 4 to 165 months) after successful Kasai HPE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/64\">",
"     64",
"    </a>",
"    ]. Other centers begin routine surveillance endoscopies only after the patient has experienced the first variceal bleed. While it is unclear whether one approach is more beneficial than the other, the risk of portal hypertension and variceal bleeding is present throughout the lives of children with BA.",
"   </p>",
"   <p>",
"    If ascites develops and is severe enough to compromise respiratory function, it is usually treated with paracentesis followed by chronic administration of diuretics, &beta;-blockers, salt",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    water dietary restriction, or a combination of these interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19844768\">",
"    <span class=\"h1\">",
"     LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of individuals with biliary atresia (BA) eventually require liver transplantation; indeed BA is the most common indication for liver transplantation in infants and children. In the current era, at least 60 to 80 percent of patients with BA will require liver transplantation, even with optimal management. (See",
"    <a class=\"local\" href=\"#H19844244\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The indications for liver transplantation for patients with BA include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/6,53,65-67\">",
"     6,53,65-67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary failure (lack of bile drainage) of the Kasai hepatoportoenterostomy",
"     </li>",
"     <li>",
"      Refractory growth failure &ndash; This is common in children with cholestasis",
"     </li>",
"     <li>",
"      Complications of portal hypertension (if these cannot be managed with other measures)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Repeated variceal bleeding",
"     </li>",
"     <li>",
"      Refractory ascites that compromises respiratory, bowel, or renal function",
"     </li>",
"     <li>",
"      Hepatopulmonary syndrome",
"     </li>",
"     <li>",
"      Portopulmonary hypertension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive liver dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Progressive cholestasis",
"     </li>",
"     <li>",
"      Refractory coagulopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients transplanted before two years of age, persistent cholestasis (often complicated by growth failure) and recurrent or resistant cholangitis are the most common indications for liver transplantation. &nbsp;",
"   </p>",
"   <p>",
"    Although it is clear that the vast majority of BA patients will ultimately require liver transplantation, preemptive transplants should be deferred as there are advantages to transplanting older and larger patients. Because the outcomes of liver transplantation improve for infants with weights &gt;10 kg, as compared to smaller infants, transplantation of infants with persistent cholestasis may be postponed if growth can be achieved and the infants are otherwise stable. Supplemental nasogastric tube feedings are often necessary to attain adequate growth. The cholestasis may cause chronic pruritus, which often responds to medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23863?source=see_link\">",
"     \"Pruritus associated with cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those children who require liver transplantation, prognosis is generally good. In the United States, the one-year patient- and liver-graft survival rates for pediatric patients undergoing primary liver transplant for BA are 92.1 and 83.6 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/66\">",
"     66",
"    </a>",
"    ]. In international series, long-term survival is approximately 70 to 80 percent at both 5 and 10 years, and these rates continue to improve in more recent case series",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/41,68-71\">",
"     41,68-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BA patients can receive whole or segmental cadaveric grafts, as well as segments from a living donor. The liver transplant surgery in BA patients is complicated by presence of intra-abdominal adhesions attributed to previous HPE. Postoperative outcomes appear to be less favorable in the subset of BA patients with BASM, due to the enhanced difficulty associated with liver dissection and vascular reconstruction in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/70\">",
"     70",
"    </a>",
"    ]. Poor nutrition is associated with increased mortality either while awaiting transplantation or after the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/72\">",
"     72",
"    </a>",
"    ]. Thus, vigorous nutritional support, including nasogastric feeds, is essential in the pre- and post-operative care of these patients. (See",
"    <a class=\"local\" href=\"#H19844523\">",
"     'Nutrition'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19844244\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although long-term prognosis for biliary atresia (BA) patients is variable, the complementary and sequential approach of HPE and liver transplantation affords long-term survival, with upwards of 90 percent of BA patients surviving into adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7032584\">",
"    <span class=\"h2\">",
"     Survival without transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall survival with native liver (ie, without transplantation) ranges from 30 to 55 percent at five years, 30 to 40 percent at 10 years, and 20 to 40 percent at 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/28,62,68,74-80\">",
"     28,62,68,74-80",
"    </a>",
"    ]. The long-term outcomes are illustrated by the following series: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 271 patients who underwent the Kasai HPE between 1968 and 1983 in France, 63 patients (23 percent) were alive with native liver at least 20 years after surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/62\">",
"       62",
"      </a>",
"      ]. The majority of survivors had evidence of chronic liver disease; all but two had cirrhosis. Most required lifelong care for management of hepatobiliary complications.",
"     </li>",
"     <li>",
"      Among 80 patients who underwent the procedure between 1970 and 1986 in Japan, the 5-, 10-, and 20-year survival rates with native livers of 63, 54, and 44 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/79\">",
"       79",
"      </a>",
"      ]. Half of the 20-year survivors had cirrhosis, and 20 percent went on to liver transplant or death within a few years.",
"     </li>",
"     <li>",
"      Among 104 patients who underwent the procedure between 1977 and 1988 in The Netherlands, 27 percent were alive with native liver 20 years later [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/80\">",
"       80",
"      </a>",
"      ]. Twenty-one percent of the long-term survivors had normal liver biochemical tests and no evidence of cirrhosis. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pregnancy in female survivors of BA is not without risk, and the pregnancy must be monitored to ensure the health and safety of the mother and child. In addition to complications from portal hypertension and late-onset cholangitis, the risk of developing cancer in the native liver remains an important concern. Careful monitoring and treatment of these late complications is essential.",
"   </p>",
"   <p>",
"    Given the improvements in medical therapy after Kasai HPE, including prophylaxis against cholangitis and improvements in nutrition and bile flow, it is reasonable to expect that long-term survival from current cases will exceed that of these older series. Experimental areas of therapy such as anti-fibrotic or anti-inflammatory agents may improve outcomes in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7032591\">",
"    <span class=\"h2\">",
"     Predictors of the need for transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although performance of the Kasai HPE clearly improves survival overall, the long-term prognosis is difficult to predict. The two most important prognostic factors for surgical outcome are younger age at operation and the expertise of the surgeon and care center at which the procedure is performed.",
"   </p>",
"   <p>",
"    Many case series have documented better outcomes when surgery is performed before 60 days of age and poorer outcomes after 90 days of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/28,68,74,75\">",
"     28,68,74,75",
"    </a>",
"    ]. As an example, in a series of 349 infants diagnosed and treated for biliary atresia in Canada, older age at time of HPE was associated with a progressive decrease in patient survival with the native liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/41\">",
"     41",
"    </a>",
"    ]. Among infants who underwent HPE at &le;30 days, 31 to 90 days, and &ge;90 days, the survival with the native liver at four years of age was 49, 36, and 23 percent, respectively. In Taiwan, after implementation of a protocol using universal screening for infant stool color increased the rate of accomplishing HPE before 60 days of life from 50 to 66 percent, improvements in several clinically important outcomes were seen: the rate of jaundice-free survival with the native liver at three years of age improved from 32 to 57 percent, and the rate of overall survival at five years of age improved from 56 to 89 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/81\">",
"     81",
"    </a>",
"    ]. However, the time at which early is early enough and late is too late is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/82\">",
"     82",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Surgical success is dependent on the expertise of the center and surgeon. Although controversial, it appears that a center that performs at least five Kasai procedures per year has a better success rate, as measured by 5- or 10-year long-term survival with the native liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/69,74,83\">",
"     69,74,83",
"    </a>",
"    ]. Another surgical factor is anatomic pattern of biliary atresia identified at time of Kasai hepatoportoenterostomy. Children born without atresia at the porta hepatis (Ohi classification 1) have the lowest risk of death or transplantation by two years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among all variables, serum bilirubin post HPE appears to be the most predictive biomarker of outcome. Data suggest that the serum total bilirubin level measured three months after Kasai HPE is predictive of native liver survival. Among patients with bilirubin &lt;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    three months post Kasai HPE, two year survival without transplantation was 84 percent. Among patients with bilirubin",
"    <span class=\"nowrap\">",
"     &ge;6mg/dL",
"    </span>",
"    three months post Kasai HPE, survival without transplantation was only 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/63/39929/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7033368\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary atresia (BA) is a progressive, idiopathic, fibro-obliterative disease of the extrahepatic biliary tree that presents with biliary obstruction in the neonatal period, and is the most common indication for liver transplantation in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BA may occur in isolation (70 percent), in association with lateralization anomalies such as situs inversus or asplenia (10 to 15 percent), or with other congenital malformations (10 to 15 percent). Those with lateralization anomalies have a somewhat worse prognosis. (See",
"      <a class=\"local\" href=\"#H19842378\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of BA are not well established and are probably multifactorial; genetic factors may play a permissive role in some cases, but infectious, toxic, or immunologic mechanisms are probably involved. (See",
"      <a class=\"local\" href=\"#H19842386\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most infants with BA are born at full term, have a normal birth weight, and initially thrive and seem healthy. Scleral icterus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      generalized jaundice typically develop by eight weeks of age. Infants may also have acholic (very pale colored) stools (",
"      <a class=\"graphic graphic_figure graphicRef74099 \" href=\"mobipreview.htm?34/51/35639\">",
"       figure 1",
"      </a>",
"      ), dark urine,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a firm liver and splenomegaly. Laboratory testing reveals elevation in serum conjugated bilirubin (&gt;2",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      and mild or moderate elevations in serum aminotransferases with a disproportionately increased GGTP. (See",
"      <a class=\"local\" href=\"#H19842421\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of BA is made with a series of imaging and laboratory tests and liver biopsy to exclude other causes of cholestasis. Infants should be evaluated as rapidly as possible because the success of the surgical intervention diminishes progressively with older age at surgery. Because timing is crucial, some infants (eg, those who are eight weeks or older or with a high clinical suspicion of BA) may not require each diagnostic step. (See",
"      <a class=\"local\" href=\"#H19842428\">",
"       'Diagnosis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The definitive diagnosis of BA is made by a cholangiogram. This is typically performed intraoperatively; if the diagnosis of BA is confirmed, the surgeon performs a hepatoportoenterostomy (HPE, Kasai procedure) (",
"      <a class=\"graphic graphic_figure graphicRef67547 \" href=\"mobipreview.htm?18/55/19318\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19845794\">",
"       'Cholangiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all infants with BA undergo a Kasai HPE (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This surgery should be performed as soon as the diagnosis of BA can be made and preferably before 60 days of age. This is because younger age at the time of the Kasai HPE is associated with better outcomes (ie, higher likelihood of resolution of cholestasis and longer survival with the native liver). (See",
"      <a class=\"local\" href=\"#H19843985\">",
"       'Kasai procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7032591\">",
"       'Predictors of the need for transplantation'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      We suggest that infants and children be treated with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/19/13621?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      (UDCA) after Kasai HPE (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). To avoid potential toxicity, UDCA therapy should be discontinued if the total bilirubin level rises above 15",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H19844509\">",
"       'Choleretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with BA who are jaundiced are at risk for fat-soluble vitamin deficiencies and should be treated with supplements of fat-soluble vitamins and monitored for fat-soluble vitamin deficiencies (",
"      <a class=\"graphic graphic_table graphicRef51569 \" href=\"mobipreview.htm?7/57/8093\">",
"       table 1",
"      </a>",
"      ). In addition, they should be given high calorie formula or other nutritional supplements as required to sustain normal rates of growth. If weight gain is below normal despite these measures, nasogastric feeds should be administered to optimize growth. Vigorous nutritional support is also indicated for non-cholestatic infants with BA. (See",
"      <a class=\"local\" href=\"#H19844523\">",
"       'Nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After Kasai HPE infants and children are at risk for ascending cholangitis. Some data has shown that repeated episodes of cholangitis can hasten the progression of liver disease. To reduce this risk, we suggest treating all patients with prophylactic antibiotics in the first year of life (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19844706\">",
"       'Ascending cholangitis'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      After Kasai HPE, if there is persistent jaundice three months later then the patient should be referred for liver transplant evaluation. Other indications for early liver transplantation include failure to thrive despite vigorous nutritional rehabilitation. (See",
"      <a class=\"local\" href=\"#H19844768\">",
"       'Liver transplantation'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      In the current era, at least 60 to 80 percent of patients with BA will eventually require liver transplantation. Indications for liver transplantation include complications of portal hypertension (recurrent variceal bleeding or intractable ascites), growth failure, and progressive liver dysfunction. (See",
"      <a class=\"local\" href=\"#H19844768\">",
"       'Liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A minority of patients with BA treated with Kasai HPE survive to 20 years or more without liver transplantation. However, many of these patients have chronic liver disease with cirrhosis and portal hypertension. (See",
"      <a class=\"local\" href=\"#H7032584\">",
"       'Survival without transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13005758\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Barbara Haber, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/1\">",
"      Haber BA, Russo P. Biliary atresia. Gastroenterol Clin North Am 2003; 32:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/2\">",
"      Danks DM, Campbell PE, Jack I, et al. Studies of the aetiology of neonatal hepatitis and biliary atresia. Arch Dis Child 1977; 52:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/3\">",
"      Matsui A, Ishikawa T. Identification of infants with biliary atresia in Japan. Lancet 1994; 343:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/4\">",
"      McKiernan PJ, Baker AJ, Kelly DA. The frequency and outcome of biliary atresia in the UK and Ireland. Lancet 2000; 355:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/5\">",
"      Yoon PW, Bresee JS, Olney RS, et al. Epidemiology of biliary atresia: a population-based study. Pediatrics 1997; 99:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/6\">",
"      Shneider BL, Brown MB, Haber B, et al. A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr 2006; 148:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/7\">",
"      Davenport M, Savage M, Mowat AP, Howard ER. Biliary atresia splenic malformation syndrome: an etiologic and prognostic subgroup. Surgery 1993; 113:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/8\">",
"      Davenport M, Tizzard SA, Underhill J, et al. The biliary atresia splenic malformation syndrome: a 28-year single-center retrospective study. J Pediatr 2006; 149:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/9\">",
"      De Matos V, Erlichman J, Russo PA, Haber BA. Does \"cystic\" biliary atresia represent a distinct clinical and etiological subgroup? A series of three cases. Pediatr Dev Pathol 2005; 8:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/10\">",
"      Muise AM, Turner D, Wine E, et al. Biliary atresia with choledochal cyst: implications for classification. Clin Gastroenterol Hepatol 2006; 4:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/11\">",
"      Caton AR, Druschel CM, McNutt LA. The epidemiology of extrahepatic biliary atresia in New York State, 1983-98. Paediatr Perinat Epidemiol 2004; 18:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/12\">",
"      Bates MD, Bucuvalas JC, Alonso MH, Ryckman FC. Biliary atresia: pathogenesis and treatment. Semin Liver Dis 1998; 18:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/13\">",
"      Hart MH, Kaufman SS, Vanderhoof JA, et al. Neonatal hepatitis and extrahepatic biliary atresia associated with cytomegalovirus infection in twins. Am J Dis Child 1991; 145:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/14\">",
"      Shivakumar P, Campbell KM, Sabla GE, et al. Obstruction of extrahepatic bile ducts by lymphocytes is regulated by IFN-gamma in experimental biliary atresia. J Clin Invest 2004; 114:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/15\">",
"      Tarr PI, Haas JE, Christie DL. Biliary atresia, cytomegalovirus, and age at referral. Pediatrics 1996; 97:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/16\">",
"      Harper P, Plant JW, Unger DB. Congenital biliary atresia and jaundice in lambs and calves. Aust Vet J 1990; 67:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/17\">",
"      Davit-Spraul A, Baussan C, Hermeziu B, et al. CFC1 gene involvement in biliary atresia with polysplenia syndrome. J Pediatr Gastroenterol Nutr 2008; 46:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/18\">",
"      Mazziotti MV, Willis LK, Heuckeroth RO, et al. Anomalous development of the hepatobiliary system in the Inv mouse. Hepatology 1999; 30:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/19\">",
"      Garcia-Barcel&oacute; MM, Yeung MY, Miao XP, et al. Genome-wide association study identifies a susceptibility locus for biliary atresia on 10q24.2. Hum Mol Genet 2010; 19:2917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/20\">",
"      Leyva-Vega M, Gerfen J, Thiel BD, et al. Genomic alterations in biliary atresia suggest region of potential disease susceptibility in 2q37.3. Am J Med Genet A 2010; 152A:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/21\">",
"      Kohsaka T, Yuan ZR, Guo SX, et al. The significance of human jagged 1 mutations detected in severe cases of extrahepatic biliary atresia. Hepatology 2002; 36:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/22\">",
"      Matthews RP, Eauclaire SF, Mugnier M, et al. DNA hypomethylation causes bile duct defects in zebrafish and is a distinguishing feature of infantile biliary atresia. Hepatology 2011; 53:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/23\">",
"      Zahm A, Hand NJ, Horner A, et al. Serum microRNA is a novel biomarker of biliary atresia. Hepatology 2011; 54 (4) Suppl:411A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/24\">",
"      Muraji T, Hosaka N, Irie N, et al. Maternal microchimerism in underlying pathogenesis of biliary atresia: quantification and phenotypes of maternal cells in the liver. Pediatrics 2008; 121:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/25\">",
"      Bezerra JA, Tiao G, Ryckman FC, et al. Genetic induction of proinflammatory immunity in children with biliary atresia. Lancet 2002; 360:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/26\">",
"      Shih HH, Lin TM, Chuang JH, et al. Promoter polymorphism of the CD14 endotoxin receptor gene is associated with biliary atresia and idiopathic neonatal cholestasis. Pediatrics 2005; 116:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/27\">",
"      Harpavat S, Finegold MJ, Karpen SJ. Patients with biliary atresia have elevated direct/conjugated bilirubin levels shortly after birth. Pediatrics 2011; 128:e1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/28\">",
"      Serinet MO, Wildhaber BE, Brou&eacute; P, et al. Impact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screening. Pediatrics 2009; 123:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/29\">",
"      Humphrey TM, Stringer MD. Biliary atresia: US diagnosis. Radiology 2007; 244:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/30\">",
"      Lee MS, Kim MJ, Lee MJ, et al. Biliary atresia: color doppler US findings in neonates and infants. Radiology 2009; 252:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/31\">",
"      Takamizawa S, Zaima A, Muraji T, et al. Can biliary atresia be diagnosed by ultrasonography alone? J Pediatr Surg 2007; 42:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/32\">",
"      Mittal V, Saxena AK, Sodhi KS, et al. Role of abdominal sonography in the preoperative diagnosis of extrahepatic biliary atresia in infants younger than 90 days. AJR Am J Roentgenol 2011; 196:W438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/33\">",
"      Park WH, Choi SO, Lee HJ, et al. A new diagnostic approach to biliary atresia with emphasis on the ultrasonographic triangular cord sign: comparison of ultrasonography, hepatobiliary scintigraphy, and liver needle biopsy in the evaluation of infantile cholestasis. J Pediatr Surg 1997; 32:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/34\">",
"      Azar G, Beneck D, Lane B, et al. Atypical morphologic presentation of biliary atresia and value of serial liver biopsies. J Pediatr Gastroenterol Nutr 2002; 34:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/35\">",
"      Moyer V, Freese DK, Whitington PF, et al. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/36\">",
"      Lee SY, Kim GC, Choe BH, et al. Efficacy of US-guided percutaneous cholecystocholangiography for the early exclusion and type determination of biliary atresia. Radiology 2011; 261:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/37\">",
"      Jensen MK, Biank VF, Moe DC, et al. HIDA, percutaneous transhepatic cholecysto-cholangiography and liver biopsy in infants with persistent jaundice: can a combination of PTCC and liver biopsy reduce unnecessary laparotomy? Pediatr Radiol 2012; 42:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/38\">",
"      Davenport M, Ure BM, Petersen C, Kobayashi H. Surgery for biliary atresia--is there a European consensus? Eur J Pediatr Surg 2007; 17:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/39\">",
"      Haber BA, Erlichman J, Thayu M, et al. Successful revision of portoenterostomy in an infant with biliary atresia. J Pediatr Surg 2006; 41:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/40\">",
"      Bondoc AJ, Taylor JA, Alonso MH, et al. The beneficial impact of revision of Kasai portoenterostomy for biliary atresia: an institutional study. Ann Surg 2012; 255:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/41\">",
"      Schreiber RA, Barker CC, Roberts EA, et al. Biliary atresia: the Canadian experience. J Pediatr 2007; 151:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/42\">",
"      HAYS DM, SNYDER WH Jr. LIFE-SPAN IN UNTREATED BILIARY ATRESIA. Surgery 1963; 54:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/43\">",
"      Oh M, Hobeldin M, Chen T, et al. The Kasai procedure in the treatment of biliary atresia. J Pediatr Surg 1995; 30:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/44\">",
"      Haber BA, Erlichman J, Loomes KM. Recent advances in biliary atresia: prospects for novel therapies. Expert Opin Investig Drugs 2008; 17:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/45\">",
"      Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/46\">",
"      Meyers RL, Book LS, O'Gorman MA, et al. High-dose steroids, ursodeoxycholic acid, and chronic intravenous antibiotics improve bile flow after Kasai procedure in infants with biliary atresia. J Pediatr Surg 2003; 38:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/47\">",
"      Stringer MD, Davison SM, Rajwal SR, McClean P. Kasai portoenterostomy: 12-year experience with a novel adjuvant therapy regimen. J Pediatr Surg 2007; 42:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/48\">",
"      Petersen C, Harder D, Melter M, et al. Postoperative high-dose steroids do not improve mid-term survival with native liver in biliary atresia. Am J Gastroenterol 2008; 103:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/49\">",
"      Davenport M, Stringer MD, Tizzard SA, et al. Randomized, double-blind, placebo-controlled trial of corticosteroids after Kasai portoenterostomy for biliary atresia. Hepatology 2007; 46:1821.",
"     </a>",
"    </li>",
"    <li>",
"     Feranchak AP, Sokol R. Medical and nutritional management of cholestasis in infants and children. In: Liver Disease in Children, Suchy FJ,  Sokol R, Balistreri W (Eds), Cambridge University Press, New York 2007. p.190.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/51\">",
"      Novy MA, Schwarz KB. Nutritional considerations and management of the child with liver disease. Nutrition 1997; 13:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/52\">",
"      Pierro A, Koletzko B, Carnielli V, et al. Resting energy expenditure is increased in infants and children with extrahepatic biliary atresia. J Pediatr Surg 1989; 24:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/53\">",
"      Ryckman F, Fisher R, Pedersen S, et al. Improved survival in biliary atresia patients in the present era of liver transplantation. J Pediatr Surg 1993; 28:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/54\">",
"      Andrews WS, Pau CM, Chase HP, et al. Fat soluble vitamin deficiency in biliary atresia. J Pediatr Surg 1981; 16:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/55\">",
"      Shneider B, Abel R, Raghunathan T. A prospective multi-centered investigation of vitamin supplementation in infants with biliary atresia: Interim analysis from the biliary atresia research consortium (BARC). Hepatology 2009; 50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/56\">",
"      Shneider BL, Magee JC, Bezerra JA, et al. Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia. Pediatrics 2012; 130:e607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/57\">",
"      Luo Y, Zheng S. Current concept about postoperative cholangitis in biliary atresia. World J Pediatr 2008; 4:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/58\">",
"      Wu ET, Chen HL, Ni YH, et al. Bacterial cholangitis in patients with biliary atresia: impact on short-term outcome. Pediatr Surg Int 2001; 17:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/59\">",
"      Bu LN, Chen HL, Chang CJ, et al. Prophylactic oral antibiotics in prevention of recurrent cholangitis after the Kasai portoenterostomy. J Pediatr Surg 2003; 38:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/60\">",
"      Ernest van Heurn LW, Saing H, Tam PK. Cholangitis after hepatic portoenterostomy for biliary atresia: a multivariate analysis of risk factors. J Pediatr 2003; 142:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/61\">",
"      Shneider BL, Abel B, Haber B, et al. Portal hypertension in children and young adults with biliary atresia. J Pediatr Gastroenterol Nutr 2012; 55:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/62\">",
"      Lykavieris P, Chardot C, Sokhn M, et al. Outcome in adulthood of biliary atresia: a study of 63 patients who survived for over 20 years with their native liver. Hepatology 2005; 41:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/63\">",
"      Miga D, Sokol RJ, Mackenzie T, et al. Survival after first esophageal variceal hemorrhage in patients with biliary atresia. J Pediatr 2001; 139:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/64\">",
"      Lampela H, Kosola S, Koivusalo A, et al. Endoscopic surveillance and primary prophylaxis sclerotherapy of esophageal varices in biliary atresia. J Pediatr Gastroenterol Nutr 2012; 55:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/65\">",
"      Jiang CB, Lee HC, Yeung CY, et al. A scoring system to predict the need for liver transplantation for biliary atresia after Kasai portoenterostomy. Eur J Pediatr 2003; 162:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/66\">",
"      Barshes NR, Lee TC, Balkrishnan R, et al. Orthotopic liver transplantation for biliary atresia: the U.S. experience. Liver Transpl 2005; 11:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/67\">",
"      Okamoto T, Yokoi A, Okamoto S, et al. Pretransplant risk factors and optimal timing for living-related liver transplantation in biliary atresia: experience of one Japanese children's hospital and transplantation center. J Pediatr Surg 2008; 43:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/68\">",
"      Chardot C, Carton M, Spire-Bendelac N, et al. Is the Kasai operation still indicated in children older than 3 months diagnosed with biliary atresia? J Pediatr 2001; 138:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/69\">",
"      Nio M, Ohi R, Miyano T, et al. Five- and 10-year survival rates after surgery for biliary atresia: a report from the Japanese Biliary Atresia Registry. J Pediatr Surg 2003; 38:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/70\">",
"      Fouquet V, Alves A, Branchereau S, et al. Long-term outcome of pediatric liver transplantation for biliary atresia: a 10-year follow-up in a single center. Liver Transpl 2005; 11:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/71\">",
"      Wildhaber BE, Coran AG, Drongowski RA, et al. The Kasai portoenterostomy for biliary atresia: A review of a 27-year experience with 81 patients. J Pediatr Surg 2003; 38:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/72\">",
"      Utterson EC, Shepherd RW, Sokol RJ, et al. Biliary atresia: clinical profiles, risk factors, and outcomes of 755 patients listed for liver transplantation. J Pediatr 2005; 147:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/73\">",
"      Wildhaber BE, Majno P, Mayr J, et al. Biliary atresia: Swiss national study, 1994-2004. J Pediatr Gastroenterol Nutr 2008; 46:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/74\">",
"      Chardot C, Carton M, Spire-Bendelac N, et al. Prognosis of biliary atresia in the era of liver transplantation: French national study from 1986 to 1996. Hepatology 1999; 30:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/75\">",
"      Laurent J, Gauthier F, Bernard O, et al. Long-term outcome after surgery for biliary atresia. Study of 40 patients surviving for more than 10 years. Gastroenterology 1990; 99:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/76\">",
"      Davenport M, Puricelli V, Farrant P, et al. The outcome of the older (&gt; or =100 days) infant with biliary atresia. J Pediatr Surg 2004; 39:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/77\">",
"      Karrer FM, Price MR, Bensard DD, et al. Long-term results with the Kasai operation for biliary atresia. Arch Surg 1996; 131:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/78\">",
"      Tagge DU, Tagge EP, Drongowski RA, et al. A long-term experience with biliary atresia. Reassessment of prognostic factors. Ann Surg 1991; 214:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/79\">",
"      Shinkai M, Ohhama Y, Take H, et al. Long-term outcome of children with biliary atresia who were not transplanted after the Kasai operation: &gt;20-year experience at a children's hospital. J Pediatr Gastroenterol Nutr 2009; 48:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/80\">",
"      de Vries W, Homan-Van der Veen J, Hulscher JB, et al. Twenty-year transplant-free survival rate among patients with biliary atresia. Clin Gastroenterol Hepatol 2011; 9:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/81\">",
"      Lien TH, Chang MH, Wu JF, et al. Effects of the infant stool color card screening program on 5-year outcome of biliary atresia in Taiwan. Hepatology 2011; 53:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/82\">",
"      Wong KK, Chung PH, Chan IH, et al. Performing Kasai portoenterostomy beyond 60 days of life is not necessarily associated with a worse outcome. J Pediatr Gastroenterol Nutr 2010; 51:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/83\">",
"      Davenport M, De Ville de Goyet J, Stringer MD, et al. Seamless management of biliary atresia in England and Wales (1999-2002). Lancet 2004; 363:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/63/39929/abstract/84\">",
"      Superina R, Magee JC, Brandt ML, et al. The anatomic pattern of biliary atresia identified at time of Kasai hepatoportoenterostomy and early postoperative clearance of jaundice are significant predictors of transplant-free survival. Ann Surg 2011; 254:577.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14369 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39929=[""].join("\n");
var outline_f38_63_39929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7033368\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19842378\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2535778\">",
"      TYPES OF BILIARY ATRESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19842386\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19842393\">",
"      Viral etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19842400\">",
"      Toxic etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19842407\">",
"      Genetic etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19842414\">",
"      Immunologic etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19842421\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9952373\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9952381\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19842428\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19845734\">",
"      Abdominal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19845741\">",
"      Hepatobiliary scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19845787\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19845794\">",
"      Cholangiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19843985\">",
"      KASAI PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19844500\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19844509\">",
"      Choleretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19844516\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19844523\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19844888\">",
"      - Caloric needs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19844897\">",
"      - Fat-soluble vitamin supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19844697\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19844706\">",
"      - Ascending cholangitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19844713\">",
"      - Portal hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19844768\">",
"      LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19844244\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7032584\">",
"      Survival without transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7032591\">",
"      Predictors of the need for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7033368\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13005758\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14369\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14369|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/51/35639\" title=\"figure 1\">",
"      Stool color card used to screen infants for biliary atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/55/19318\" title=\"figure 2\">",
"      Kasai hepatoportoenterostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14369|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/57/8093\" title=\"table 1\">",
"      Fat soluble vitamin supplements for biliary atresia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24519?source=related_link\">",
"      Approach to neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/50/16169?source=related_link\">",
"      Causes of neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20536?source=related_link\">",
"      ERCP for biliary disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11529?source=related_link\">",
"      Enteral nutrition in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30985?source=related_link\">",
"      Management of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23863?source=related_link\">",
"      Pruritus associated with cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43526?source=related_link\">",
"      Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_63_39930="Prurigo nodularis 4";
var content_f38_63_39930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86817%7EDERM%2F53475%7EDERM%2F66268%7EDERM%2F86816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86817%7EDERM%2F53475%7EDERM%2F66268%7EDERM%2F86816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Discrete, excoriated nolules on the leg of a patient with nodular prurigo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple nodules, some of which excoriated, on the lower limb of a patient with nodular prurigo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A prurigo nodularis nodule showing periferal hyperpigmentation and central scale.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39930=[""].join("\n");
var outline_f38_63_39930=null;
var title_f38_63_39931="Regulation of T4 5 deiodinase";
var content_f38_63_39931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions affecting thyroxine 5'-deiodinase activity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Enzyme type affected*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Type 1",
"       </td>",
"       <td class=\"subtitle2\">",
"        Type 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetus",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthyroidism",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Starvation",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uremia",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propylthiouracil",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propranolol",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Type 1 deiodinase predominates in the liver, kidneys, and thyroid; type 2 deiodinase in the brain, pituitary, and skin.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39931=[""].join("\n");
var outline_f38_63_39931=null;
var title_f38_63_39932="Life exp CRC stage III";
var content_f38_63_39932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated life expectancy, in years, after a diagnosis of stage III colorectal cancer, stratified by age at diagnosis and number of chronic conditions*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Male",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Female",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Age",
"      </td>",
"      <td class=\"subtitle2\">",
"       Chronic conditions",
"      </td>",
"      <td class=\"subtitle2\">",
"       Survival (95% confidence interval)",
"      </td>",
"      <td class=\"subtitle2\">",
"       Age",
"      </td>",
"      <td class=\"subtitle2\">",
"       Chronic conditions",
"      </td>",
"      <td class=\"subtitle2\">",
"       Survival (95% confidence interval)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       67",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       8.4 (7.6-9.2)",
"      </td>",
"      <td rowspan=\"3\">",
"       67",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       8.5 (7.6-9.5)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       6.8 (6.1-7.6)",
"      </td>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       7.9 (7.0-8.9)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;3",
"      </td>",
"      <td>",
"       4.6 (3.3-6.0)",
"      </td>",
"      <td>",
"       &ge;3",
"      </td>",
"      <td>",
"       4.7 (3.5-6.1)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       71",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       7.4 (7.0-7.9)",
"      </td>",
"      <td rowspan=\"3\">",
"       71",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       8.3 (7.8-8.8)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       6.1 (5.7-6.5)",
"      </td>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       6.6 (6.1-7.0)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;3",
"      </td>",
"      <td>",
"       4.4 (3.9-5.0)",
"      </td>",
"      <td>",
"       &ge;3",
"      </td>",
"      <td>",
"       3.7 (3.1-4.3)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       76",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       6.3 (5.8-6.8)",
"      </td>",
"      <td rowspan=\"3\">",
"       76",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       7.4 (7.0-7.9)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       5.2 (4.8-5.6)",
"      </td>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       5.8 (5.5-6.2)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;3",
"      </td>",
"      <td>",
"       3.6 (3.2-4.0)",
"      </td>",
"      <td>",
"       &ge;3",
"      </td>",
"      <td>",
"       3.8 (3.4-4.2)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       81",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       5.5 (5.0-6.1)",
"      </td>",
"      <td rowspan=\"3\">",
"       81",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       6.4 (5.9-6.9)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       4.9 (4.5-5.3)",
"      </td>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       4.8 (4.4-5.1)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;3",
"      </td>",
"      <td>",
"       2.9 (2.6-3.3)",
"      </td>",
"      <td>",
"       &ge;3",
"      </td>",
"      <td>",
"       2.8 (2.5-3.2)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Including but not limited to AIDS, atrial fibrillation, cerebrovascular disease, chronic obstructive pulmonary disease, congestive heart failure, dementia, diabetes, hip fracture, liver disease, myocardial infarction, paralysis, peripheral vascular disease, renal failure, rheumatologic disease, and ulcers.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gross C, McAvay G, Krumholz H, et al. Ann Int Med 2006; 145:646.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39932=[""].join("\n");
var outline_f38_63_39932=null;
var title_f38_63_39933="Antibiotic prophylaxis in dermatologic surgery";
var content_f38_63_39933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Recommendations for antibiotic prophylaxis in dermatologic surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 304px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IE: infective endocarditis; HTJI: hematogenous total joint infection.",
"    </div>",
"    <div class=\"reference\">",
"     From: Wright TI, Baddour LM, Berbari EF, et al. Antibiotic prophylaxis in dermatologic surgery: advisory statement 2008. J Am Acad Dermatol 2008; 59:464. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39933=[""].join("\n");
var outline_f38_63_39933=null;
var title_f38_63_39934="ANA disease associations I";
var content_f38_63_39934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58564%7ERHEUM%2F71307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58564%7ERHEUM%2F71307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity of different antinuclear antibodies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"8\" rowspan=\"1\">",
"       Antibody",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       ds DNA",
"      </td>",
"      <td class=\"subtitle2\">",
"       ss DNA",
"      </td>",
"      <td class=\"subtitle2\">",
"       Histone",
"      </td>",
"      <td class=\"subtitle2\">",
"       Nucleoprotein",
"      </td>",
"      <td class=\"subtitle2\">",
"       Sm",
"      </td>",
"      <td class=\"subtitle2\">",
"       RNP",
"      </td>",
"      <td class=\"subtitle2\">",
"       Ro",
"      </td>",
"      <td class=\"subtitle2\">",
"       La",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       SLE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       70 percent",
"      </td>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       30-80",
"      </td>",
"      <td>",
"       58",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       25-35",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       95 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       96 percent",
"      </td>",
"      <td>",
"       82 percent",
"      </td>",
"      <td>",
"       87-94",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Drug LE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       95",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       1 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       1-5 percent",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       high",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       RA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       1 percent",
"      </td>",
"      <td>",
"       47",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       1 percent",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Scleroderma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       PM/DM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Sj&ouml;gren's",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       1-5 percent",
"      </td>",
"      <td>",
"       5-60",
"      </td>",
"      <td>",
"       8-70",
"      </td>",
"      <td>",
"       14-60",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       1-5 percent",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       87",
"      </td>",
"      <td>",
"       94",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Sen: sensitivity; Spec: specificity.",
"     <br>",
"      Other associations: RNP: Mixed connective tissue disease (MCTD); Ro: Subacute cutaneous lupus erythematosus, Primary biliary cirrhosis, Vasculitis, Congenital heart block.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity of different antinuclear antibodies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"8\" rowspan=\"1\">",
"       Antibody",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       PCNA",
"      </td>",
"      <td class=\"subtitle2\">",
"       Scl-70",
"      </td>",
"      <td class=\"subtitle2\">",
"       PM-1",
"      </td>",
"      <td class=\"subtitle2\">",
"       Mi-1",
"      </td>",
"      <td class=\"subtitle2\">",
"       Jo-1",
"      </td>",
"      <td class=\"subtitle2\">",
"       Ku",
"      </td>",
"      <td class=\"subtitle2\">",
"       Nucleoli",
"      </td>",
"      <td class=\"subtitle2\">",
"       Centromere",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       SLE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       95",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Drug LE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       RA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Scleroderma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       15-20",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       54",
"      </td>",
"      <td>",
"       25-30",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       high",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       PM/DM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       30-50",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       30-50",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Sj&ouml;gren's",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Sen: sensitivity; Spec: specificity.",
"     <br>",
"      Other associations: Centromere: Limited systemic sclerosis (CREST syndrome).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39934=[""].join("\n");
var outline_f38_63_39934=null;
var title_f38_63_39935="2 to 1 block in AV Node";
var content_f38_63_39935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    2:1 AV nodal block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 258px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The baseline 12-lead electrocardiogram in this patient demonstrated sinus rhythm with 2:1 AV block, prolonged AV conduction, and a left bundle branch block. Surface leads represented are I, II, III, V1, and V6. The intracardiac tracing shown is the distal His bundle electrogram (HIS d). Every other atrial depolarization is not proceeded by either a His or ventricular depolarization (arrows) indicating AV nodal block.",
"    <div class=\"footnotes\">",
"     A: atrial depolarization; AV: atrioventricular; H: His bundle depolarization; V: ventricular depolarization.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph J Germano, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_63_39935=[""].join("\n");
var outline_f38_63_39935=null;
